Gastric inhibitory peptide receptor ligand

Modified cyclic peptides targeting GIPR enhance tumor uptake and efficacy in diagnosing and treating GIPR-expressing diseases by conjugating with radionuclides for targeted delivery.

JP2024542966APending Publication Date: 2024-11-193B PHARM GMBH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024524423
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-25
Filing Date
2022-10-25
Publication Date
2024-11-19

Smart Images

  • Figure 2024542966000001_ABST
    Figure 2024542966000001_ABST
Patent Text Reader

Abstract

The present invention relates to compounds comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib), each optionally comprising an N-terminal modification group A attached to Xaa1, and each optionally comprising a C-terminal group C-term attached to Xaa11.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] FIELD OF THE INVENTION The present invention relates to chemical compounds; peptides; gastric inhibitory peptide receptor (GIPR)-binding compounds; gastric inhibitory peptide receptor (GIPR)-binding peptides; compositions comprising said compounds; compositions comprising said gastric inhibitory peptide receptor (GIPR)-binding compounds; compositions comprising said peptides; compositions comprising gastric inhibitory peptide receptor (GIPR)-binding peptides; each of said compounds, gastric inhibitory peptide receptor (GIPR)-binding compounds, said peptides, gastric inhibitory peptide receptor (GIPR)-binding peptides and said compositions for use in methods for diagnosing a disease; and methods for treating a disease. the compound, the gastric inhibitory peptide receptor (GIPR)-binding compound, and the composition, respectively, for use in a method for placing a radionuclide-binding compound (GIP) against a gastric inhibitory peptide receptor (GIPR) in a patient receiving a GIPR-binding treatment; the compound, the gastric inhibitory peptide receptor (GIPR)-binding compound, the peptide, the gastric inhibitory peptide receptor (GIPR)-binding peptide, and the composition, respectively, for use in a method for diagnosing and treating disease (also called "ther(gnosis)" or "ther(gnostics)"); and a method for delivering a radionuclide against the gastric inhibitory peptide receptor (GIPR) to cells, preferably GIPR-overexpressing tumor cells or pancreatic beta cells. a method for diagnosing a disease using said compound, gastric inhibitory peptide receptor (GIPR)-binding compound, said peptide, gastric inhibitory peptide receptor (GIPR)-binding peptide and said composition, respectively; a method for diagnosing a disease using said compound, gastric inhibitory peptide receptor (GIPR)-binding compound, said peptide, gastric inhibitory peptide receptor (GIPR)-binding peptide and said composition, respectively; a method for diagnosing a disease using said compound, gastric inhibitory peptide receptor (GIPR)-binding compound, said peptide, gastric inhibitory peptide receptor (GIPR)-binding peptide and said composition, respectively. The present invention relates to methods for treating diseases using the compounds, gastric inhibitory peptide receptor (GIPR)-binding compounds, the peptides, the binding peptides, and the compositions; methods for diagnosing and treating diseases (also called "ther(gnosis)" or "ther(gnostics)") using the compounds, gastric inhibitory peptide receptor (GIPR)-binding compounds, the peptides, gastric inhibitory peptide receptor (GIPR)-binding peptides, and the compositions, respectively; and methods for delivering radionuclides to gastric inhibitory peptide receptor (GIPR)-expressing tissues using the compounds, gastric inhibitory peptide receptor (GIPR)-binding compounds, the peptides, gastric inhibitory peptide receptor (GIPR)-binding peptides, and the compositions, respectively.

[0002] background Human gastric inhibitory polypeptide (GIP) is a 42-amino acid incretin hormone (H-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asn-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-OH) secreted from enteroendocrine K cells, which enforces meal-related insulin secretion via the GIPR signaling cascade (Cho et al., Vitam Horm, 2010, 84, 111-150). It was first discovered in the 1970s by John Brown and Raymond Pederson during their studies of cholecystokinin (Brown et al., Scand J Gastroenterol, 1970, 5, 537-541).

[0003] GIPR is a seven-transmembrane class B1 G protein-coupled receptor (GPCR) (Fredriksson et al., Mol Pharmacol, 2003, 63, 1256-1272). It is expressed in the gastrointestinal tract and pancreatic islet cells (Usdin et al., Endocrinology, 1993, 133, 2861-2870). The extracellular N-terminal domain recognizes ligands at its middle or C-terminal portion, and the N-terminal portion subsequently docks into the transmembrane domain of the receptor (Parthier et al., Proc Natl Acad Sci USA, 2007, 104, 13942-13947). Depending on the receptor's conformation, Ca 2+GIP(1-42)NH2 and GIP(1-30)NH2 are both GIPR agonists and dipeptidyl peptidase-4 (DPP4) substrates, resulting in potent GIPR inhibitors (GIP(3-42)NH2; GIP(3-30)NH2). N-terminal truncation reduces receptor activation and antagonism (Hansen et al., Br J Pharmacol, 2016, 173, 826-838), whereas C-terminal modifications have little effect on stability or tissue distribution.

[0004] Recently, GIPR has gained attention in peptide receptor radionuclide therapy (PRRT). In contrast to non-cancerous tissues, GIPR is highly expressed in several subgroups of neuroendocrine neoplasms (Waser et al., J Clin Endocrinol Metab, 2012, 97, 482-488).

[0005] In 2012, a study was published demonstrating high expression of the GIP receptor in gastroenteropancreatic and bronchial neuroendocrine tumors (Waser et al., J Clin Endocrinol Metab, 2012, 97, 482-488). The authors proposed that the GIPR represents a novel molecular target for clinical applications, such as in vivo scintigraphy and targeted radiotherapy. WO 2012 / 168464 describes a method for imaging and treating endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors by targeting the GIPR. The expression rate and density of the receptor in human neuroendocrine tumors and non-neoplastic tissues were analyzed by autoradiography. Among these tumors, functional pancreatic neuroendocrine tumors, including insulinomas, gastrinomas, glucagonomas, and VIP-secreting tumors, as well as non-functioning pancreatic NETs and ileal NETs, ​​showed the highest receptor expression. Among non-neoplastic tissues, the highest expression was found in human pancreatic islets. Several academic groups have published studies using radiolabeled GIP analogs for nuclear medicine imaging (Gourni et al., J Nucl Med, 2014, 55, 976-982; Willekens et al., Sci Rep, 2018, 8, 2948). While these studies were successful as proof-of-concept, tumor uptake of the labeled peptide was approximately 20-fold lower than that of the kidney.

[0006] Detailed Description of the Invention The problem underlying the present invention is to provide compounds that are suitable as diagnostic and / or therapeutic agents, in particular when conjugated to diagnostically and / or therapeutically active radionuclides.

[0007] A further object of the present invention is to provide a compound suitable as a diagnostic and / or therapeutic agent, in particular when conjugated with a diagnostically active radionuclide and / or a therapeutically active radionuclide, which has a pEC value of 8.0 or more for the gastric inhibitory peptide receptor (GIPR). 50 and / or pIC ≥ 7.5 50 The object of the present invention is to provide a compound having the formula:

[0008] A further problem underlying the present invention is to provide compounds that are suitable as diagnostic and / or therapeutic agents in the diagnosis and / or treatment of diseases in which the diseased cells and / or tissue express a gastric inhibitory peptide receptor (GIPR), in particular when conjugated to a diagnostically and / or therapeutically active radionuclide.A further problem underlying the present invention is to provide compounds that are suitable for delivering diagnostically and / or therapeutically active radionuclides to diseased cells and / or diseased tissue, respectively, more particularly to diseased cells and / or diseased tissue expressing a GIPR, preferably diseased tissue comprising cancer or tumor cells.

[0009] The problem underlying the present invention is also to provide methods for diagnosing, treating and / or preventing diseases and combined methods for diagnosing and treating diseases, preferably wherein such diseases involve GIPR-expressing cells and / or tissues, more particularly GIPR-expressing diseased cells and / or diseased tissues, and preferably wherein the diseased tissue comprises or contains cancer or tumor cells or pancreatic beta cells.

[0010] A further problem underlying the present invention is to provide a method for identifying a subject, the subject being likely to respond or not respond to treatment of a disease, a method for selecting a subject from a group of subjects, the subject being likely to respond or not respond to treatment of a disease, preferably the disease is cancer, more preferably the disease is a neuroendocrine tumor.

[0011] The present invention also provides a pharmaceutical composition containing a compound having the characteristics outlined above, and a kit suitable for use in any of the above methods.

[0012] These and other problems are solved by the subject matter of the attached independent claims. Preferred embodiments can be taken from the attached dependent claims.

[0013] These and other problems are also solved by the subject matter of the following embodiments.

[0014] Embodiment 1 Formula (Ia) [ka] or a cyclic peptide represented by formula (Ib) [ka] The cyclic peptide comprises: each optionally comprising an N-terminal modification group A attached to Xaa1; each optionally comprising a C-terminus C-term that is bound to Xaa11; where: The peptide sequences are depicted from left to right, N- to C-terminal. Xaa1 is an α-amino acid residue containing a side chain, where the side chain contains an acidic or polar group, or Xaa1 is a residue of an aliphatic carboxylic acid containing an acidic or polar group at the ω position, wherein the carbonyl group of Xaa1 is covalently bonded to the α-nitrogen atom of residue Xaa2, Xaa2 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a heteroaryl or aryl ring, preferably Xaa2 is an α-amino acid residue having a side chain comprising a heteroaryl ring; wherein the carbonyl group of Xaa2 is covalently bonded to the α-nitrogen atom of residue Xaa3, Xaa3 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a heteroaryl or aryl ring, preferably Xaa3 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a heteroaryl ring; wherein the carbonyl group of Xaa3 is covalently bonded to the α-nitrogen atom of residue Xaa4, Xaa4 is an α-amino acid residue optionally containing a Z group or an N-alkylated α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa4 is covalently bonded to the α-nitrogen atom of residue Xaa5, Xaa5 is an α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa5 is covalently bonded to the α-nitrogen atom of residue Xaa6, Xaa6 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a branched aliphatic group; wherein the carbonyl group of Xaa6 is covalently bonded to the α-nitrogen atom of residue Xaa7, Xaa7 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms; wherein the carbonyl group of Xaa7 is covalently bonded to the α-nitrogen atom of residue Xaa8, Xaa8 is an α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa8 is covalently bound to the α-nitrogen atom of residue Xaa9, Xaa9 is an α-amino acid residue, wherein the carbonyl group of Xaa9 is covalently bonded to the α-nitrogen atom of residue Xaa10, Xaa10 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring; wherein the carbonyl group of Xaa10 is covalently bonded to the α-nitrogen atom of Xaa11 when Xaa11 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms, or when Xaa11 is a residue of an aliphatic bis-nucleophile, wherein a first nucleophile of the bis-nucleophile is a nitrogen atom and a second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms relative to the first nucleophile; Xaa11 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms; or Xaa11 is a residue of an aliphatic bis-nucleophile, wherein a first nucleophile of the bis-nucleophile is a nitrogen atom and a second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group consisting of a sulfur atom and a nitrogen atom; wherein Xaa7 and Xaa11 are indirectly linked or directly covalently linked to each other to form a macrocyclic ring; wherein Xaa7 and Xaa11 are indirectly linked to form a cyclic peptide of formula (Ia), the heteroatom of Xaa7 and the heteroatom of Xaa11 are linked via a ring interposed between the heteroatom of Xaa7 and the heteroatom of Xaa11 to form Yc, wherein the ring is a heteroaryl ring, an aryl ring or a heterocycle optionally containing a Z group, wherein the heteroatoms are each individually selected from the group consisting of sulfur atoms and nitrogen atoms, and wherein Xaa7 is a sulfur atom, Xaa7 is covalently bonded to the ring by a thioether bond; when the heteroatom of Xaa7 is a nitrogen atom, Xaa7 is covalently bonded to the ring by an amine or amide bond; when the heteroatom of Xaa11 is a sulfur atom, Xaa11 is covalently bonded to the ring by a thioether bond; when the heteroatom of Xaa11 is a nitrogen atom, Xaa11 is covalently bonded to the ring by an amine or amide bond; wherein, when Xaa7 and Xaa11 are directly covalently bonded to form a cyclic peptide represented by formula (Ib), the heteroatom of Xaa7 is a sulfur atom, and the heteroatom of Xaa11 is a sulfur atom, and they form a disulfide bond; and wherein, when N-terminal modification group A is present, N-terminal modification group A is a) a Z group (wherein a linker is optionally interposed between the Z group and Xaa1); b) the blocking group AblN; c) an amino acid residue optionally comprising a Z group and an amino acid residue optionally comprising a blocking group Ab1N; d) an N-terminal dipeptide group comprising a first amino acid residue and a second amino acid residue, wherein the first amino acid residue is the N-terminal amino acid residue and the second amino acid residue is the C-terminal amino acid residue, wherein the first amino acid residue optionally comprises a blocking group Ab1N, wherein the first amino acid residue and the second amino acid residue are covalently linked to each other, preferably by a peptide bond, and wherein the second amino acid residue is covalently linked to the Xaa1 residue or a linker is interposed between the second amino acid residue and the Xaa1 residue, and wherein the Z group is optionally covalently linked to the first amino acid residue and / or the Z group is optionally covalently linked to the second amino acid residue. and selected from the group comprising: and wherein, if a C-terminal group C-term is present, the C-terminal group C-term is a) an amino acid residue, wherein the amino acid residue is covalently linked to Xaa11 or a linker is interposed between the amino acid residue and Xaa11, wherein a Z group is optionally covalently linked to the amino acid residue, and wherein the amino acid residue comprises a blocking group AbIC. b) a C-terminal dipeptide group, which comprises a first amino acid residue and a second amino acid residue, wherein the first amino acid residue is the N-terminal amino acid residue and the second amino acid residue is the C-terminal amino acid residue, and wherein the first amino acid residue and the second amino acid residue are covalently linked to each other, preferably by a peptide bond, and wherein the first amino acid residue is covalently linked to the Xaa11 residue or a linker is interposed between the first amino acid residue and the Xaa1 residue, and wherein the Z group is optionally covalently linked to the first amino acid residue and / or the Z group is optionally covalently linked to the second amino acid residue, and wherein the second amino acid residue comprises a blocking group AbIC; c) Z groups and d) Blocking group AblC selected from the group comprising: compound.

[0015] Embodiment 2 Xaa1 is (a) an α-amino acid residue containing a side chain, where the side chain contains an acidic or polar group; or (b) A residue of an aliphatic carboxylic acid containing an acidic group or a polar group at the ω-position, preferably, Xaa1 is an amino acid residue represented by formula (IIa), (IIb) or (IIc), more preferably, Xaa1 is an amino acid residue represented by formula (IIa) [ka] [In the formula, R 1a is selected from the group consisting of -NH-, H, -NH((C1-C4)alkyl)-, OH, and (C1-C4)alkyl; where R 1a is selected from the group consisting of -NH- and -NH((C1-C4) alkyl)-, the N-terminal modifying group A is 1a is covalently bonded to the nitrogen atom of R 1a is selected from the group consisting of H, OH, or (C1-C4) alkyl, the N-terminal modifying group A is absent; R 1b is selected from the group consisting of CO2H, SO3H, OPO3H2, CONH2 and OH; R 1c is R 1b is selected from the group consisting of H, OH, and (C1-C2) alkyl, with the proviso that R is selected from the group consisting of CO2H, SO3H, and CONH2; 1b is selected from the group consisting of OH and OPO3H2, 1c is selected from the group consisting of H and (C1-C2) alkyl; R 1d is selected from the group consisting of H and (C1-C2) alkyl, preferably R 1c is (C1-C2) alkyl, R 1d are the same (C1-C2) alkyl, R 1e is selected from the group consisting of H, OH, and (C1-C2) alkyl; R 1fis selected from the group consisting of H and (C1-C2) alkyl, preferably R 1e is (C1-C2) alkyl, R 1f are the same (C1-C2) alkyl] is an amino acid residue represented by The carbonyl group of Xaa1 is covalently bound to the α-nitrogen atom of residue Xaa2, Xaa2 is (a) an α-amino acid residue comprising a side chain, wherein the side chain comprises a heteroaryl or aryl ring, preferably Xaa2 is an amino acid residue of formula (IIIa) or (IIIb), more preferably formula (IIIa) [ka] [In the formula, X 2a is selected from the group consisting of NH, NCH3 and S, preferably selected from the group consisting of NH and S; X 2b is selected from the group consisting of N, CH, CF and C-CH3, preferably selected from the group consisting of N and CH; R 2a is selected from the group consisting of H, halogen, methyl and OCH3, preferably R 2a is selected from the group consisting of H and F; R 2b is selected from the group consisting of H, halogen, methyl and OCH3, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2b is selected from the group consisting of H, Cl, and Br; R 2c is selected from the group consisting of H, OH, halogen, methyl and OCH3, preferably halogen is selected from the group consisting of F, Cl and Br, more preferably R 2c is selected from the group consisting of H, F and OH; R 2d is selected from the group consisting of H, halogen, methyl and OCH3, where halogen is selected from the group consisting of F, Cl and Br, preferably R2d is H, R 2e is selected from the group consisting of H, halogen and methyl, preferably halogen is Cl, more preferably R 2e is H, R 2f is selected from the group consisting of H and OCH3, preferably R 2f is H, R 2g is selected from the group consisting of H, OH, methyl and OCH3, preferably R 2g but H] or an amino acid residue represented by (b) Xaa2 is an α-amino acid residue comprising a side chain, wherein the side chain comprises an aryl ring, preferably Xaa2 is an α-amino acid residue comprising a side chain of formula (IIIc), provided that Xaa3 is of formula (IVa) or (IVb), preferably Xaa3 is of formula (IVa). [ka] [In the formula, R 2h is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and halogen, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2h is H, Cl or Br, R 2i is selected from the group consisting of H, methyl, C(CH3)3, CF3, OH, OCH3, OCH2CH3, OCF3, CONH2, CO2H and halogen, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2i is selected from the group consisting of H, Cl, and Br; R 2k is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and halogen, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2k is selected from the group consisting of H, Cl, and Br; R 2m is selected from the group consisting of H, methyl, CF3, OH, OCH3, OCF3, CONH2 and halogen, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2m is selected from the group consisting of H, Cl and Br. is an amino acid residue represented by The carbonyl group of Xaa2 is covalently bound to the α-nitrogen atom of residue Xaa3, Xaa3 is (a) an α-amino acid residue comprising a side chain, wherein the side chain comprises a heteroaryl or aryl ring, preferably Xaa3 is an amino acid residue of formula (IVa) or (IVb), more preferably Xaa3 is an amino acid residue of formula (IVa) [ka] [In the formula, X 3a is selected from the group consisting of NH, NCH3 and S, preferably selected from the group consisting of NH and S; X 3b is selected from the group consisting of CH, CF, C—Cl, C—Br, C—CH3, C—OCH3 and N, preferably X 3b is CH or CF, X 3c is selected from the group consisting of C and N, preferably X 3c But C, R 3b is selected from the group consisting of H, halogen, methyl and OCH3, preferably halogen is selected from the group consisting of F and Cl, more preferably R 3b is selected from the group consisting of H and F; R 3c is selected from the group consisting of H, halogen, methyl and OCH3, preferably halogen is selected from the group consisting of Cl, Br and F, more preferably R 3c is selected from the group consisting of Cl and Br; R 3dis selected from the group consisting of H, halogen, methyl and OCH3, preferably halogen is F; R 3e is selected from the group consisting of H, halogen and methyl, preferably halogen is Cl; R 3f is selected from the group consisting of H and OCH3; R 3g is selected from the group consisting of H, F, OH, methyl and OCH3. or an amino acid residue represented by (b) Xaa3 is an α-amino acid residue containing a side chain, wherein the side chain contains an aryl ring, provided that Xaa2 is an amino acid residue of formula (IIIa), and preferably Xaa3 is an α-amino acid residue containing an aryl ring, and preferably Xaa3 is an α-amino acid residue of formula (IVc) or (IVd): [ka] [In the formula, R 3h is selected from the group consisting of halogen, OH, methyl, CF3, OCH3, OCF3 and CONH2, preferably halogen is selected from the group consisting of Cl and Br; R 3i is selected from the group consisting of halogen, OH, methyl, CF3, OCH3, OCF3 and CONH2, preferably halogen is selected from the group consisting of Cl and Br. is an amino acid residue represented by The carbonyl group of Xaa3 is covalently bound to the α-nitrogen atom of residue Xaa4, Xaa4 is (a) a cyclic non-aromatic α-amino acid residue, preferably Xaa4 is a residue of formula (Va): [ka] [In the formula, R 4a is selected from the group consisting of H, OH, methyl, and CF3; R 4b is selected from the group consisting of H and methyl, preferably R4a is methyl, R 4b is methyl, X 4 is CHR 4c , S, and O, wherein R 4c is not present or NH2, OH, H, NHR 4d , methyl and F, preferably R 4c is NH2 or OH, where R 4d is selected from the group consisting of Ac and Z groups; m is 1 or 2, preferably m is 1. or an amino acid residue represented by (b) Xaa4 is an N-alkylated amino acid residue, preferably Xaa4 is a group represented by formula (Vb) [ka] [In the formula, n is 0, 1, 2, 3, 4 or 5, preferably n is 0, 1 or 3; R 4e When n is 0, H, methyl, aryl rings, COOH, CONH2 and C(=O)R 4h or when n is 1, 2, 3, 4 or 5, R 4e is H, methyl, aryl ring, OH, NH2, COOH, CONH2 and C(=O)R 4h selected from the group consisting of R 4f is selected from the group consisting of H and (C1-C2) alkyl; R 4g is selected from the group consisting of H and methyl; R 4h is a Z group, preferably the Z group is a biodistribution modifier, more preferably the biodistribution modifier is AGLU. or an amino acid residue represented by (c) Xaa4 is a bicyclic non-aromatic amino acid residue, preferably Xaa4 is a group represented by formula (Vc): [ka] [Wherein, o is 1 or 2] is an amino acid residue represented by The carbonyl group of Xaa4 is covalently bound to the α-nitrogen atom of residue Xaa5, Xaa5 is (a) an α-amino acid residue optionally containing a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted with (C1-C4) alkyl, or (b) a cyclic α-amino acid, wherein the carbonyl group of Xaa5 is covalently bonded to the α-nitrogen atom of Xaa6; Xaa6 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a branched chain aliphatic group, preferably Xaa6 is of formula (VIIa) [ka] [In the formula, p is 1, 0 or 2, preferably p is 1; R 6a is selected from the group consisting of (C1-C2) alkyl; R 6b is methyl, R 6c is H when p is 0, or is selected from the group consisting of H and methyl when p is 1 or 2. is an amino acid residue represented by The carbonyl group of Xaa6 is covalently bound to the α-nitrogen atom of residue Xaa7, Xaa7 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa7 is of formula (VIIIa) [ka] [In the formula, X 7 contains a heteroatom and is selected from the group consisting of -S- and -NH-; q is 1 or 2, preferably q is 1. is an α-amino acid residue represented by The carbonyl group of Xaa7 is covalently bound to the α-nitrogen atom of residue Xaa8, Xaa8 is (a) an aliphatic cyclic α-amino acid residue, an aliphatic heterocyclic α-amino acid residue, or an aliphatic cyclic α-amino acid residue containing a cyclic aromatic ring, preferably an amino acid residue represented by formula (IXa) or (IXb), more preferably an amino acid residue represented by formula (IXa) [ka] [In the formula, X 8 is NR 8a , O, NH, and CH2, wherein R 8a is a Z group or R 8a is acetyl, r is 2 or 1, preferably r is 2; s is 1 or 2, preferably s is 1; t is 1 or 2, and preferably, when s is 1, t is 1, and when s is 2, t is 2. or an amino acid residue represented by (b) Xaa8 is an α-amino acid residue or an α-alkyl-α-amino acid residue, wherein Xaa8 is preferably a group represented by formula (IXc): [ka] [In the formula, R 8b are H, OH, NH2, and NHR. 8e , (C1-C2) alkyl, COOH, CONH2, an aryl ring, and a heteroaryl ring, preferably the aryl ring is phenyl and the heteroaryl ring is 3-indolyl, wherein R 8e is a Z group, preferably the Z group is a chelator optionally including a linker; R 8c is R 8b OH, NH2 and NHR 8e When selected from the group consisting of H and methyl, or R 8b is selected from the group consisting of H, (C1-C2) alkyl, COOH, CONH2, aryl rings, and heteroaryl rings; 8c is selected from the group consisting of H, methyl and OH; R 8d is selected from the group consisting of H and (C1-C2) alkyl; u is 0, 1, 2, 3, 4 or 5, preferably u is 0, 1 or 3. is an amino acid residue represented by The carbonyl group of Xaa8 is covalently bound to the α-nitrogen atom of residue Xaa9, Xaa9 is an acyclic α-amino acid residue, wherein the acyclic α-amino acid is in the L-configuration and the carbonyl group of Xaa9 is covalently bonded to the α-nitrogen atom of Xaa10; Xaa10 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring, preferably Xaa10 is of formula (XIa) [ka] [In the formula, R 10a is selected from the group consisting of (C1-C2) alkyl and phenyl; R 10b is selected from the group consisting of methyl and H; R 10c is selected from the group consisting of H and methyl; w is 0 or 1. is an α-amino acid residue represented by when Xaa11 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising S and N, or when Xaa11 is a residue of an aliphatic bis-nucleophile, wherein a first nucleophile of the bis-nucleophile is a nitrogen atom and a second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising S and N relative to the first nucleophile, the carbonyl group of Xaa10 is covalently bonded to the α-nitrogen of Xaa11; Xaa11 is (a) an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms; or (b) Xaa11 is a residue of an aliphatic bis-nucleophile, wherein a first nucleophile of the bis-nucleophile is a nitrogen atom and a second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising sulfur and nitrogen atoms; Preferably, Xaa11 is a group of formula (XIIa) [ka] [In the formula, X 11 contains a heteroatom and is selected from the group consisting of -S- and -NH-; R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2] It is shown by Here, R in Xaa1 1a is selected from the group consisting of -NH- and -NH((C1-C4) alkyl)-, the N-terminal modifying group A is 1a wherein the N-terminal modifying group A is a) a Z group (wherein a linker is optionally interposed between the Z group and Xaa1); or b) a blocking group AblN, where the blocking group AblN is acetyl, formula (AblN-Ia) [ka] [In the formula, R Abl1 is selected from the group consisting of H, OH and halogen, where halogen is preferably selected from the group consisting of F and Cl, and preferably R Abl1 is OH] and Nph2p, preferably, AblN is of formula (AblN-Ia) or is acetyl, more preferably, AblN is acetyl) or c) an amino acid residue according to embodiment 1, wherein said amino acid is an α-amino acid, wherein said amino acid residue optionally comprises a Z group covalently attached to the side chain of said amino acid residue, optionally comprises a Z group covalently attached to the α-amino group of said amino acid residue, or wherein said amino acid residue optionally comprises a blocking group Ab1N covalently attached to the α-amino group of said amino acid residue, preferably wherein said blocking group Ab1N is acetyl and wherein the carbonyl group of said amino acid residue is linked to the R group of residue Xaa1. 1a covalently bonded to the nitrogen atom in d) an N-terminal dipeptide group according to embodiment 1, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally comprise a Z group, wherein an optional blocking group Ab1N is covalently attached to the α-amino group of the first amino acid residue, and wherein a linker is optionally interposed between the second amino acid residue and residue Xaa1, and wherein, in the absence of an intervening linker, the carbonyl group of the first amino acid residue is covalently attached to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is 1aor where, when an intervening linker is present, the carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is covalently bonded to a nitrogen atom of the linker, and the carbonyl group of the linker is covalently bonded to a nitrogen atom of R 1a (covalently bonded to the nitrogen atom in and selected from the group comprising: wherein Xaa11 is a group represented by formula (XIIa) [In the formula, R 11b But C(=O)R 11c and R 11c is the C-terminal group C-terminus], the C-terminus is a) an amino acid residue according to embodiment 1, wherein said amino acid is an α-amino acid optionally comprising a Z group and optionally comprising an intervening linker between the residue of Xaa11 and said amino acid residue, and wherein if there is no intervening linker, the carbonyl group R of residue Xaa11 11b is covalently attached to the α-nitrogen of this amino acid residue, or where an intervening linker is present, R of residue Xaa11 11b is covalently bonded to the nitrogen atom of a linker, wherein the carbonyl group of the linker is covalently bonded to the α-nitrogen of said amino acid residue, and wherein a blocking group Ab1C is covalently bonded to the carbonyl group of said amino acid residue, wherein the blocking group Ab1C is selected from the group consisting of NH2 and OH, and wherein the blocking group Ab1C is preferably NH2; or b) a C-terminal dipeptide group, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally contain a Z group, and wherein a linker is optionally interposed between the residue Xaa11 and the first amino acid residue, and wherein, in the absence of an intervening linker, the carbonyl group R of residue Xaa11 11bis covalently bound to the α-nitrogen of a first amino acid residue, and the carbonyl group of the first amino acid residue is covalently bound to the α-nitrogen of a second amino acid residue, or where an intervening linker is present, the carbonyl group R of residue Xaa11 11b is covalently bonded to a nitrogen atom of the linker, a carbonyl group of the linker is covalently bonded to the α-nitrogen of a first amino acid residue, the carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of a second amino acid residue, and a blocking group AblC is covalently bonded to the carbonyl group of the second amino acid residue, and the blocking group AblC is selected from the group consisting of NH and OH, and wherein the blocking group AblC is preferably NH; and c) Z group 2. The compound of embodiment 1, selected from the group comprising:

[0016] Embodiment 3 Xaa7 is a group represented by formula (VIIIa) [ka] [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a compound represented by the formula (XIIIa) [ka] [In the formula, R Ya is -CH2-, R Yb is -CH2-, Y 1 is selected from the group consisting of N and CH; Y 2 is selected from the group consisting of CH and N. The structure is represented by Xaa11 is a group represented by formula (XIIa) [ka] [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ic) [ka] The cyclic peptide comprises: More preferably, the compound has the formula (Ic) [where, X 7 is -S- and X 11 is -S- and Y 1 is N or CH, and Y 2 is CH, q is 1, and x is 1; Most preferably, the compound has the formula (Ic) [where, X 7 is -S- and X 11 is -S- and Y 1 is N and Y 2 is CH, q is 1, and x is 1.

[0017] Embodiment 4 X 7 is -S- and X 11 is -S- and Y 1 is N or CH, and Y 2 is CH; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0018] Embodiment 5 X 7 is -S- and X 11 is -S- and Y 1 is N and Y 2

[0023] Embodiment 5. The compound according to any one of embodiments 3 and 4, wherein is CH, q is 1, and x is 1.

[0019] EMBODIMENT 6 4. The compound of embodiment 3, wherein Xaa7 is an α-amino acid residue selected from the group consisting of Cys, cys, Hcy, and Dap, wherein Xaa11 is a residue selected from the group consisting of Cys, cys, Hcy, AET, Cysol, en, and Dap, and wherein Yc is selected from the group consisting of 2Lut, 3MeBn, and 3Lut.

[0020] EMBODIMENT 7 A compound according to any one of embodiments 3, 4 and 6, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is selected from 2Lut and 3MeBn, preferably 2Lut.

[0021] EMBODIMENT 8 A compound according to any one of embodiments 3, 4, 5, 6 and 7, preferably embodiment 7, wherein Xaa7 is a Cys residue, wherein Xaa11 is a Cys residue, and wherein Yc is 2Lut.

[0022] EMBODIMENT 9 X 7 is -NH- and X 11 is -S- and Y 1 is N or CH, preferably Y 1 is N and Y 2 is CH; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0023] EMBODIMENT 10 A compound according to any one of embodiments 3 and 9, preferably embodiment 9, wherein Xaa7 is a Dap residue, wherein Xaa11 is a residue selected from the group consisting of Cys, cys, Hcy, AET, Cysol, and wherein Yc is selected from 2Lut and 3MeBn, preferably Yc is 2Lut.

[0024] EMBODIMENT 11 X 7 is -S- and X 11 is -NH- and Y 1 is N or CH, preferably Y 1 is N and Y 2 is CH and q is 1 or 2, preferably q is 1 and x is 1.

[0025] EMBODIMENT 12 A compound according to any one of embodiments 3, 6 and 11, preferably embodiment 11, wherein Xaa7 is a Cys or Hcy residue, preferably Xaa7 is a Cys residue, and wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is selected from 2Lut and 3MeBn, preferably Yc is 2Lut.

[0026] EMBODIMENT 13 X 7 is -NH- and X 11 is -NH- and Y 1 is N or CH, preferably Y 1 is N and Y 2 is CH; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0027] EMBODIMENT 14 A compound according to any one of embodiments 3, 6 and 13, preferably embodiment 13, wherein Xaa7 is a Dap residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is selected from 2Lut and 3MeBn, preferably Yc is 2Lut.

[0028] EMBODIMENT 15 Xaa7 is a group represented by formula (VIIIa) [ka] [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a compound represented by the formula (XIIIh) [ka] [In the formula, R Ya is -CH2-, R Yb is -CH2-, R Yc is -CH2-R Yd and R Yd is represented by formula (XIIIc), (XIIId) or (XIIIe) [ka] [In the formula, R Ye and R Yf are each independently selected from the group consisting of H and (C1-C4) alkyl; each i is independently 1, 2, 3, 4, 5 or 6, preferably i is 1 or 2; j and k are each independently 1, 2, or 3; X is O or S, preferably X is S; Here, in formulas (XIIIc) and (XIIIe), One of the two nitrogen atoms is R Yc is covalently bonded to -CH2- in In formula (XIIId), -X- is R Yc is covalently bonded to -CH2- in while the remaining nitrogen atom optionally has a Z group covalently attached thereto, preferably the Z group comprising a chelator and optionally a linker. The structure is shown below. The structure is represented by Xaa11 is a group represented by formula (XIIa) [ka] [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ii) [ka] The cyclic peptide comprises: More preferably, the compound has the formula (Ii) [In the formula, X 7 is -S- and X 11 is -S-, R Yc is -CH2-R Yd and R Yd is represented by formula (XIIId) or (XIIIe) [In the formula, R Yfis H, i is 1, j is 1, k is 1, wherein in formula (XIIId), -X- is S and R Yc In formula (XIIIe), one of the two nitrogen atoms is bonded to -CH2-, and in formula (XIIIe), one of the two nitrogen atoms is bonded to -CH2-. Yc is bonded to -CH2- while the remaining nitrogen atom of either (XIIId) or (XIIIe) optionally has a Z group covalently attached thereto, preferably the Z group comprises a chelator and optionally a linker; q is 1, x is 1] The cyclic peptide comprises: Most preferably, the compound has the formula (Ii) [In the formula, R Yd is a structure represented by formula (XIIId), where -X- is S and R Yf is H and i is 1] 3. The compound of any one of embodiments 1 and 2, comprising a cyclic peptide of the formula:

[0029] EMBODIMENT 16 The compound according to embodiment 15, wherein Xaa7 is a Cys residue, wherein Xaa11 is a Cys residue, and wherein Yc is tMeBn(DOTA-AET) or tMeBn(DOTA-PP).

[0030] EMBODIMENT 17 Xaa7 is a group represented by formula (VIIIa) [ka] [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a compound represented by the formula (XIIIb) [ka] [In the formula, R Ya is -CH2-, R Yb is -CH2-] The structure is represented by Xaa11 is a group represented by formula (XIIa) [ka] [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Id) [ka] The cyclic peptide comprises: More preferably, the compound has formula (Id) [where, X 7 is -S- and X 11 is -S-, q is 1, and x is 1] 3. The compound of embodiment 1 or 2, comprising a cyclic peptide of the formula:

[0031] EMBODIMENT 18 X 7 is -S- and X 11 is -S-; q ​​is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0032] EMBODIMENT 19 A compound according to any one of embodiments 17 and 18, preferably embodiment 18, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is 2MeBn.

[0033] EMBODIMENT 20 X 7 is -NH- and X 11 is -S-; q ​​is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0034] EMBODIMENT 21 A compound according to any one of embodiments 17 and 20, preferably embodiment 20, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is 2MeBn.

[0035] EMBODIMENT 22 X 7 is -S- and X 11 is —NH—; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0036] EMBODIMENT 23 A compound according to any one of embodiments 17 and 22, preferably embodiment 22, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is 2MeBn.

[0037] EMBODIMENT 24 X 7 is -NH- and X 11 is —NH—; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0038] EMBODIMENT 25 A compound according to any one of embodiments 17 and 24, preferably embodiment 24, wherein Xaa7 is a Dap residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is 2MeBn.

[0039] EMBODIMENT 26 Xaa7 is a group represented by formula (VIIIb) [ka] [In the formula, q is 1 or 2, and preferably q is 1] is a residue represented by Yc is a group represented by the formula (XIIIg) [ka] [In the formula, R Yi is selected from the group consisting of H and (C1-C6) alkyl. The structure is represented by Xaa11 is a group represented by formula (XIIb) [ka] [In the formula, R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ig) [ka] The cyclic peptide comprises: More preferably, the compound has the formula (Ig) [Wherein q is 1 and x is 1 or 2] 3. The compound of any one of embodiments 1 and 2, comprising a cyclic peptide of the formula:

[0040] EMBODIMENT 27 27. The compound according to embodiment 26, wherein Xaa7 is a Cys residue, wherein Xaa7 is selected from the group comprising Cys, Hcy, Cysol and AET, and wherein Yc is mli.

[0041] EMBODIMENT 28 Yc is a compound represented by the formula (XIIIf) [ka] [In the formula, R Yg is -C(=O)-, R Yh is -CH2-] The structure is represented by Xaa7 is a group represented by formula (VIIIa) [ka] [In the formula, X 7 is -S- or -NH-, and R Yh is covalently bonded to q is 1 or 2, preferably q is 1. is a residue represented by Xaa11 is a group represented by formula (XIIa) [ka] [In the formula, X 11 is -NH- and R Yg is covalently bonded to R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (If) [ka] The cyclic peptide comprises: More preferably, the compound has the formula (If) 7 is -S-, q is 1, and x is 1.

[0042] EMBODIMENT 29 X 7 is -S-; q ​​is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0043] EMBODIMENT 30 A compound according to any one of embodiments 28 and 29, preferably embodiment 29, wherein Xaa7 is a Cys or Hcy residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is 3CbBn.

[0044] EMBODIMENT 31 X 7 is —NH—; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0045] EMBODIMENT 32 A compound according to any one of embodiments 28 and 30, preferably embodiment 30, wherein Xaa7 is a Dap residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is 3CbBn.

[0046] EMBODIMENT 33 Yc is a compound represented by the formula (XIIIf) [ka] [In the formula, R Yg is -C(=O)-, R Yh is -CH2-] The structure is represented by Xaa7 is a group represented by formula (VIIIa) [ka] [In the formula, X 7 is -NH- and R Yg is covalently bonded to q is 1 or 2, preferably q is 1. is a residue represented by Xaa11 is a group represented by formula (XIIa) [ka] [In the formula, X 11 is -S- or -NH-, and R Yh is covalently bonded to R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ie) [ka] The cyclic peptide comprises: More preferably, the compound has the formula (Ie) 11 is -S-, q is 1, and x is 1.

[0047] EMBODIMENT 34 X 11 is -S-; q ​​is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0048] EMBODIMENT 35 A compound according to any one of embodiments 33 and 34, preferably embodiment 34, wherein Xaa7 is a Dap residue, wherein Xaa11 is a Cys or Hcy residue, and wherein Yc is 3MeBz.

[0049] EMBODIMENT 36 X 11 is —NH—; q is 1 or 2, preferably q is 1; and x is 1 or 2, preferably x is 1.

[0050] EMBODIMENT 37 A compound according to any one of embodiments 33 and 36, preferably embodiment 36, wherein Xaa7 is a Dap residue, wherein Xaa11 is an 'en' or Dap residue, and wherein Yc is 3MeBz.

[0051] EMBODIMENT 38 The compound comprises a cyclic peptide of formula (Ib): Xaa7 is a group represented by formula (VIIIc) [ka] is a residue represented by Xaa11 is a group represented by the formula (XIIc) [ka] [In the formula, R 11b is C(=O)R 11c , CONH2, CO2H, CH2OH, and H, wherein R 11c is the C-terminus] is a residue represented by Preferably, the compound has the formula (Ih) [ka] 3. The compound of any one of embodiments 1 and 2, comprising a cyclic peptide of the formula:

[0052] EMBODIMENT 39 The compound of embodiment 38, wherein Xaa7 is an Hcy residue and Xaa11 is an Hcy residue.

[0053] EMBODIMENT 40 Xaa1 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a residue of an aliphatic carboxylic acid comprising an acidic or polar group in the side chain or a further acidic or polar group in the ω-position of formula (IId) or (IIe), preferably Xaa1 is of formula (IId) [ka] [In the formula, R 1a is selected from the group consisting of -NH-, H, or -N(CH3)-; R 1b is selected from the group consisting of CO2H, CONH2, OH, SO3H and OPO3H2; R 1a is —NH— or —N(CH3)—, and the N-terminal modifying group A is R 1a covalently bonded to the nitrogen atom of 40. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 and 39, wherein

[0054] EMBODIMENT 41 Xaa1 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a residue of an aliphatic carboxylic acid comprising an acidic or polar group in the side chain or a further acidic or polar group in the ω-position of formula (IIf) or (IIg), more preferably Xaa1 is a residue of formula (IIf) [ka] [In the formula, R 1a is selected from the group consisting of -NH-, H, or -N(CH3)-; R 1b is selected from the group consisting of CO2H, CONH2, OH, SO3H and OPO3H2; R 1a is —NH— or —N(CH3)—, and the N-terminal modifying group A is R 1a covalently bonded to the nitrogen atom of 41. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 and 40, wherein

[0055] EMBODIMENT 42 Xaa1 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a residue of an aliphatic carboxylic acid comprising an acidic or polar group in the side chain or a further acidic or polar group in the ω-position of formula (IIf) or (IIg), more preferably Xaa1 is a residue of formula (IIf) [In the formula, R 1a is —NH— or H, R 1b is selected from the group consisting of CO2H, CONH2, OH, and SO3H; R 1a is -NH-, and the N-terminal modifying group A is R 1a covalently bonded to the nitrogen atom of 42. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, preferably the compound according to embodiment 41, wherein

[0056] EMBODIMENT 43 Xaa1 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a residue of an aliphatic carboxylic acid comprising an acidic or polar group in the side chain or a further acidic or polar group in the ω-position of formula (IIf) or (IIg), more preferably Xaa1 is a residue of formula (IIf) [In the formula, R 1a is -NH-, R 1b is CO2H or CONH2, The N-terminal modification group A is R 1a covalently bonded to the nitrogen atom of 36, 37, 38, 39, 40, 41 and 42, preferably a compound according to embodiment 42, wherein the amino acid residue is

[0057] EMBODIMENT 44 42. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, wherein Xaa1 is an α-L-amino acid residue selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya, Pse, Nmd and Ser, or a dicarboxylic acid residue selected from the group consisting of succinyl and glutaric acid.

[0058] EMBODIMENT 45 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 and 44, preferably the compound according to embodiment 44, wherein Xaa1 is an α-L-amino acid residue selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya and Ser, or a dicarboxylic acid residue selected from the group consisting of succinyl and glutaric acid.

[0059] EMBODIMENT 46 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and 45, preferably the compound according to any one of embodiments 44 and 45, wherein Xaa1 is an α-L-amino acid residue selected from the group consisting of Asp, Asn, Glu and Gln.

[0060] EMBODIMENT 47 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 and 46, preferably the compound according to any one of embodiments 44, 45 and 46, wherein Xaa1 is an Asp residue.

[0061] EMBODIMENT 48 Xaa2 is a group represented by the formula (IIId) [ka] [In the formula, X 2ais NH or S, preferably NH, R 2a is H or F, R 2b is selected from the group consisting of H, F and Cl; R 2c is selected from the group consisting of H, F, Cl, Br and OH. 48. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, wherein

[0062] EMBODIMENT 49 Xaa2 is a group represented by the formula (IIId) [In the formula, X 2a is NH, R 2a is H or F, R 2b is H, R 2c is H, F or OH] 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 48, preferably a compound according to embodiment 47, wherein

[0063] EMBODIMENT 50 49. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48, wherein Xaa2 is an α-L-amino acid residue selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, Bta, 5Clw, 5Brw, and 6Fw.

[0064] EMBODIMENT 51 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 and 50, preferably the compound according to embodiment 50, wherein Xaa2 is an α-L-amino acid residue selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, 5Clw, 5Brw and 6Fw.

[0065] EMBODIMENT 52 52. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 and 51, preferably the compound according to any one of embodiments 50 and 51, wherein Xaa2 is an α-L-amino acid residue selected from the group consisting of Trp, Hyw, 5Fw and 7Fw.

[0066] EMBODIMENT 53 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 and 52, preferably the compound according to any one of embodiments 50, 51 and 52, wherein Xaa2 is a Trp residue.

[0067] EMBODIMENT 54 48. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, and 47, wherein Xaa2 is 1Ni.

[0068] EMBODIMENT 55 Xaa2 is of formula (IIIc) provided that Xaa3 is of formula (IVa) or (IVb), preferably provided that Xaa3 is of formula (IVa). [ka] [In the formula, R 2h is H or Cl, R 2i is H or Cl, R 2k is H or Cl, R 2m is H or Cl] 48. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, wherein

[0069] EMBODIMENT 56 A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 and 55, preferably a compound according to embodiment 55, wherein Xaa2 is an α-L-amino acid residue selected from the group consisting of Phe, Ocf, Mcf, Pcf, Eaa, Egm, Egn and Egp, provided that Xaa3 is of formula (IVa) or (IVb), preferably provided that Xaa3 is of formula (IVa).

[0070] EMBODIMENT 57 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 55 and 56, preferably the compound according to any one of embodiments 55 and 56, provided that Xaa3 is of formula (IVa) or (IVb), preferably Xaa3 is of formula (IVa).

[0071] EMBODIMENT 58 Xaa3 is a group represented by the formula (IVe) or (IVf) [ka] [In the formula, R 3b is H or F, R 3c is selected from the group consisting of Cl, Br, H and F; X 3a is NH or S, X3b is selected from the group consisting of CH, CF and N; X 3c is CH or N, preferably X 3c but CH] 58. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 and 57, wherein

[0072] EMBODIMENT 59 Xaa3 is a group represented by the formula (IVg) [ka] [In the formula, R 3b is H or F, R 3c is selected from the group consisting of Cl, Br and H. 57, 58, preferably a compound according to embodiment 58, wherein the amino acid residue is

[0073] EMBODIMENT 60 58. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, and 57, wherein Xaa3 is an α-L-amino acid residue selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw, 7Fw, 6Clw, and 7Nw.

[0074] EMBODIMENT 61 60, preferably a compound according to any one of embodiments 58 and 60, wherein Xaa3 is an α-L-amino acid residue selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw and 7Fw.

[0075] EMBODIMENT 62 52, 53, 54, 55, 56, 57, 58, 59, 60 and 61, preferably a compound according to any one of embodiments 58, 59, 60 and 61, wherein Xaa3 is an α-L-amino acid residue selected from the group consisting of 5Clw and 5Brw.

[0076] 63. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 and 62, preferably a compound according to any one of embodiments 58, 59, 60, 61 and 62, wherein Xaa3 is a 5Clw residue.

[0077] 64th embodiment Xaa2 is of formula (IIIa) or (IIIb), preferably Xaa3 is of formula (IVc) or (IVd), provided that Xaa2 is of formula (IIIa). [ka] [In the formula, R 3i and R 3h are each independently Cl] 55. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 and 54, wherein

[0078] EMBODIMENT 65 A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 and 64, preferably a compound according to embodiment 64, provided that Xaa2 is of formula (IIIa) or (IIIb), preferably Xaa3 is Eaa or Egp, provided that Xaa2 is of formula (IIIa).

[0079] 66. The method of claim 66, Xaa4 is a group represented by the formula (Va) [ka] [In the formula, m is 1 or 2, preferably m is 1; R 4a is selected from the group consisting of H, OH, and methyl; R 4b is either H or methyl, preferably R 4a is methyl, R 4b is methyl, X 4 is CHR 4c , CH2, S and O, wherein R 4c However, NHR 4d , NH2, H, OH, methyl, and F, wherein R 4d is an Ac or Z group, preferably when the Z group is a chelator optionally comprising a linker, more preferably the chelator is DOTA, and when the Z group is a biodistribution modifier optionally comprising a linker, more preferably the biodistribution modifier is AGLU, and the optional linker is preferably glutaric acid. 66. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 and 65, wherein

[0080] 67. The method of claim 67, Xaa4 is a group represented by the formula (Vd) [ka] [In the formula, R 4a is selected from the group consisting of H, OH, and methyl; R 4b is H or methyl, preferably R 4a is methyl, R 4b is methyl, R 4i are NH2, OH, and NHR 4d , H and F, wherein R 4d is H, Ac or a Z group, and when the Z group is a chelating agent including an optional linker, preferably the chelating agent is DOTA, and when the Z group is a biodistribution modifier including an optional linker, preferably the biodistribution modifier is AGLU, and the optional linker is preferably glutaric acid. 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66, preferably a compound according to embodiment 66, wherein the amino acid residue is

[0081] 68. The method of claim 68, Xaa4 is a group represented by the formula (Ve) [ka] [In the formula, R 4i is selected from the group consisting of NH2, OH and H. 67, preferably a compound according to any one of embodiments 66 and 67, wherein the amino acid residue is

[0082] 69. The method of claim 69, 10. The method of claim 1, wherein Xaa4 is an α-L-amino acid residue selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), Tap(AGLU-glutaric), 4Tfp, H3p, Eaz, Oxa, Dtc, and Pip. , 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66, preferably a compound according to embodiment 66.

[0083] EMBODIMENT 70 10. The method of claim 1, wherein Xaa4 is an alpha-L-amino acid residue selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), Tap(AGLU-glutaric), 4Tfp, H3p, Eaz, Oxa, and Dtc. , 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 and 69, preferably a compound according to any one of embodiments 66 and 69.

[0084] EMBODIMENT 71 10. The method of claim 1, wherein Xaa4 is an alpha-L-amino acid residue selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), Tap(AGLU-glutaric), 4Tfp and H3p. , 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69 and 70, preferably a compound according to any one of embodiments 66, 67, 69 and 70.

[0085] EMBODIMENT 72 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70 and 71, preferably a compound according to any one of embodiments 66, 67, 68, 69, 70 and 71.

[0086] EMBODIMENT 73 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71 and 72, preferably a compound according to any one of embodiments 66, 67, 68, 69, 70, 71 and 72.

[0087] EMBODIMENT 74 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71 and 72, preferably a compound according to any one of embodiments 66, 67, 68, 69, 70, 71 and 72.

[0088] EMBODIMENT 75 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71 and 72, preferably a compound according to any one of embodiments 66, 67, 68, 69, 70, 71 and 72.

[0089] EMBODIMENT 76 Xaa4 is a group represented by the formula (Vf) [ka] [In the formula, n is 0, 1 or 3; R 4e is selected from the group consisting of H and phenyl when n=0, or R 4e is NH2 or n=1, R 4e Methyl, COH and C(=O)R 4h wherein R 4h is a Z group, preferably the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is more preferably AGLU; R 4f is selected from the group consisting of H and methyl. 66. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, and 65, wherein

[0090] EMBODIMENT 77 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 76, preferably the compound according to embodiment 76, wherein Xaa4 is an N-alkylated amino acid residue selected from the group consisting of Nmg, Nlys, Nleu, Nphe, Nglu and Nglu(AGLU).

[0091] EMBODIMENT 78 66. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, and 65, wherein Xaa4 is an Oic residue.

[0092] EMBODIMENT 79 Xaa5 is an α-amino acid residue optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by a methyl group, , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 and 78.

[0093] EMBODIMENT 80 Xaa5 is represented by formula (VIa) or (IVb), and preferably Xaa5 is represented by formula (VIa) [ka] [In the formula, R 5a are H, COOH, SO3H, OPO3H, CONH2, OH, NH2, and NHR 5d , NHC(=NH)NH, aryl and heteroaryl rings (preferably, the aryl ring is phenyl and the heteroaryl ring is 3-indolyl or 4-imidazolyl), and (C1-C4) alkyl, preferably R 5a is COOH, where R 5d is a Z group, R 5b is selected from the group of H and methyl, preferably R 5b is H, d is 1, 2, 3, 4 or 5, preferably d is 2; R 5c is selected from the group comprising H and OH, e is 1 or 2. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, The compound according to any one of embodiments 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 and 79, preferably a compound according to embodiment 79.

[0094] EMBODIMENT 81 Xaa5 is a group represented by formula (VIa) [In the formula, R 5a is selected from the group comprising COOH, CONH2, OH, NH2, NHC(=NH)NH2 and a heteroaryl ring, preferably the heteroaryl ring is 3-indolyl or 4-imidazoyl, preferably R 5a is COOH, d is 1, 2, 3, 4 or 5, preferably d is 2; R 5b is H] 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 330, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 7, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80, preferably a compound according to any one of embodiments 79 and 80.

[0095] EMBODIMENT 82 Xaa5 is a group represented by formula (VIa) [In the formula, R5a is selected from the group comprising COOH, CONH2, OH, preferably R 5a is COOH, d is 1 or 2, preferably d is 2. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 330, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 8, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 and 81, preferably a compound according to any one of embodiments 79, 80 and 81.

[0096] 83rd Embodiment The configuration of Xaa5 is L- or D-configuration, preferably L-configuration, according to embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46. , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 and 82, preferably a compound according to any one of embodiments 80, 81 and 82, more preferably a compound according to embodiment 82.

[0097] 84th embodiment 10. The amino acid residues of any one of the preceding embodiments, wherein Xaa5 is an α-amino acid residue selected from the group consisting of Glu, Gln, Asp, Asn, Ser, Hse, Pse, Nme, glu, Ala, Trp, Lys, Arg, His, Hly, Har, Val and Phe. 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80, preferably a compound according to any one of embodiments 79 and 80.

[0098] EMBODIMENT 85 30, 31, 32, 33, 34, 35, 36, 37, 38, wherein Xaa5 is an α-amino acid residue selected from the group consisting of Glu, Gln, Asp, Asn, Ser, Hse, Trp, Lys, Arg, His, Hly and Har; A compound according to any one of embodiments 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83 and 84, preferably a compound according to any one of embodiments 79, 80, 81, 83 and 84.

[0099] 86. The method of claim 85, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, wherein Xaa5 is an α-amino acid residue selected from the group consisting of Glu, Gln, Asp, Asn, Ser and Hse. 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84 and 85, preferably any one of the compounds according to embodiments 79, 80, 81, 83, 84 and 85.

[0100] EMBODIMENT 87 3. The amino acid sequence of claim 1, wherein Xaa5 is a Glu residue. A compound according to any one of embodiments 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85 and 86, preferably a compound according to any one of embodiments 76, 77, 78, 79, 80, 81, 83, 84, 85 and 86.

[0101] 88. Embodiment 88 Xaa5 is a cyclic α-amino acid residue, preferably Xaa5 is a Pro residue, 6, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 and 78.

[0102] EMBODIMENT 89 Xaa6 is a group represented by formula (VIIa) [ka] [In the formula, p is 1 or 0, preferably p is 1; R 6a is (C1-C2) alkyl, R 6b is methyl, R 6c is H when p is 0, and is H or methyl when p is 1. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87 and 88.

[0103] EMBODIMENT 90 Xaa6 is in the L- or D-configuration, preferably in the D-configuration, The compound according to any one of 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88 and 89, preferably a compound according to embodiment 89.

[0104] EMBODIMENT 91 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44. In one embodiment, Xaa6 is an α-amino acid residue selected from the group consisting of leu, Leu, Npg, Val, Ile, and Hle. , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89 and 90, preferably a compound according to any one of embodiments 89 and 90.

[0105] EMBODIMENT 92 Xaa6 is an α-amino acid residue selected from the group consisting of leu, Leu, Npg, Val and He, 6, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90 and 91, preferably a compound according to any one of embodiments 89, 90 and 91.

[0106] EMBODIMENT 93 3. The amino acid sequence of claim 1, wherein Xaa6 is a leu residue. 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91 and 92, preferably a compound according to any one of embodiments 89, 90, 91 and 92.

[0107] EMBODIMENT 94 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, wherein Xaa5 is in the L configuration and Xaa6 is in the D configuration, or Xaa5 is in the D configuration and Xaa6 is in the L configuration, preferably Xaa5 is in the L configuration and Xaa6 is in the D configuration. , 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 and 93, preferably a compound according to any one of embodiments 83 and 90.

[0108] EMBODIMENT 95 Xaa8 is a group represented by the formula (IXa) [ka] [In the formula, r is 2 or 1, preferably r is 2; X 8 is NR 8a , O, NH, and CH2, wherein R 8a is a Z group or R 8ais acetyl, and wherein when the Z group is a chelating agent optionally comprising a linker, preferably the chelating agent is DOTA, or when the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid, or when the Z group is a combination of a chelating agent optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelating agent optionally comprising a linker and the biodistribution modifier optionally comprising a linker, preferably the chelating agent is DOTA, the biodistribution modifier is preferably AGLU, and the amino acid residue linking the chelating agent and the biodistribution modifier is preferably a glu residue. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94.

[0109] EMBODIMENT 96 Xaa8 is a group represented by the formula (IXd) [ka] [In the formula, X 8 is NR 8a , O, and NH, wherein R 8a is a Z group or R 8ais acetyl, where if the Z group is a chelator optionally with a linker, preferably the chelator is DOTA, or if the Z group is a biodistribution modifier optionally with a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 95, preferably a compound according to embodiment 95.

[0110] EMBODIMENT 97 Xaa8 is a group represented by the formula (IXd) [In the formula, X 8 is NR 8a or O, where R 8a is a Z group or R 8a is acetyl, where the Z group is a chelator optionally including a linker, preferably the chelator is DOTA. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 and 96, preferably a compound according to any one of embodiments 95 and 96.

[0111] EMBODIMENT 98 Xaa8 is Apc(R 8a ), Apc, Thp, Egz, and Eca, and 8a is a Z group, wherein when the Z group is a chelating agent optionally comprising a linker, preferably the chelating agent is DOTA, or when the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid; or when the Z group is a combination of a chelating agent optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelating agent optionally comprising a linker and the biodistribution modifier optionally comprising a linker, preferably the chelating agent is DOTA, the biodistribution modifier is preferably AGLU, and the amino acid residue linking the chelating agent and the biodistribution modifier is preferably a glu residue or R 8ais acetyl. , 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 95, preferably a compound according to embodiment 95.

[0112] EMBODIMENT 99 Xaa8 is Apc(R 8a ), Apc, and Thp, wherein R 8a is a Z group, where if the Z group is a chelator optionally comprising a linker, preferably the chelator is DOTA or if the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid or R 8a is acetyl, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 and 98, preferably a compound according to any one of embodiments 95, 96 and 98.

[0113] Embodiment 100 Xaa8 is Apc(R 8a ), where R 8a is a Z group, wherein the Z group is a chelator optionally including a linker, wherein the chelator is a) Preferably DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Mac Ropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcophagin, FSC, NETA, NE3TA, H4 Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99m selected from the group consisting of Tc(CO)3-chelators and analogs thereof; b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) Most preferably, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 are selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof. , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99, preferably a compound according to any one of embodiments 95, 96, 97, 98 and 99.

[0114] EMBODIMENT 101 3. The method of claim 1, wherein the chelating agent is DOTA. A compound according to any one of embodiments 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100, preferably a compound according to any one of embodiments 95, 96, 97, 98, 99 and 100, most preferably a compound according to embodiment 100.

[0115] EMBODIMENT 102 Xaa8 is Apc(R 8a ), where R 8a is a Z group, wherein the Z group is an in vivo modifying agent optionally including a linker, wherein the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) More preferably, AGLU or NTASEROL with glutaric acid as the linker; c) most preferably AGLU with glutar as linker, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 98 and 99, preferably a compound according to any one of embodiments 95, 96, 98 and 99.

[0116] EMBODIMENT 103 Xaa8 is Apc(R 8a ), where R 8a is a Z group, wherein the Z group is a combination of a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker, preferably the chelator is DOTA, the biodistribution modifier is AGLU, and the amino acid linking the chelator and the biodistribution modifier is glu, wherein this combination is represented by formula (IXe) [ka] 3. The method of claim 1, wherein the compound is selected from the group consisting of: 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 95, preferably a compound according to embodiment 95.

[0117] EMBODIMENT 104 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94.

[0118] EMBODIMENT 105 Xaa8 is Lys, Lys(R 8e ), lys(R 8e ), Amk(R 8e ), Dab(R 8e ) and dab(R 8e ), wherein R 8eis a Z group, preferably wherein the Z group is a chelator optionally comprising a linker; 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94.

[0119] EMBODIMENT 106 Xaa8 is Lys(R 8e ), lys(R 8e ), Amk(R 8e ), Dab(R 8e ) and dab(R 8e ), wherein R 8e is a Z group, wherein the Z group is a chelator optionally including a linker, wherein the chelator is a) Preferably DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Mac Ropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcophagin, FSC, NETA, NE3TA, H4 Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99m selected from the group consisting of Tc(CO)3-chelators and analogs thereof; b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) Most preferably, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 and 105, preferably a compound according to embodiment 105.

[0120] EMBODIMENT 107 30, 31, 32, 33, 34, 35, 36, 37, 38, wherein Xaa8 is an α-amino acid residue selected from the group consisting of Aib, Deg, Ams, ala, Ala, Gln, Thr, Trp, Phe and Glu. 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 and 94.

[0121] EMBODIMENT 108 Xaa9 is a group represented by the formula (Xa) [ka] [In the formula, R 9ais selected from the group consisting of (C1-C4) alkyl, COOH, CONH2, OH, NH2, NHC(=NH)NH2, an aryl ring, and a heteroaryl ring, preferably, the aryl ring is phenyl, and the heteroaryl ring is 3-indolyl and cyclohexyl; R 9b is methyl or H, R 9c is H or methyl, v is 0, 1, or 2, and preferably v is 1. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 and 107.

[0122] EMBODIMENT 109 Xaa9 is a group represented by the formula (Xa) [In the formula, R 9a is selected from the group consisting of (C1-C2) alkyl, COOH, OH, NHC(=NH)NH2, an aryl ring, and a heteroaryl ring, preferably, the aryl ring is phenyl, and the heteroaryl ring is 3-indolyl and cyclohexyl; R 9b is methyl or H, R 9c is H, v is 0, 1, or 2, and preferably v is 1. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 107, 108, 110, 111a, 111b, 111c, 111d, 111e, 111f, 111g, 111h, 111i ...

[0123] EMBODIMENT 110 Xaa9 is an alpha-L-amino acid residue selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe, Ser, Cha, Npg and Tle, , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 and 108, preferably a compound according to embodiment 108.

[0124] EMBODIMENT 111 Xaa9 is an α-L-amino acid residue selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe and Ser, , 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109 and 110, preferably a compound according to any one of embodiments 108, 109 and 110.

[0125] EMBODIMENT 112 Xaa9 is a Leu residue, 102, 103, 104, 105, 106, 107, 108, 109, 110 and 111, preferably a compound according to any one of embodiments 108, 109, 110 and 111.

[0126] EMBODIMENT 113 Xaa10 is a group represented by formula (XIa) [ka] [In the formula, R 10a is selected from the group consisting of (C1-C2) alkyl and phenyl, preferably R 10a is (C1-C2) alkyl, more preferably, the (C1-C2) alkyl is ethyl; R 10b is selected from the group consisting of methyl and H, preferably R 10b is methyl, R 10c is selected from the group consisting of H and methyl, and when w is 1, R 10C is H, preferably R 10c is H, w is 0 or 1, preferably w is 0. 3. The amino acid residues of any one of the following embodiments are represented by the formula: 9, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 and 112.

[0127] EMBODIMENT 114 Xaa10 is a group represented by formula (XIa) [In the formula, R 10a is selected from (C1-C2) alkyl, preferably ethyl; R 10b is selected from the group consisting of methyl and H, preferably R10b is methyl, R 10c is selected from the group consisting of H and methyl, and when w is 1, R 10C is H, preferably R 10c is H, w is 0 or 1, preferably w is 0. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 112 and 113, preferably a compound according to embodiment 113.

[0128] EMBODIMENT 115 3. The amino acid sequence of claim 1, wherein Xaa10 is an alpha-L-amino acid residue selected from the group consisting of Ile, Leu, Tle, Val and Phe. 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, and 113, preferably a compound according to embodiment 113.

[0129] EMBODIMENT 116 and Xaa10 is an α-L-amino acid residue selected from the group consisting of Ile, Leu and Tle. 114 and 115, preferably a compound according to any one of embodiments 113, 114 and 115.

[0130] EMBODIMENT 117 Xaa10 is an He residue, 115, and 116, preferably a compound according to any one of embodiments 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, and 116, preferably a compound according

[0131] EMBODIMENT 118 R in Xaa1 1a is —NH— or —N(CH3)—, or a compound according to any one of embodiments 44, 45, 46, and 47, wherein Xaa1 is an amino acid residue selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya, Pse, Nmd, and Ser, the N-terminal modification group A is R at Xaa1. 1aIn one embodiment, the compound is covalently bonded to a 116, and 117, preferably a compound according to any one of embodiments 40, 41, 42, and 43.

[0132] EMBODIMENT 119 The N-terminal modifying group A is a) a Z group (wherein a linker is optionally interposed between the Z group and Xaa1, and where the Z group is a chelator optionally comprising a linker, or the Z group is a biodistribution modifier optionally comprising a linker, or the Z group is a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and a combination of amino acid residues linking a chelator optionally comprising a linker and a biodistribution modifier optionally comprising a linker). b) a blocking group AblN, wherein the blocking group AblN is selected from the group consisting of acetyl and a group of formula (AblN-Ia) [ka] [In the formula, R Abl1 is selected from the group consisting of H, OH and halogen, preferably halogen is selected from the group consisting of F and Cl, preferably R Abl1 is OH] and preferably, AblN is selected from the group consisting of Ac, 4OHPhp, 4FPhp, 4ClPhp and Php. c) an amino acid residue, wherein the amino acid is an α-amino acid, wherein the amino acid residue optionally comprises a Z group covalently attached to a side chain of the amino acid residue, optionally comprises a Z group covalently attached to the α-amino group of the amino acid residue, or wherein the amino acid residue optionally comprises a blocking group Ab1N covalently attached to the α-amino group of the amino acid residue, preferably the blocking group Ab1N is acetyl, wherein the amino acid residue is preferably a Tyr residue with an optional Z group covalently attached to the α-amino group of the Tyr residue, and wherein the Z group is a chelator with an optional linker, wherein the chelator is preferably DOTA and the linker is preferably Ttds. d) N-terminal dipeptide groups, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally comprise a Z group, wherein a blocking group Ab1N is optionally covalently attached to the α-amino group of the first amino acid residue, wherein a linker is optionally interposed between the second amino acid residue and residue Xaa1, and wherein, in the absence of an intervening linker, the carbonyl group of the first amino acid residue is covalently attached to the α-nitrogen of the second amino acid residue, and wherein the carbonyl group of the second amino acid residue is optionally linked to the α-nitrogen of R 1a or the α-nitrogen atom of residue Xaa1, or where, when an intervening linker is present, the carbonyl group of the first amino acid residue is covalently bound to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is covalently bound to a nitrogen atom of the linker, and the carbonyl group of the linker is covalently bound to the nitrogen atom of R 1a or the α-nitrogen atom of residue Xaa1, wherein the first amino acid residue is a Met residue and the second amino acid residue is selected from the group consisting of Ala, Tyr and tyr. 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117 and 118, preferably a compound according to embodiment 118.

[0133] EMBODIMENT 120 16. The N-terminal modification group A is a Z group, wherein a linker is optionally interposed between the Z group and residue Xaa1, wherein the Z group is a chelator optionally comprising a linker, or the Z group is a biodistribution modifier optionally comprising a linker, or the Z group is a combination of a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker, wherein the linker is optionally interposed between the amino acid residue linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker and residue Xaa1, preferably any linker is APAc, 020c, or PEG6. 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 116, 117, 118 and 119, preferably a compound according to any one of embodiments 118 and 119.

[0134] EMBODIMENT 121 The Z group is a biodistribution modifier optionally comprising a linker, wherein the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) More preferably, AGLU or NTASEROL with glutaric acid as the linker; c) Most preferably, it is an AGLU having glutar as a linker, A compound according to any one of embodiments 1, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably a compound according to any one of embodiments 118, 119 and 120, more preferably a compound according to embodiment 120.

[0135] EMBODIMENT 122 3. The method of claim 1, wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is AGLU and the linker is glutaric acid. 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 121, preferably a compound according to any one of embodiments 118, 119, 120 and 121, more preferably a compound according to embodiment 121.

[0136] EMBODIMENT 123 The Z group is a chelator, optionally including a linker, where the chelator is a) Preferably DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Mac Ropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcophagin, FSC, NETA, NE3TA, H4 Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99m selected from the group consisting of Tc(CO)3-chelators and analogs thereof; b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) Most preferably, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, MACROPA, PCTA and analogs thereof. , 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably a compound according to any one of embodiments 118, 119 and 120, more preferably a compound according to embodiment 120.

[0137] EMBODIMENT 124 31. The Z group is a chelator optionally comprising a linker, wherein the chelator is DOTA with an optional linker, preferably wherein the linker is APAc or Ttd. , 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 123, preferably a compound according to any one of embodiments 118, 119, 120 and 123, more preferably a compound according to embodiment 123.

[0138] EMBODIMENT 125 The Z group is a combination of a chelator optionally with a linker, a biodistribution modifier optionally with a linker, and an amino acid residue connecting the chelator optionally with a linker and the biodistribution modifier optionally with a linker, wherein the chelator is a) Preferably DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Mac Ropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcophagin, FSC, NETA, NE3TA, H4 Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99m selected from the group consisting of Tc(CO)3-chelators and analogs thereof; b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof; The biodistribution modifier is a) preferably selected from the group consisting of AGLU, GLUSEROL, AHOL, APOL, ABOL, APrOL, b) More preferably, AGLU, wherein the amino acid residue linking the chelating agent, optionally including a linker, and the biodistribution modifier, optionally including a linker, is a glu residue; wherein an optional linker is interposed between the amino acid residue connecting the chelator, optionally comprising a linker, and the biodistribution modifier, optionally comprising a linker, and residue Xaa1, and preferably the linker is APAc, O2Oc or PEG6. , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120, preferably a compound according to embodiment 120.

[0139] EMBODIMENT 126 the Z group is a combination of a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker, wherein the linker is optionally interposed between the amino acid residue linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker and residue Xaa1; the chelating agent is DOTA, the linker optionally included in the chelating agent is O2Oc or PEG6; the biodistribution modifier is AGLU; the amino acid residue connecting the chelator, optionally including a linker, and the biodistribution modifier, optionally including a linker, is a glu residue; 55. The linker optionally interposed between the amino acid residue connecting the chelator, optionally including a linker, and the biodistribution modifier, optionally including a linker, and residue Xaa1, is APAc, O2Oc, or PEG6. , 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 and 125, preferably a compound according to embodiment 125.

[0140] EMBODIMENT 127 Xaa11 is a group represented by formula (XIIa), (XIIb) or (XIIc) [In the formula, R11b But C(=O)R 11c where R 11c is the C-terminus] In embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 2 9, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125 and 126.

[0141] EMBODIMENT 128 C-terminal group is a) an amino acid residue, which is an α-amino acid optionally containing a Z group and optionally containing an intervening linker between the residue of Xaa11 and said amino acid residue, and in the absence of an intervening linker, the carbonyl group R of residue Xaa11 11b is covalently attached to the α-nitrogen of this amino acid residue, or where an intervening linker is present, R of residue Xaa11 11b is covalently bonded to the nitrogen atom of a linker, wherein the carbonyl group of the linker is covalently bonded to the α-nitrogen of said amino acid residue, and wherein a blocking group Ab1C is covalently bonded to the carbonyl group of said amino acid residue, wherein the blocking group Ab1C is selected from the group consisting of NH2 and OH, and wherein the blocking group Ab1C is preferably NH2; or b) a C-terminal dipeptide group, wherein the first amino acid residue is an α-amino acid residue and the second amino acid residue is an α-amino acid residue, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally contain a Z group, and wherein a linker is optionally interposed between the residue at Xaa11 and the first amino acid residue, and wherein, in the absence of an intervening linker, the carbonyl group R of Xaa11 11b is covalently linked to the α-nitrogen of a first amino acid residue, and the carbonyl group of the first amino acid residue is covalently linked to the α-nitrogen of a second amino acid residue, or where an intervening linker is present, the carbonyl group R of Xaa11 11b is covalently bonded to a nitrogen atom of a linker, a carbonyl group of the linker is covalently bonded to the α-nitrogen of a first amino acid residue, the carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of a second amino acid residue, and a blocking group AblC is covalently bonded to the carbonyl group of the second amino acid residue, and the blocking group AblC is selected from the group consisting of NH2 and OH, and wherein the blocking group AblC is preferably NH2; or c) Z group 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126 and 127, preferably a compound according to embodiment 127.

[0142] EMBODIMENT 129 The C-terminus is an α-amino acid residue, wherein the α-amino acid is i) an α-amino acid comprising a side chain AaaA, wherein the side chain comprises an amino group, wherein a Z group is covalently attached to the amino group by an amide bond, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator is a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A″-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcofadin, FSC, NETA, NE3TA, H4Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99mTc(CO)3-chelators and analogues thereof; b) More preferably, it is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof) or ii) an α-amino acid comprising a side chain AaaB, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond, wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) More preferably, it is MeO36PEG or NTASEROL. or iii) an α-amino acid comprising a side chain AaaC, wherein the side chain comprises a COOH group, wherein a Z group is covalently attached to the COOH group by an amide bond, wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is a) preferably selected from the group consisting of AGLU, GLUSEROL, AHOL, APOL, ABOL and APrOL; b) More preferably, it is AGLU. is selected from wherein the blocking group AblC is NH2; 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127 and 128, preferably a compound according to any one of embodiments 127 and 128.

[0143] EMBODIMENT 130 the C-terminal group C-term is an α-amino acid residue comprising a side chain AaaA, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the α-amino acid residue is preferably a Lys or lys residue; wherein the Z group is a chelator optionally comprising a linker, wherein the chelator is preferably DOTA; wherein any linker intervening between residue Xaa11 and this α-amino acid residue is preferably APAc or Ttds, , 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 and 129, preferably a compound according to any one of embodiments 127, 128 and 129, more preferably a compound according to embodiment 129.

[0144] EMBODIMENT 131 the C-terminal group C-term is an α-amino acid residue comprising a side chain AaaB, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the α-amino acid residue is preferably an α-amino acid residue selected from the group comprising Lys, dap and lys; 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, A compound according to any one of embodiments 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129 and 130, preferably a compound according to any one of embodiments 127, 128 and 129, more preferably a compound according to embodiment 129.

[0145] EMBODIMENT 132 the C-terminal group C-term is an α-amino acid residue comprising a side chain AaaC, wherein the side chain comprises a COOH group to which a Z group is covalently attached via an amide bond; wherein the α-amino acid residue is preferably a glu residue, wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is preferably AGLU; wherein any linker intervening between residue Xaa11 and this α-amino acid residue is preferably APAc or Ttds, , 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 and 129, preferably a compound according to any one of embodiments 127, 128 and 129, more preferably a compound according to embodiment 129.

[0146] EMBODIMENT 133 16. The method of claim 1, wherein the α-amino acid residue is a glu residue, the biodistribution modifier is AGLU, and the linker intervening between residue Xaa11 and the glu residue is APAc. , 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129 and 132, preferably a compound according to any one of embodiments 127, 128, 129 and 132, more preferably a compound according to embodiment 132.

[0147] EMBODIMENT 134 the C-terminal group C-term is a C-terminal dipeptide group, wherein the first of the two amino acid residues is an α-amino acid residue comprising a side chain AaaB, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) More preferably, it is MeO2kDaPEGAc; wherein the second of the two amino acid residues is an α-amino acid residue comprising a side chain AaaA, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the Z group is a chelator optionally including a linker, wherein the chelator is a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A″-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcofadin, FSC, NETA, NE3TA, H4Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99mTc(CO)3-chelators and analogues thereof; b) More preferably, it is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof; wherein the blocking group AblC is NH2; 31. The method of claim 1, wherein an optional linker is interposed between residue Xaa11 and the first of the two amino acid residues of the C-terminal dipeptide group, wherein the linker is preferably APAc or Ttds. , 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 127 and 128, preferably a compound according to any one of embodiments 127 and 128.

[0148] EMBODIMENT 135 a first of the two amino acid residues is an α-amino acid residue comprising a side chain AaaB, wherein the side chain comprises an amino group to which a Z group is covalently linked by an amide bond; wherein the first amino acid residue is preferably a Lys residue; wherein the Z group attached to the first of the two amino acid residues is a biodistribution modifier, optionally including a linker; wherein the biodistribution modifier is preferably a MeO2kDaPEGAc residue; wherein the second of the two amino acid residues is an α-amino acid residue comprising a side chain AaaA, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the second amino acid residue is preferably a Lys residue; 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 , 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 and 134, preferably a compound according to any one of embodiments 127, 128 and 134, more preferably a compound according to embodiment 134.

[0149] EMBODIMENT 136 the C-terminal group C-term is a C-terminal dipeptide group, wherein the first of the two amino acid residues is an α-amino acid residue comprising a side chain AaaC, wherein the side chain comprises a COOH group to which a Z group is covalently attached by an amide bond; wherein the first amino acid residue is preferably a glu residue; wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is a) preferably selected from the group consisting of AGLU, GLUSEROL, AHOL, APOL, ABOL and APrOL; b) More preferably, AGLU, wherein the second of the two amino acid residues is an α-amino acid residue comprising a side chain AaaA, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the first amino acid residue is preferably a Lys residue; wherein the Z group is a chelator optionally including a linker, wherein the chelator is a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A″-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcofadin, FSC, NETA, NE3TA, H4Octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99mTc(CO)3-chelators and analogues thereof; b) More preferably, it is selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof; 31. The method of claim 1, wherein an optional linker is interposed between residue Xaa11 and the first of the two amino acid residues of the C-terminal dipeptide group, wherein the linker is preferably APAc or Ttds. , 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106 127 and 128, preferably a compound according to any one of embodiments 127 and 128.

[0150] EMBODIMENT 137 a first of the two amino acid residues is an α-amino acid residue comprising a side chain AaaC, wherein the side chain comprises a COOH group to which a Z group is covalently linked by an amide bond; wherein the first amino acid residue is preferably a glu residue; wherein the Z group is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is preferably an AGLU residue; wherein the second of the two amino acid residues is an α-amino acid residue comprising a side chain AaaA, wherein the side chain comprises an amino group to which a Z group is covalently attached via an amide bond; wherein the first amino acid residue is preferably a Lys residue or a lys residue; 3. Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 , 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 and 136, preferably a compound according to any one of embodiments 127, 128 and 136, more preferably a compound according to embodiment 136.

[0151] EMBODIMENT 138 the C-terminus is a Z group; wherein when the Z group is a chelator optionally comprising a linker, the chelator is preferably DOTA, and the optional linker is preferably selected from the group consisting of PP and Ape; wherein when the Z group is a biodistribution modifier optionally comprising a linker, the biodistribution modifier is preferably GLUSEROL and the optional linker is preferably APAc, , 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127 and 128, preferably a compound according to any one of embodiments 127 and 128.

[0152] EMBODIMENT 139 Xaa11 is a group represented by formula (XIIa) [In the formula, R 11b But C(=O)R 11c where R 11c but is C-term] and the C-terminal group C-term is a group Z, wherein the group Z is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is preferably GLUSEROL, and the optional linker is preferably APAc. 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 , 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 and 138, preferably a compound according to any one of embodiments 127, 128 and 138, more preferably a compound according to embodiment 138.

[0153] EMBODIMENT 140 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138 and 139.

[0154] EMBODIMENT 141 The Z group is a) Provided that Xaa4 is a structure represented by formula (Va), (Vd) or (Ve), a substituent R 4d is covalently bonded to or part of b) Provided that Xaa4 is a structure represented by formula (Vb) or (Vf), a substituent R 4h is covalently bonded to or part of c) providing that Xaa5 is a structure represented by formula (VIa), a substituent R 5d is covalently bonded to or part of d) Substituent R 8a is covalently bonded to or part of e) providing that Xaa8 is a structure represented by formula (XIc), a substituent R 8e is covalently bonded to or part of f) Yc is residue RYc Formula (XIIIh) containing [In the formula, R Yc to residue R Yd are covalently bonded, where R Yd is a structure represented by formula (XIIIc), (XIIId) or (XIIIe). The substituent R Yd is covalently bonded to or part of g) N-terminal modification group A is covalently attached to the α-amino acid residue of h) covalently attached to one of the two residues of the N-terminal dipeptide group; i) covalently attached to an α-amino acid residue at the C-terminus; j) is part of or forms the N-terminal modification group A; or k) the C-terminus, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139 and 140, preferably a compound according to embodiment 140.

[0155] EMBODIMENT 142 The Z group is a) Provided that Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a is covalently bonded to or part of b) providing that Xaa8 is a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; d) is part of or forms the N-terminal modification group A; or e) the C-terminus, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 140 and 141, preferably a compound according to embodiment 141.

[0156] EMBODIMENT 143 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 1 4, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138 and 139.

[0157] EMBODIMENT 144 Each of the two or more Z groups is a) Provided that Xaa4 is a structure represented by formula (Va), (Vd) or (Ve), a substituent R 4d is covalently bonded to or part of b) Provided that Xaa4 is a structure represented by formula (Vb) or (Vf), a substituent R 4h is covalently bonded to or part of c) providing that Xaa5 is a structure represented by formula (VIa), a substituent R 5d is covalently bonded to or part of d) Substituent R 8a is covalently bonded to or part of e) providing that Xaa8 is a structure represented by formula (XIc), a substituent R 8e is covalently bonded to or part of f) Yc is residue R Yc Formula (XIIIh) comprising: Yc to residue R Yd are covalently bonded, where R Yd is a structure represented by formula (XIIIc), (XIIId) or (XIIIe), Yd is covalently bonded to or part of g) N-terminal modification group A is covalently attached to the α-amino acid residue of h) covalently attached to one of the two residues of the N-terminal dipeptide group; i) covalently attached to an α-amino acid residue at the C-terminus; j) covalently attached to one of the two residues of the C-terminal dipeptide group; k) is part of or forms the N-terminal modification group A; or l) the C-terminus, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139 and 143, preferably a compound according to embodiment 143.

[0158] EMBODIMENT 145 Each of the two or more Z groups is a) Provided that Xaa4 is a structure represented by formula (Va), (Vd) or (Ve), a substituent R 4d is covalently bonded to or part of b) Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), and the substituent R 8a is covalently bonded to or part of c) providing that Xaa8 has a structure represented by formula (XIc), a substituent R 8e is covalently bonded to or part of d) covalently attached to an α-amino acid residue at the C-terminus; e) covalently attached to one of the two residues of the C-terminal dipeptide group; f) is part of or forms the N-terminal modification group A, or g) the C-terminus, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 200, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 238, 239, 243, and 244, preferably a compound according to embodiment 244.

[0159] EMBODIMENT 146 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, wherein the compound comprises two to four Z groups, preferably two to three Z groups, more preferably three Z groups, and most preferably one of the three Z groups is a chelator, optionally including a linker, and the other two of the three Z groups are biodistribution modifiers, each optionally including a linker. , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 6, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115 , 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144 and 145, preferably a compound according to any one of embodiments 144 and 145, more preferably a compound according to embodiment 145.

[0160] EMBODIMENT 147 The compound comprises two Z groups, wherein one of the two Z groups is a chelator optionally comprising a linker, and the other of the two Z groups is a biodistribution modifier optionally comprising a linker, wherein the chelator optionally comprising a linker is preferably a) Provided that Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a is covalently bonded to or part of b) providing that Xaa8 is a structure represented by formula (XIc), 8eis covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; or d) covalently attached to one of the two residues of the C-terminal dipeptide group; wherein the biodistribution modifier, optionally including a linker, is a) Provided that Xaa4 is a structure represented by formula (Va), (Vd) or (Ve), a substituent R 4d is covalently bonded to or part of b) covalently attached to an α-amino acid residue at the C-terminus; c) covalently attached to one of the two residues of the C-terminal dipeptide group; or d) being part of or forming the N-terminal modification group A, , 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, A compound according to any one of embodiments 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0161] EMBODIMENT 148 The chelating agent, optionally including a linker, preferably comprises a substituent R 8a is covalently bonded to or part of wherein the biodistribution modifier optionally comprising a linker is preferably a) covalently attached to an α-amino acid residue at the C-terminus; or b) part of or forming the N-terminal modification group A, 9, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 1 143, 144, 145, 146 and 147, preferably a compound according to any one of embodiments 143, 144, 145, 146 and 147, more preferably a compound according to embodiment 147.

[0162] EMBODIMENT 149 a chelator, optionally including a linker, is preferably covalently attached to one of the two residues of the C-terminal dipeptide group; wherein a biodistribution modifier, optionally including a linker, is covalently attached to the other of the two residues of the C-terminal dipeptide group. 2, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146 and 147, preferably a compound according to any one of embodiments 143, 144, 145, 146 and 147, more preferably a compound according to embodiment 147.

[0163] EMBODIMENT 150 the compound comprises two Z groups, wherein one of the two Z groups is a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and a combination of amino acid residues connecting the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker, and the other of the two Z groups is a biodistribution modifier optionally comprising a linker, wherein the combination of the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker forms an N-terminal modification group A; wherein the biodistribution modifier optionally comprising a linker is preferably a) providing that Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), a substituent R8a is covalently bonded to or part of b) providing that Xaa8 is a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus, , 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, A compound according to any one of embodiments 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0164] EMBODIMENT 151 The compound comprises three Z groups, wherein one of the three Z groups is a chelator optionally comprising a linker, and the other two of the three Z groups are biodistribution modifiers optionally comprising linkers, wherein the chelator optionally comprising a linker is preferably a) Provided that Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a is covalently bonded to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; or d) is part of or forms the N-terminal modification group A; wherein either of the two biodistribution modifiers, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a is covalently bonded to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; or d) being part of or forming the N-terminal modification group A, , 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, A compound according to any one of embodiments 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0165] EMBODIMENT 152 a chelator, optionally including a linker, is part of or forms the N-terminal modification group A; wherein one of the two biodistribution modifiers, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, wherein the other of the two biodistribution modifiers, optionally including a linker, is covalently attached to an α-amino acid residue at the C-terminus. 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 , 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 1 3, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146 and 151, preferably a compound according to any one of embodiments 143, 144, 145, 146 and 151, more preferably a compound according to embodiment 151.

[0166] EMBODIMENT 153 The chelating agent, optionally including a linker, a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of wherein one of the two biodistribution modifiers, each optionally comprising a linker, is part of or forms the N-terminal modification group A; wherein the other of the two biodistribution modifiers, each optionally comprising a linker, is covalently attached to an α-amino acid residue at the C-terminus. 0, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 8 0, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 3, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146 and 151, preferably a compound according to any one of embodiments 143, 144, 145, 146 and 151, more preferably a compound according to embodiment 151.

[0167] EMBODIMENT 154 a chelator, optionally including a linker, covalently attached to an α-amino acid residue at the C-terminus; wherein one of the two biodistribution modifiers, each optionally comprising a linker, is part of or forms the N-terminal modification group A; wherein the other of the two biodistribution modifiers, each optionally containing a linker, is a) Provided that Xaa8 is a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 128, 130, 131, 132, 133, 134, 135, 1 1, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88 , 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146 and 151, preferably a compound according to any one of embodiments 143, 144, 145, 146 and 151, more preferably a compound according to embodiment 151.

[0168] EMBODIMENT 155 the compound comprises three Z groups, wherein one of the three Z groups is a chelator optionally with a linker, a biodistribution modifier optionally with a linker, and a combination of amino acid residues linking the chelator optionally with a linker and the biodistribution modifier optionally with a linker, and the other two of the three Z groups are each a biodistribution modifier optionally with a linker, wherein the combination of the chelator optionally with a linker and the biodistribution modifier optionally with a linker forms an N-terminal modification group A; One of the two biodistribution modifiers, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of wherein the other of the two biodistribution modifiers, each optionally comprising a linker, is covalently attached to an α-amino acid residue at the C-terminus. 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 , 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 , 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0169] EMBODIMENT 156 The compound comprises three Z groups, wherein one of the three Z groups is a chelator optionally with a linker, a biodistribution modifier optionally with a linker, and a combination of amino acid residues connecting the chelator optionally with a linker and the biodistribution modifier optionally with a linker, and the other two of the three Z groups are biodistribution modifiers optionally with a linker, wherein the combination of the chelator optionally with a linker and the biodistribution modifier optionally with a linker is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of wherein one of the two biodistribution modifiers, each optionally comprising a linker, is part of or forms the N-terminal modification group A; wherein the other of the two biodistribution modifiers, each optionally comprising a linker, is covalently attached to an α-amino acid residue at the C-terminus. , 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 8, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 , 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0170] EMBODIMENT 157 the compound comprises four Z groups, wherein one of the four Z groups is a chelator optionally comprising a linker, and the other three of the four Z groups are biodistribution modifiers, each optionally comprising a linker, wherein the chelator optionally comprising a linker is preferably covalently attached to one of the two residues of the C-terminal dipeptide group; the first of the three biodistribution modifiers, optionally including a linker, is part of or forms the N-terminal modification group A; The second of the three biodistribution modifiers, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 140, 8, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 The compound according to any one of embodiments 1, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably the compound according to any one of embodiments 143, 144, 145 and 146, more preferably the compound according to embodiment 146.

[0171] EMBODIMENT 158 the compound comprises four Z groups, wherein each of the four Z groups is a chelator optionally including a linker; wherein the first of the four chelating agents, each optionally including a linker, has a substituent R 4d is covalently bonded to or part of a second chelator of the four chelators, each optionally comprising a linker, a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of a third of the four chelators, each optionally including a linker, is part of or forms the N-terminal modification group A; 20. Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, wherein a fourth chelator of the four chelators, each optionally including a linker, is covalently attached to an α-amino acid residue at the C-terminus. , 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0172] EMBODIMENT 159 the compound comprises three Z groups, wherein each of the three Z groups is a chelator optionally including a linker; wherein a first of three chelating agents, each optionally comprising a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of wherein a second of the three chelators, each optionally including a linker, is part of or forms the N-terminal modification group A; 20. The method of claim 1, wherein the third of the three chelators, each optionally comprising a linker, is covalently attached to an α-amino acid residue at the C-terminus. , 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0173] EMBODIMENT 160 the compound comprises two Z groups, wherein each of the two Z groups is a chelator optionally comprising a linker; wherein a first of the two chelating agents, each optionally comprising a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), a substituent R 8a or is covalently bound to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of a second of the two chelating agents, each optionally comprising a linker, a) is part of or forms the N-terminal modification group A; or b) covalently attached to an α-amino acid residue at the C-terminus, , 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, A compound according to any one of embodiments 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0174] EMBODIMENT 161 the compound comprises two Z groups, wherein each of the two Z groups is a chelator optionally comprising a linker; wherein a first of the two chelators, each optionally including a linker, is part of or forms the N-terminal modification group A; 20. The method of claim 1, wherein the second of the two chelators, each optionally comprising a linker, is covalently attached to an α-amino acid residue at the C-terminus. , 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145 and 146, preferably a compound according to any one of embodiments 143, 144, 145 and 146, more preferably a compound according to embodiment 146.

[0175] EMBODIMENT 162 Xaa1 is Asp, Asn, Glu, Gln, succinyl, glutaric acid, or Cya; Xaa2 is Trp, Hyw, 5Fw, 6Clw, or 7Fw; Xaa3 is 5Clw, 5Brw, 5Fw, Trp, 1Ni, Bta, 6Fw, or Trp; Xaa4 is Tap, Hyp, 4Tfp, Pro, H3p, Eaz, Oxa, Dtc, Nmg, Nleu, Nlys, Nphe, or Nglu; Xaa5 is Glu, glu, Nme, Gln, Asp, Asn, or Hse; and Xaa6 is leu, Leu, or Npg. 9. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa7 is Cys or Hcy, Xaa8 is Apc(DOTA), Thp, Apc, Aib, Deg, Ams, Amk(DOTA), Egz, Eca or ala, Xaa9 is Leu, Hle, Ile, Phe, Glu, Arg, Ser or Trp, Xaa10 is Ile, Leu, Val or Tle, Xaa11 is Cys, Hcy or AET, and Yc is 3MeBn or 3Lut.

[0176] EMBODIMENT 163 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa1 is Asp, Glu or succinyl, Xaa2 is Trp or Hyw, Xaa3 is 5Clw or 5Brw, Xaa4 is Tap, Hyp or Pro, Xaa5 is Glu, Xaa6 is leu or Leu, Xaa7 is Cys, Xaa8 is Apc(DOTA) or Thp, Xaa9 is Leu, Xaa10 is Ile, Xaa11 is Cys, and Yc is 3Lut.

[0177] EMBODIMENT 164 A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7 and 8, wherein Xaa1 is Asp, Xaa2 is Trp, Xaa3 is 5Clw, Xaa4 is Tap or Hyp, Xaa5 is Glu, Xaa6 is leu, Xaa7 is Cys, Xaa8 is Apc(DOTA), Xaa9 is Leu, Xaa10 is Ile, Xaa11 is Cys, and Yc is 3Lut.

[0178] EMBODIMENT 165 The N-terminal modifying group A is a) a Z group (wherein a linker is optionally interposed between the Z group and Xaa1, and where the Z group is a chelator optionally comprising a linker, or the Z group is a biodistribution modifier optionally comprising a linker, or the Z group is a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and a combination of amino acid residues linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker); b) a blocking group AblN, wherein the blocking group AblN is selected from the group consisting of acetyl and a group of formula (AblN-Ia) [ka] [In the formula, R Abl1 is selected from the group consisting of H, OH and halogen, where halogen is preferably selected from the group consisting of F and Cl, and preferably R Abl1 is OH] and preferably, AblN is selected from the group consisting of Ac, 4OHPhp, 4FPhp, 4ClPhp and Php), c) an α-amino acid residue, wherein the α-amino acid residue optionally comprises a Z group covalently attached to a side chain of the α-amino acid residue, optionally comprises a Z group covalently attached to the α-amino group of the α-amino acid residue, or wherein the α-amino acid residue optionally comprises a blocking group Ab1N covalently attached to the α-amino group of the α-amino acid residue, preferably the blocking group Ab1N is acetyl, and wherein the α-amino acid residue is preferably a Tyr residue, and wherein the Z group is optionally covalently attached to the α-amino group of the Tyr residue, and wherein the Z group is a chelator optionally comprising a linker, and wherein the chelator is preferably DOTA and the linker is preferably Ttds, d) N-terminal dipeptide groups, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally comprise a Z group, wherein a blocking group Ab1N is optionally covalently attached to the α-amino group of the first amino acid residue, wherein a linker is optionally interposed between the second amino acid residue and residue Xaa1, and wherein, in the absence of an intervening linker, the carbonyl group of the first amino acid residue is covalently attached to the α-nitrogen of the second amino acid residue, and wherein the carbonyl group of the second amino acid residue is optionally linked to the α-nitrogen of R 1a or the α-nitrogen atom of residue Xaa1, or where, when an intervening linker is present, the carbonyl group of the first amino acid residue is covalently bound to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is covalently bound to a nitrogen atom of the linker, and the carbonyl group of the linker is covalently bound to the nitrogen atom of R 1a or the α-nitrogen atom of residue Xaa1, wherein the first amino acid residue is a Met residue and the second amino acid residue is selected from the group consisting of Ala, Tyr and tyr. 9. The compound of any one of embodiments 1, 2, 3, 4, 5, 6, 7, and 8, wherein

[0179] EMBODIMENT 166 the N-terminal modification group A is: a) selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL; or b) selected from the group consisting of Ac, Php, 4FPhp, 4ClPhp and 4OHPhp, preferably 4OHPhp; or c) DOTA-Ttds-Tyr or Ac-Tyr, or d) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162 and 165, preferably a compound according to any one of embodiments 162 and 165, which is Met-Tyr, Met-tyr or Met-Ala.

[0180] EMBODIMENT 167 The N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA, provided that Xaa1 is selected from the group consisting of Asp, Asn, Glu, Gln, and Cya. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 165 and 166, preferably the compound according to any one of embodiments 162, 165 and 166, more preferably the compound according to embodiment 166, which is selected from the group consisting of DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL.

[0181] EMBODIMENT 168 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162 and 165 to 167, preferably the compound according to any one of embodiments 162 and 165 to 167, more preferably the compound according to embodiment 167, wherein the N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, DOTA-glu(AGLU)-APAc, DOTA and DOTA-Ttds, preferably AGLU-glutaric or NTASEROL, provided that Xaa1 is selected from the group consisting of Asp, Asn, Glu, Gln and Cya.

[0182] EMBODIMENT 169 the N-terminal modification group A is: a) selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL; or b) selected from the group consisting of Ac, Php, 4FPhp, 4ClPhp and 4OHPhp, preferably 4OHPhp; or c) DOTA-Ttds-Tyr or Ac-Tyr, or d) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 163 and 165, preferably a compound according to any one of embodiments 163 and 165, which is Met-Tyr, Met-tyr or Met-Ala.

[0183] EMBODIMENT 170 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 163, 165 and 169, preferably the compound according to any one of embodiments 163, 165 and 169, more preferably the compound according to embodiment 169, wherein the N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL, with the proviso that Xaa1 is selected from the group consisting of Asp and Glu.

[0184] EMBODIMENT 171 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 163, 165, 169 and 170, preferably the compound according to any one of embodiments 163, 165, 169 and 170, more preferably the compound according to embodiment 170, wherein the N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, DOTA-glu(AGLU)-APAc, DOTA and DOTA-Ttds, preferably AGLU-glutaric or NTASEROL, provided that Xaa1 is selected from the group consisting of Asp and Glu.

[0185] EMBODIMENT 172 The N-terminal modification group A is a) selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL; or b) selected from the group consisting of Ac, Php, 4FPhp, 4ClPhp and 4OHPhp, preferably 4OHPhp; or c) DOTA-Ttds-Tyr or Ac-Tyr, or d) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164 and 165, preferably a compound according to any one of embodiments 164 and 165, which is Met-Tyr, Met-tyr or Met-Ala.

[0186] EMBODIMENT 173 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 165 and 172, preferably the compound according to any one of embodiments 164, 165 and 172, more preferably the compound according to embodiment 172, wherein the N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, DOTA, DOTA-Ttds, DOTA-APAc, MeO36PEG-APAc, MeO2kDaPEGAc, DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU) and DOTA-glu(AGLU)-PEG6, preferably AGLU-glutaric or NTASEROL.

[0187] EMBODIMENT 174 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 165, 172 and 173, preferably the compound according to any one of embodiments 164, 165, 172 and 173, more preferably the compound according to embodiment 173, wherein the N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, DOTA-glu(AGLU)-APAc, DOTA and DOTA-Ttds, preferably AGLU-glutaric or NTASEROL.

[0188] EMBODIMENT 175 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 165, 172, 173 and 174, preferably the compound according to any one of embodiments 164, 165, 172, 173 and 174, more preferably the compound according to embodiment 174, wherein the N-terminal modification group A is AGLU-glutaric.

[0189] EMBODIMENT 176 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 165, 172, 173 and 174, preferably the compound according to any one of embodiments 164, 165, 172, 173 and 174, more preferably the compound according to embodiment 174, wherein the N-terminal modification group A is NTASEROL.

[0190] EMBODIMENT 177 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 165, 172, 173 and 174, preferably the compound according to any one of embodiments 164, 165, 172, 173 and 174, more preferably the compound according to embodiment 174, wherein the N-terminal modification group A is DOTA-glu(AGLU)-APAc.

[0191] EMBODIMENT 178 C-terminal group is a) an α-amino acid residue (the α-amino acid residue optionally comprises a Z group and optionally comprises an intervening linker between the residue of Xaa11 and the α-amino acid residue, where, if no intervening linker is present, the carbonyl group R of Xaa11 11b is covalently attached to the α-nitrogen of the α-amino acid residue, or where an intervening linker is present, R of Xaa 11b is covalently bonded to a nitrogen atom of a linker, wherein the carbonyl group of the linker is covalently bonded to the α-nitrogen of an α-amino acid residue, and wherein a blocking group Ab1C is covalently bonded to the carbonyl group of the α-amino acid residue, wherein the blocking group Ab1C is selected from the group consisting of NH2 and OH, and wherein the blocking group Ab1C is preferably NH2; or b) a C-terminal dipeptide group, wherein the first amino acid residue is an α-amino acid residue and the second amino acid residue is an α-amino acid residue, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally contain a Z group, and wherein a linker is optionally interposed between the residue at Xaa11 and the first amino acid residue, and wherein, in the absence of an intervening linker, the carbonyl group R of residue Xaa11 11b is covalently bound to the α-nitrogen of a first amino acid residue, and the carbonyl group of the first amino acid residue is covalently bound to the α-nitrogen of a second amino acid residue, or where an intervening linker is present, the carbonyl group R of residue Xaa11 11b is covalently bonded to a nitrogen atom of a linker, a carbonyl group of the linker is covalently bonded to the α-nitrogen of a first amino acid residue, the carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of a second amino acid residue, and a blocking group AblC is covalently bonded to the carbonyl group of the second amino acid residue, and the blocking group AblC is selected from the group consisting of NH2 and OH, and wherein the blocking group AblC is preferably NH2; or c) Z group 9. The compound of any one of embodiments 1, 2, 3, 4, 5, 6, 7, and 8, wherein

[0192] EMBODIMENT 179 When Xaa11 is Cys, the C-terminus is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2, Ttds-Lys(DOTA)-NH2, glu(AGLU)-NH2, Lys(DOTA)-NH2, lys(DOTA)-NH2, APAc-dap(NTASEROL)-NH2 and lys(MeO36PEG)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2, or c) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 166, 167, 168 and 178, preferably a compound according to any one of embodiments 166, 167, 168 and 178, selected from the group consisting of APAc-GLUSEROL, Ape-DOTA and PP-DOTA.

[0193] EMBODIMENT 180 When Xaa11 is Cys, the C-terminus is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2 and APAc-dap(NTASEROL)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or c) The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 166, 167, 168, 178 and 179, preferably the compound according to any one of embodiments 166, 167, 168, 178 and 179, more preferably the compound according to embodiment 179, which is APAc-GLUSEROL.

[0194] EMBODIMENT 181 C-terminal group is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2, Ttds-Lys(DOTA)-NH2, glu(AGLU)-NH2, Lys(DOTA)-NH2, lys(DOTA)-NH2, APAc-dap(NTASEROL)-NH2 and lys(MeO36PEG)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2, or c) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 163, 169, 170, 171 and 178, preferably a compound according to any one of embodiments 169, 170, 171 and 178, selected from the group consisting of APAc-GLUSEROL, Ape-DOTA and PP-DOTA.

[0195] EMBODIMENT 182 When Xaa11 is Cys, the C-terminus is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2 and APAc-dap(NTASEROL)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or c) The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 163, 169, 170, 171, 178 and 181, preferably the compound according to any one of embodiments 169, 170, 171, 178 and 181, more preferably the compound according to embodiment 181, which is APAc-GLUSEROL.

[0196] EMBODIMENT 183 C-terminal group is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2, Ttds-Lys(DOTA)-NH2, glu(AGLU)-NH2, Lys(DOTA)-NH2, lys(DOTA)-NH2, APAc-dap(NTASEROL)-NH2 and lys(MeO36PEG)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2, or c) A compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 172, 173, 174, 175, 176, 177 and 178, preferably a compound according to any one of embodiments 172, 173, 174, 175, 176, 177 and 178, selected from the group consisting of APAc-GLUSEROL, Ape-DOTA and PP-DOTA.

[0197] EMBODIMENT 184 When Xaa11 is Cys, the C-terminus is a) selected from the group consisting of APAc-glu(AGLU)-NH2, APAc-Lys(DOTA)-NH2 and APAc-dap(NTASEROL)-NH2; or b) APAc-glu(AGLU)-Lys(DOTA)-NH2 or c) The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 172, 173, 174, 175, 176, 177, 178 and 183, preferably the compound according to any one of embodiments 172, 173, 174, 175, 176, 177, 178 and 183, more preferably the compound according to embodiment 183, which is APAc-GLUSEROL.

[0198] EMBODIMENT 185 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 172, 173, 174, 175, 176, 177, 178, 183 and 184, preferably the compound according to any one of embodiments 172, 173, 174, 175, 176, 177, 178, 183 and 184, more preferably the compound according to embodiment 184, wherein the C-terminal group C-term is APAc-glu(AGLU)-NH2, provided that Xaa11 is Cys.

[0199] EMBODIMENT 186 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 172, 173, 174, 175, 176, 177, 178, 183 and 184, preferably the compound according to any one of embodiments 172, 173, 174, 175, 176, 177, 178, 183 and 184, more preferably the compound according to embodiment 184, wherein the C-terminal group C-term is APAc-glu(AGLU)-Lys(DOTA)-NH2, provided that Xaa11 is Cys.

[0200] EMBODIMENT 187 The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 164, 172, 173, 174, 175, 176, 177, 178, 183 and 184, preferably the compound according to any one of embodiments 172, 173, 174, 175, 176, 177, 178, 183 and 184, more preferably the compound according to embodiment 184, wherein Xaa11 is Cys and the C-terminal group C-term is APAc-GLUSEROL.

[0201] EMBODIMENT 188 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 300, 301, 302, 84, 185, 186 and 187, preferably a compound according to any one of embodiments 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186 and 187.

[0202] EMBODIMENT 189 one of the two or more Z groups is a chelator optionally including a linker, wherein the chelator optionally including a linker is a) covalently linked to Xaa8, where Xaa8 is Apc or Amk b) being part of or forming an N-terminal modification group A, wherein the N-terminal modification group A is selected from the group comprising DOTA, DOTA-Ttds, and DOTA-APAc. c) covalently linked to an α-amino acid residue at the C-terminus, wherein the C-terminus is selected from the group comprising APAc-Lys(DOTA)-NH2, Ttds-Lys(DOTA)-NH2, Lys(DOTA)-NH2 and lys(DOTA)-NH2; d) covalently attached to one of the two residues of an amino acid of the C-terminal dipeptide group, wherein the C-terminal group C-term is APAc-glu(AGLU)-Lys(DOTA)-NH2 or APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187 and 188, preferably a compound according to any one of embodiments 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187 and 188, more preferably a compound according to embodiment 188.

[0203] EMBODIMENT 190 One of the two or more Z groups is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier optionally comprising a linker is a) being part of or forming an N-terminal modification group A, wherein N-terminal modification group A is selected from the group consisting of AGLU-glutaric, NTASEROL, AGLU-glutaric-APAc, MeO36PEG-APAc and MeO2kDaPEGAc, and is preferably AGLU-glutaric or NTASEROL; b) covalently attached to an α-amino acid residue at the C-terminus, wherein the C-terminus is selected from the group consisting of APAc-glu(AGLU)-NH, glu(AGLU)-NH, Lys(DOTA)-NH, lys(DOTA)-NH, APAc-dap(NTASEROL)-NH, and lys(MeOPEG)-NH; c) covalently attached to one of the two residues of an amino acid in a C-terminal dipeptide group, where the C-terminal group C-term is APAc-glu(AGLU)-Lys(DOTA)-NH2 or APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2; or d) being part of or forming the C-terminal group C-term, wherein the C-terminal group C-term is APAc-GLUSEROL, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 2 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187 and 188, more preferably a compound according to embodiment 188.

[0204] EMBODIMENT 191 One of the two or more Z groups comprises a combination of a chelator optionally with a linker, a biodistribution modifier optionally with a linker, and an amino acid residue connecting the chelator optionally with a linker and the biodistribution modifier optionally with a linker, wherein the combination of the chelator and the biodistribution modifier is part of or forms the N-terminal modification group A, wherein the N-terminal modification group A is selected from the group comprising DOTA-glu(AGLU), DOTA-glu(AGLU)-APAc, DOTA-O2Oc-glu(AGLU), DOTA-glu(AGLU)-O2Oc, DOTA-PEG6-glu(AGLU), and DOTA-glu(AGLU)-PEG6. The compound according to any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187 and 188, More preferably, a compound according to any one of embodiments 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, and 188, more preferably a compound according to embodiment 188.

[0205] EMBODIMENT 192 the compound comprises three Z groups, wherein a first of the three Z groups is a chelator, wherein the chelator is covalently linked to Xaa8, wherein Xaa8 is an Apc residue, and wherein the chelator is DOTA; wherein the second of the three Z groups is a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier and the linker form an N-terminal modification group A, wherein N-terminal modification group A is AGLU-glutaric; 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 190, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 300, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190 and 191, more preferably a compound according to any one of embodiments 188, 189, 190 and 191.

[0206] EMBODIMENT 193 the compound comprises two Z groups, wherein one Z group is a combination of a chelator optionally with a linker, a biodistribution modifier optionally with a linker, and an amino acid residue connecting the chelator optionally with a linker and the biodistribution modifier optionally with a linker, wherein the combination of the chelator and the biodistribution modifier is part of or forms an N-terminal modification group A, wherein the N-terminal modification group A is DOTA-glu(AGLU); wherein the other Z group is a biodistribution modifier, wherein the biodistribution modifier is covalently attached to an α-amino acid residue at the C-terminus, wherein the C-terminus is APAc-glu(AGLU)-NH2, , 187, 188, 189, 190 and 191, preferably a compound according to any one of embodiments 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190 and 191, more preferably a compound according to any one of embodiments 188, 189, 190 and 191.

[0207] EMBODIMENT 194 the compound comprises three Z groups, wherein a first of the three Z groups is a chelator, wherein the chelator is covalently attached to one of two residues of an amino acid of the C-terminal dipeptide group; wherein the second of the three Z groups is a biodistribution modifier, and wherein the biodistribution modifier is covalently attached to the other of the two amino acid residues of the C-terminal dipeptide group; wherein the C-terminal dipeptide group is the C-terminal group C-term, wherein C-term is APAc-glu(AGLU)-Lys(DOTA)-NH; 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 190, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 300, 301, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190 and 191, more preferably a compound according to any one of embodiments 188, 189, 190 and 191.

[0208] EMBODIMENT 195 The compound is The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-001), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-002), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutaric)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-003), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH2 (GIP-004), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-005), The following formula [ka] the compound represented by the formula: AGLU-glutaric-APAc-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-006), The following formula [ka] the compound represented by the formula: AGLU-glutaric-APAc-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-007), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-008), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-009), The following formula [ka] the compound represented by the formula: AGLU-glutaric-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutaric)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-010), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-011), The following formula [ka] The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutaric)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-012), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-013), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-014), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-015), The following formula [ka] The compound represented by the formula: AGLU-glutar-Hse-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-016), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-017), The following formula [ka] The compound represented by the formula: DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-018), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-PEG6-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-019), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-020), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH2 (GIP-021), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH2 (GIP-022), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-023), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-024), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-025), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-026), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-027), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-028), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NOPO)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-029), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(N4Ac)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-030), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA-Gly)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-031), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH2 (GIP-033), The following formula [ka] The compound represented by the formula: AGLU-glutar-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-034), The following formula [ka] the compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-Leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-035), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-036), The following formula [ka] The compound represented by the formula: DOTA-PEG6-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-037), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH2 (GIP-038), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-lys(MeO36PEG)-NH2 (GIP-039), The following formula [ka] The compound MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH2 (GIP-040) represented by the formula: The following formula [ka] The compound MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-041) represented by the formula: The following formula [ka] The compound MeO36PEG-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-042) The following formula [ka] the compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-043), The following formula [ka] The compound represented by the formula: DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-044), The following formula [ka] The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutaric)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-045), The following formula [ka] The compound represented by the formula: AGLU-glutaric-APAc-Ser-Trp-5Clw-Tap(AGLU-glutaric)-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-046), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-047), The following formula [ka] The compound represented by the formula: AGLU-glutaric-APAc-Ser-Trp-5Clw-Tap-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-048), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-049), The following formula [ka] The compound represented by the formula: AGLU-glutaric-APAc-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-050), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-051), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH2 (GIP-052), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-AET] (GIP-053), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH2 (GIP-054), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH2 (GIP-055), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH2 (GIP-056), The following formula [ka] the compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-059), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-060), The following formula [ka] The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-061), The following formula [ka] The compound represented by the formula: LuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-062), The following formula [ka] the compound InDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-063), The following formula [ka] The compound EuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-064) The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-065), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-066), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-067), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-068), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-069), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-070), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaNODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-071), The following formula [ka] A compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-072), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-073), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-074), The following formula [ka] the compound Ac-Asp-Trp-Bta-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-075), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-076), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-077), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-078), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-079), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-080), The following formula [ka] the compound Ac-Asp-Trp-5Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-081), The following formula [ka] the compound Ac-Asp-Trp-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-082), The following formula [ka] the compound Ac-Asp-5Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-083), The following formula [ka] the compound Ac-Asp-6Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-084), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-085), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-AET] (GIP-086), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-087), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc-Leu-Ile-AET] (GIP-088), The following formula [ka] a compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-089); The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-090), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3Lut)-Aib-Leu-Ile-AET] (GIP-091), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AET] (GIP-092), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-en] (GIP-093), The following formula [ka] The compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-094) represented by the formula: The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-095), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-4Ap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-096), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(Ac)-Leu-Ile-AET] (GIP-097), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AETO] (GIP-098), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Hle-Ile-AET] (GIP-099), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-100), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-101), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-H3p-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-102), The following formula [ka] a compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-103); The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-6Fw-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-104), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-6Fw-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-105), The following formula [ka] The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(2Lut)-Thp-Leu-Ile-AET] (GIP-106), The following formula [ka] The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(3MeBn)-Thp-Leu-Ile-AET] (GIP-107), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-108), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-109), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-110), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-4Ap(Ac)-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-111), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-112), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Dap(2Lut)-Apc-Leu-Ile-AET] (GIP-113), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-114), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH2 (GIP-115), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH2 (GIP-116), The following formula [ka] HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ape-DOTA (GIP-117), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-PP-DOTA (GIP-118), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-119), The following formula [ka] The compound represented by the formula: MeO2kDaPEGAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH2 (GIP-120), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-121), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH2 (GIP-122), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH2 (GIP-123), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-AET))-Thp-Leu-Ile-Cys]-NH2 (GIP-124), The following formula [ka] The compound represented by the formula: DOTA-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-125), The following formula [ka] the compound DOTA-Ttds-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-126), The following formula [ka] the compound Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-127), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-128), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-129), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Nmd-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-130), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-131), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Npg-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-132), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Npg-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-133), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Cha-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-134), The following formula [ka] the compound Php-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-135), The following formula [ka] the compound 4FPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-136), The following formula [ka] the compound 4OHPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-137), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Val-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-138), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Deg-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-139), The following formula [ka] the compound Ac-Asp-Trp-6Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-140), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-6Clw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-141), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO10kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-142), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO2kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH2 (GIP-143), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH2 (GIP-144), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-PP))-Thp-Leu-Ile-Cys]-NH2 (GIP-145), The following formula [ka] The compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-146), The following formula [ka] The compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(ZnDOTA)-Leu-Ile-AET] (GIP-147), The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-148); The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-149); The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-150); The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-151); The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-152); The following formula [ka] a compound represented by the formula: InDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-153), The following formula [ka] a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-154); The following formula [ka] a compound represented by the formula: InDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-155); The following formula [ka] the compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH2 (GIP-156), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-157), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-158), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-159), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-160), The following formula [ka] LuDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-161), The following formula [ka] LuDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-162), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-163), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH2 (GIP-164), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH2 (GIP-165), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH2 (GIP-166), The following formula [ka] LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-167), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(InDOTA)-NH2 (GIP-168), The following formula [ka] The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-169), The following formula [ka] the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(LuDOTA)-NH2 (GIP-170), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-AET] (GIP-171), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH2 (GIP-172), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH2 (GIP-173), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-174), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-175), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nglu(AGLU)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-176), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-177), The following formula [ka] The compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-178), The following formula [ka] Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-179), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-180), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-OH (GIP-181), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cysol]-OH (GIP-182), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-183), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nleu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-184), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nphe-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-185), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nlys-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-186), The following formula [ka] the compound Ac-Asp-Trp-5Clw-4Tfp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-187), The following formula [ka] the compound Ac-Ser-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-188), The following formula [ka] the compound Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-189), The following formula [ka] the compound Ac-Asn-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-190), The following formula [ka] the compound Ac-Glu-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-191), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Asp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-192), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Gln-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-193), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Hse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-194), The following formula [ka] the compound Ac-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-195), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Nglu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-196), The following formula [ka] the compound Ac-Hse-Trp-5Brw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-197), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-198), The following formula [ka] the compound represented by the formula: HO-succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH2 (GIP-199), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-200), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Hcy]-NH2 (GIP-201), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Hcy]-NH2 (GIP-202), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Eca-Leu-Ile-Cys]-NH2 (GIP-203), The following formula [ka] the compound Ac-Gln-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-204), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Asn-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-205), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aic-Leu-Ile-Cys]-NH2 (GIP-206), The following formula [ka] the compound Ac-Pse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-207), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Pse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-208), The following formula [ka] the compound Ac-Asp-Mcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-209), The following formula [ka] the compound Ac-Asp-Pcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-210), The following formula [ka] the compound Ac-Asp-Eaa-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-211), The following formula [ka] the compound Ac-Asp-Egm-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-212), The following formula [ka] the compound Ac-Asp-Trp-Eaa-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-213), The following formula [ka] The compound represented by the formula: HO-Gluta-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-214), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Dtc-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-215), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Oxa-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-216), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Nme-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-217), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-Ile-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-218), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-Val-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-219), The following formula [ka] the compound Ac-Asp-Hyw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-220), The following formula [ka] the compound Ac-Asp-7Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-221), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Eaz-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-222), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-glu-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-223), The following formula [ka] the compound Ac-Asp-Phe-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-224), The following formula [ka] the compound Ac-Asp-Egp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-226), The following formula [ka] the compound Ac-Asp-Trp-7Fw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-227), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Phe-Leu-Ile-Cys]-NH2 (GIP-228), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ile-Ile-Cys]-NH2 (GIP-229), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Arg-Ile-Cys]-NH2 (GIP-230), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Glu-Ile-Cys]-NH2 (GIP-231), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Phe-Ile-Cys]-NH2 (GIP-232), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Trp-Ile-Cys]-NH2 (GIP-233), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Trp-Leu-Ile-Cys]-NH2 (GIP-234), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Glu-Leu-Ile-Cys]-NH2 (GIP-235), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ser-Ile-Cys]-NH2 (GIP-236), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Leu-Cys]-NH2 (GIP-237), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Tle-Cys]-NH2 (GIP-238), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-239), The following formula [ka] the compound Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-240), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Gln-Leu-Ile-Cys]-NH2 (GIP-241), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thr-Leu-Ile-Cys]-NH2 (GIP-242), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Lys-Leu-Ile-Cys]-NH2 (GIP-243), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-244), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-245), The following formula [ka] the compound represented by the formula: H-Met-tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-246), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-247), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH2 (GIP-248), The following formula [ka] The compound represented by the formula: H-Met-Ala-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-249), The following formula [ka] a compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-AET] (GIP-250), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-251), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Oic-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-252), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pip-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-253), The following formula [ka] the compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-254), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH2 (GIP-255), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-AET] (GIP-256), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(2Lut)-Ala-Leu-Ile-Cys]-NH2 (GIP-257), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-258), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-259), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Hle-Ile-Cys]-NH2 (GIP-260), The following formula [ka] the compound represented by the formula: HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH2 (GIP-261), The following formula [ka] the compound Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-262), The following formula [ka] the compound Ac-Asp-Egn-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-263), The following formula [ka] the compound Ac-Asp-Trp-Egp-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-265), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH2 (GIP-266), The following formula [ka] the compound Ac-Asp-Trp-7Nw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-267), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-270), The following formula [ka] The compound represented by the formula: DOTA-Ttds-asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH2 (GIP-271), The following formula [ka] the compound Ac-Asp-Bta-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-273), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Nme-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-274), The following formula [ka] the compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Tle-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-276), The following formula [ka] the compound Ac-Asp-5Clw-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-277), The following formula [ka] the compound 4ClPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-279), The following formula [ka] The compound Nph2p-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-281), The following formula [ka] the compound Ac-Asp-Trp-6Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH2 (GIP-282), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-6Fw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-283), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-315), The following formula [ka] the compound HO-succinyl-Trp-Trp-Hyp-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-319), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBz)-Aib-Leu-Ile-AET] (GIP-358), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3CbBn)-Aib-Leu-Ile-en] (GIP-359), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Cys]-NH2 (GIP-360), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Hcy]-NH2 (GIP-361), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(mli)-Thp-Leu-Ile-Cys]-NH2 (GIP-362), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy-Thp-Leu-Ile-Hcy]-NH2 (GIP-363), The following formula [ka] The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTAM)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-370), The following formula [ka] the compound AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH2 (GIP-371), The following formula [ka] a compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-372); The following formula [ka] The compound represented by the formula: NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-dap(NTASEROL)-NH2 (GIP-373), The following formula [ka] NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-374), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Lys-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-375), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Arg-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-376), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-His-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-377), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Hly-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-378), The following formula [ka] the compound Ac-Asp-5Clw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-379), The following formula [ka] the compound Ac-Asp-1Ni-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-380), The following formula [ka] the compound Ac-asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-381), The following formula [ka] the compound Ac-Asp-5Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-382), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Cha-Ile-Cys]-NH2 (GIP-383), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Ser-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-384), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Val-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-385), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Ala-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-386), The following formula [ka] The compound represented by the formula: DOTA-Ttds-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-387), The following formula [ka] The compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH2 (GIP-388) represented by the formula: The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-lys(DOTA)-NH2 (GIP-389), The following formula [ka] the compound Ac-Asp-Ocf-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-390), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH2 (GIP-391), The following formula [ka] the compound Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH2 (GIP-392), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Phe-Cys]-NH2 (GIP-393), The following formula [ka] the compound Ac-Asp-Trp-1Ni-Tap(DOTA)-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH2 (GIP-394), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Har-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-395), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Phe-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-396), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Trp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-397), The following formula [ka] the compound Ac-Asp-Trp-5Clw-Hyp-Pro-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH2 (GIP-398), The following formula [ka] The compound represented by the formula: Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH2 (GIP-399) and The following formula [ka] The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-Cys]-NH2 (GIP-400) 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156 , 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193 and 194.

[0209] EMBODIMENT 196 The compound is a) GIP-001~GIP-031, GIP-033~GIP056, GIP-059~GIP-224, GIP-226~GIP263, GIP-265~GIP-267, GIP-270, GIP-271, GIP-273, GIP-27 4, selected from the group consisting of GIP-276, GIP-277, GIP-279, GIP-281, GIP-283, GIP-315, GIP-319, GIP-358, GIP-359, GIP-363 and GIP-370~GIP-400, b) preferably selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-059 to GIP-224, GIP-226 to GIP-263, GIP-265 to GIP-267, and GIP-370 to GIP-386; c) More preferably, it is selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-059 to GIP-071, and GIP-370 to GIP-374, d) Most preferably, the compound of any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 5, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 , 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213 194 and 195, preferably a compound according to embodiment 195.

[0210] EMBODIMENT 197 The compound is a)GIP-001~GIP-031, GIP-033~GIP056, GIP-072~GIP-145, GIP-147, GIP-270, GIP-271, GIP-273, GIP-274, GIP-276, GIP-2 77, GIP-279, GIP-281, GIP-283, GIP-358, GIP-359, GIP-370~GIP-374, GIP-387~GIP-394, GIP-399 and GIP-400, b) preferably selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-072 to GIP-145, GIP-147, and GIP-370 to GIP-374, c) More preferably, it is selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, and GIP-370 to GIP-374, d) Most preferably, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 selected from the group consisting of GIP-001 to GIP-024 and GIP-370 to GIP-374 , 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 , 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 195 and 196, preferably a compound according to any one of embodiments 195 and 196.

[0211] EMBODIMENT 198 The compound is a) selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP056, GIP-072 to GIP-145, GIP-147, and GIP-370 to GIP-374, b) preferably selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, and GIP-370 to GIP-374, c) More preferably, it is selected from the group consisting of GIP-001 to GIP-024 and GIP-370 to GIP-374, d) Most preferably, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 , 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196 and 197, preferably a compound according to any one of embodiments 195, 196 and 197.

[0212] EMBODIMENT 199 Any S atom may be oxidized, and preferably any sulfur atom of the thioether group is present as -S-, -S(O)-, or -S(O2)-, or a combination thereof, embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 , 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 1 01, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 1 55, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197 and 198.

[0213] Embodiment 200 The compound comprises a diagnostically active radionuclide, wherein the radionuclide is a) A radionuclide used in diagnosis, b) preferably, 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga,68 Ga, 86 Y, 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 177 Lu, 201 Tl, 203 Pb, 18 F, 76 Br, 77 Br, 123 I, 124 I and 125 selected from the group including (but not limited to): c) More preferably, 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, 111 In, 152 Tb, 155 Tb and 203 Pb, d) Most preferably, 64 Cu, 68 Ga, 111 In and 203Pb, 5, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 10, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 209, 206, 209, 209, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 60, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198 and 199.

[0214] Embodiment 201 The compound comprises a therapeutically active radionuclide, wherein the radionuclide is a) A radionuclide used in therapy, b) preferably, 47 Sc, 67 Cu, 89 Sr, 90 Y, 111 In, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re, 188Re, 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I and 211 selected from the group including At, c) More preferably, 47 Sc, 67 Cu, 90 Y, 177 Lu, 212 Pb, 213 Bi, 225 Ac and 227 selected from the group including Th, d) Most preferably, 90 Y, 177 Lu, 212 Pb, 225 Ac and 227Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 22, 23, 24, 2 5, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 10, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 209, 206, 209, 209, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 60, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198 and 199.

[0215] EMBODIMENT 202 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 , 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161 1, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201.

[0216] EMBODIMENT 203 3. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 for use in a method for treating a disease , 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 19 ...9, 100, 101, 102, 103, 104, 62, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201 and 202.

[0217] EMBODIMENT 204 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27. For use in a method for identifying a subject, the subject likely to respond or likely not to respond to treatment of a disease, wherein the method for identifying a subject comprises carrying out a method for diagnosing the disease using a compound according to any one of embodiments 1 to 201. , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 9 6, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154 , 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201.

[0218] EMBODIMENT 205 201. A compound according to any one of embodiments 1 to 201, for use in a method for selecting a subject from a group of subjects, the subject being likely to respond or not likely to respond to treatment of a disease, wherein the method for selecting a subject from a group of subjects comprises carrying out a method for diagnosing the disease using a compound according to any one of embodiments 1 to 201. 5, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 , 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 1 54, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201.

[0219] EMBODIMENT 206 201. A compound according to any one of embodiments 1 to 201, for use in a method for stratifying a group of subjects into those likely to respond to treatment of a disease and those likely to not respond to treatment of a disease, wherein the method for stratifying a group of subjects comprises performing a method for diagnosing a disease using a compound according to any one of embodiments 1 to 201. 6, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 9 5, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 2 15. The compound according to any one of claims 4, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201.

[0220] EMBODIMENT 207 The compound for use according to any one of embodiments 201, 202, 203, 204 and 205, wherein the disease is cancer.

[0221] EMBODIMENT 208 The compound for use according to embodiment 207, wherein the cancer expresses a gastric inhibitory peptide receptor (GIPR), preferably the cancer overexpresses a GIPR.

[0222] EMBODIMENT 209 The compound for use according to any one of embodiments 207 and 208, wherein the cancer is a neuroendocrine cancer or a neuroendocrine neoplasm.

[0223] EMBODIMENT 210 209. The compound for use according to any one of embodiments 207, 208 and 209, wherein the cancer is selected from the group consisting of medullary thyroid carcinoma, gastrointestinal neuroendocrine neoplasm, ileal neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm, non-functioning neuroendocrine neoplasm, insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma, ACTHoma, pulmonary neuroendocrine neoplasm, typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumor, Merkel cell carcinoma, adrenal pheochromocytoma, adrenal carcinoma, parathyroid carcinoma, paraganglioma, pituitary tumor, ovarian neuroendocrine tumor and testicular neuroendocrine tumor.

[0224] EMBODIMENT 211 The compound for use according to any one of embodiments 203, 204 and 205, wherein the disease is a metabolic disease.

[0225] EMBODIMENT 212 The compound for use according to embodiment 211, wherein the diseased cells and / or diseased tissue, preferably the diseased cells and / or diseased tissue of a metabolic disease, expresses GIPR.

[0226] EMBODIMENT 213 The compound for use according to embodiment 212, wherein the diseased cells and / or diseased tissue overexpress GIPR.

[0227] EMBODIMENT 214 214. The compound for use according to any one of embodiments 212 and 213, wherein the diseased cells are pancreatic cells.

[0228] EMBODIMENT 215 The compound for use according to any one of embodiments 211, 212, 213 and 214, wherein the metabolic disease is selected from the group consisting of type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose and impaired glucose tolerance.

[0229] EMBODIMENT 216 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171 15, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201, and a pharmaceutically acceptable excipient. composition.

[0230] EMBODIMENT 217 217. The composition of embodiment 216, wherein the composition is a pharmaceutical composition.

[0231] EMBODIMENT 218 Embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 1 2, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172 17, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 138, 139, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200 and 201, and one or more optional excipients, and optionally one or more devices. kit.

[0232] EMBODIMENT 219 219. The kit of embodiment 218, wherein the device is selected from the group comprising a labeling device, a purification device, a handling device, a radiation protection device, an analytical device or an administration device.

[0233] According to the invention, the compounds of the invention covered by embodiment 1 will also be referred to herein as the first aspect of the invention.

[0234] According to the present invention, the compound of the first aspect of the invention (including any embodiment thereof) for use in a method for diagnosing a disease, which is the subject of embodiment 202, will also be referred to herein as the second aspect of the invention.

[0235] According to the present invention, the compound of the first aspect of the invention (including any embodiment thereof) for use in a method for treating a disease, which is the subject of embodiment 203, will also be referred to herein as the third aspect of the invention.

[0236] According to the present invention, the compound of the invention of the first aspect (including any embodiment thereof) for use in a method for identifying a subject who is likely to respond or not to respond to treatment of a disease, which method for identifying a subject, which is subject to embodiment 204, comprises carrying out a method for diagnosing the disease using a compound of the first aspect of the invention, will also be referred to herein as the fourth aspect of the invention.

[0237] According to the present invention, the compound of the invention of the first aspect (including any embodiment thereof) for use in a method for selecting a subject from a group of subjects, the subject being likely to respond or not to respond to treatment of a disease, which method for selecting a subject from a group of subjects comprises carrying out a method for diagnosing the disease using a compound of the first aspect (including any embodiment thereof) of the invention, which will also be referred to herein as the fifth aspect of the invention.

[0238] According to the present invention, the compound of the invention of the first aspect (including any embodiment thereof) for use in a method for stratifying a group of subjects into those likely to respond to treatment of a disease and those likely to not respond to treatment of a disease, which method for stratifying a group of subjects comprises carrying out a method for diagnosing a disease using a compound of the first aspect (including any embodiment thereof) of the invention, which will also be referred to herein as the sixth aspect of the invention.

[0239] According to the present invention, the composition subject to embodiment 216, comprising a compound of the first aspect of the invention (including any embodiment thereof) and a pharmaceutically acceptable excipient, will also be referred to herein as the seventh aspect of the invention.

[0240] According to the present invention, the kit according to embodiment 217, comprising a compound of the first aspect of the invention (including any embodiment thereof), one or more optional excipients, and optionally one or more devices, will also be referred to herein as the eighth aspect of the invention.

[0241] According to the present invention, each and every embodiment of the compound of the first aspect is also an embodiment of the peptide of the second aspect, and vice versa.

[0242] The present inventors have surprisingly found that the compounds of the present invention exhibit high affinity for the gastric inhibitory peptide receptor (GIPR). Furthermore, the present inventors have surprisingly found that the compounds of the present invention exhibit other properties that define them for use in the diagnosis and treatment of diseases involving the gastric inhibitory peptide receptor (GIPR). These other properties include high stability in plasma and selectivity for the gastric inhibitory peptide receptor (GIPR). Another surprising property of the compounds of the present invention is their low retention in normal tissues, i.e., non-diseased tissues.

[0243] According to the present invention, the compounds of the present invention may contain one or more chelating agents. The chelating agent is attached to the compounds of the present invention directly or via a linker. However, it is preferred that the compounds of the present invention contain only one chelating agent. More preferably, such one chelating agent is attached to Xaa8 or such one chelating agent is included in the N-terminal group A. Most preferably, such one chelating agent is attached directly to Xaa8 without any linker.

[0244] In an embodiment, and preferably as used herein, a diagnostically active compound is a compound suitable or useful for diagnosing a disease.

[0245] In an embodiment, and preferably as used herein, a diagnostic agent or diagnostically active agent is a compound suitable or useful for diagnosing a disease.

[0246] In an embodiment, and preferably as used herein, a therapeutically active compound is a compound suitable or useful in the treatment of a disease.

[0247] In an embodiment, and preferably as used herein, a therapeutic agent or therapeutically active agent is a compound suitable or useful for the treatment of a disease.

[0248] In an embodiment, and preferably as used herein, a theranostically active compound is a compound that is suitable or useful for both the diagnosis and treatment of a disease.

[0249] In an embodiment, and preferably as used herein, a theranostic agent or theranostic active agent is a compound that is suitable or useful for both the diagnosis and treatment of a disease.

[0250] In an embodiment, and preferably as used herein, theranostics is a method for the combined diagnosis and treatment of disease. Preferably, the combination of diagnostically and therapeutically active compounds used in theranostics is radiolabeled.

[0251] In an embodiment, and preferably as used herein, treatment of a disease is treatment and / or prevention of the disease.

[0252] In an embodiment, and preferably as used herein, pEC50 is determined in a FACS binding assay, wherein the FACS binding assay is as described in the Examples part.

[0253] In an embodiment, and preferably as used herein, pIC50 is determined in a FACS binding assay, wherein the FACS binding assay is as described in the Examples part.

[0254] In an embodiment, and preferably as used herein, a disease involving GIPR is a disease in which cells, including (but not limited to) tumor cells or pancreatic beta cells, expressing GIPR, preferably in an upregulated manner, and tissues, respectively, expressing GIPR, preferably in an upregulated manner, are the cause of the disease and / or disease symptoms or part of the underlying pathology of the disease. A preferred GIPR-expressing cell is a tumor cell. In a disease embodiment, preferably when used in connection with treatment, treatment and / or therapy of the disease, affecting cells, tissues, and pathologies, respectively, results in a cure, treatment, or amelioration of the disease and / or disease symptoms. In a disease embodiment, preferably when used in connection with diagnosis and / or diagnosing the disease, labeling GIPR-expressing cells and / or GIPR-expressing tissues makes it possible to distinguish or differentiate said cells and / or tissues from healthy cells or non-GIPR-expressing cells and / or healthy tissues or non-GIPR-expressing tissues. More preferably, such distinction or differentiation forms the basis of said diagnosis and diagnosing, respectively. In that embodiment, labeling refers to the interaction of a detectable label, either directly or indirectly, with GIPR-expressing cells and / or GIPR-expressing tissues or tissues containing such GIPR-expressing cells, and more preferably, such interaction includes or is based on the interaction of the label or a compound bearing such a label with the GIPR.

[0255] In an embodiment, and preferably as used herein, a target cell is a cell that expresses a GIPR and is responsible for a disease and / or symptoms of a disease or is part of the underlying pathology of a disease.

[0256] In an embodiment, and preferably as used herein, a non-target cell is a cell that does not express a GIPR and / or is either not responsible for the disease and / or symptoms of the disease or is not part of the underlying pathology of the disease.

[0257] In an embodiment, and preferably as used herein, a neoplasm is an abnormal new growth of cells. Cells in a neoplasm proliferate more rapidly than normal cells and will continue to proliferate if untreated. Neoplasms can be benign or malignant.

[0258] In an embodiment, and preferably as used herein, a tumor is a mass lesion which may be benign or malignant.

[0259] In an embodiment, and preferably as used herein, cancer is a malignant neoplasm.

[0260] In an embodiment, and preferably as used herein, cells and / or tissues that express GIPR overexpress GIPR. More preferably, GIPR is overexpressed when the level of expression is the same as that observed in cells and / or tissues of humans diagnosed with a disease, preferably the cancer and metabolic diseases disclosed herein.

[0261] Therefore, the compounds of the present invention are particularly suitable and useful for the diagnosis and treatment of these diseases, respectively. To that extent, the above-mentioned indications are indications that can be treated by the compounds of the present invention. Those skilled in the art will understand that, in particular, metastases and metastatic foci of the above-mentioned indications can also be treated and diagnosed by the compounds of the present invention and the diagnostic and treatment methods using the compounds of the present invention.

[0262] It is also within the scope of the present invention that the compounds of the present invention are used in or for use in a method for treating the diseases disclosed herein. Such methods preferably comprise administering a therapeutically effective amount of a compound of the present invention to a subject in need thereof. Such methods include, but are not limited to, curative or adjuvant cancer treatments. Such methods may be used as palliative treatments where a cure is not possible and the aim is local disease control or symptomatic relief, or as therapeutic treatments where the treatment has a survival benefit and may be curative.

[0263] The methods for treating diseases disclosed herein include the treatment of diseases disclosed herein, including tumors and cancers, as well as metabolic diseases, and may be used either as a first-line treatment or as a second-, third-, fourth-, or definitive treatment. It is also within the scope of the present invention to combine the compounds of the present invention with additional therapeutic approaches. It is well known to those skilled in the art that the exact treatment intent, including intent for curative, adjuvant, neoadjuvant, therapeutic, or palliative treatment, will depend on the type, location, and stage of the tumor and the general health of the patient.

[0264] Without wishing to be bound by any theory, the therapeutic effect of the compounds of the present invention is based on the delivery of a radionuclide to a diseased GIPR-expressing cell or structure, which is destroyed by the radiation emitted by the radionuclide. Preferably, GIPR is overexpressed by such a cell or structure.

[0265] Without wishing to be bound by any theory, the therapeutic use of the compounds of the present invention occurs by binding to GIPR-expressing cells, particularly cancer cells, where the cells are killed by the radiation emitted by radionuclides.Those skilled in the art will also understand that GIPR is the target of all neuroendocrine tumors.Therefore, any cancers and tumors can be treated and diagnosed, respectively.

[0266] In an embodiment of the present invention, the disease is selected from the group comprising cancers and tumors that express GIPR, preferably overexpress GIPR, respectively. In a preferred embodiment, the cancer is a neuroendocrine cancer or neuroendocrine tumor, preferably expressing or overexpressing GIPR, respectively.

[0267] In a further embodiment, the disease is selected from the group comprising medullary thyroid carcinoma, gastrointestinal neuroendocrine neoplasm, ileal neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm, non-functioning neuroendocrine neoplasm, insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma, ACTHoma, pulmonary neuroendocrine neoplasm, typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumor, Merkel cell carcinoma, adrenal pheochromocytoma, adrenal carcinoma, parathyroid carcinoma, paraganglioma, pituitary tumor, ovarian neuroendocrine tumor, and testicular neuroendocrine tumor.

[0268] In a further embodiment, the disease is a metabolic disease.Preferably, the metabolic disease is a disease in which GIPR is expressed, more preferably, GIPR is overexpressed in pancreatic beta cells.In a further embodiment, the disease is selected from the group consisting of metabolic diseases and disorders, preferably type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose and impaired glucose tolerance.

[0269] In an embodiment, the compounds of the present invention are used to detect cells and tissues that overexpress GIPR, and such detection is achieved by conjugating the compounds of the present invention with a detectable label, preferably a detectable radionuclide.In a preferred embodiment, the cells and tissues that are detected are diseased cells and tissues and / or are either the cause of disease and / or disease symptoms or part of the underlying pathology of disease.In a more preferred embodiment, the diseased cells and tissues are the cause of and / or part of oncological indications (for example, neoplasms, tumors and cancers).

[0270] In another embodiment, the compounds of the present invention are used to treat cells and tissues that overexpress GIPR. In a preferred embodiment, the treated cells and tissues are diseased cells and tissues and / or are either responsible for the disease and / or symptoms of the disease or are part of the underlying pathology of the disease. In a further preferred embodiment, the diseased cells and tissues are responsible for and / or are part of oncological indications (e.g., neoplasms, tumors, and cancers), and therapeutic activity is achieved by conjugating the compounds of the present invention with a therapeutically active effector, preferably a therapeutically active radionuclide.

[0271] An effective amount is a dosage of a compound sufficient to provide a therapeutically or medically desired result or effect in a subject to which the compound is administered. The effective amount will vary depending on the particular condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of treatment, the nature of any concurrent or concomitant therapy, the particular route of administration, and factors within the knowledge and expertise of the medical practitioner, etc. For example, in the context of a method directed to treating a subject having a condition characterized by abnormal cell proliferation, an amount effective to inhibit proliferation would be an amount sufficient to reduce or completely halt abnormal cell proliferation, so as to slow or halt the development or progression of a cell mass, e.g., a tumor, etc. As used in the embodiments, "inhibit" encompasses all of the foregoing.

[0272] In other embodiments, a therapeutically effective amount will be the amount necessary to prolong the dormancy of micrometastases or the amount necessary to stabilize any primary tumor cells remaining after surgical or drug therapy.

[0273] In a preferred embodiment, the compounds of the present invention are for use in the treatment and / or prevention of disease, wherein such treatment is targeted radionuclide therapy. Targeted radionuclide therapy is a form of radiation therapy (also called radiotherapy) that uses radionuclide-labeled molecules to deliver toxic levels of radiation to the site of disease. Targeted radionuclide therapy can be applied systemically or locally. In contrast, external beam radiation therapy generates a high-energy beam from a source outside the body, which then passes through the skin and is focused internally at the diseased site. This is significantly different from internal radiation therapy (brachytherapy), in which a radioactive implant is placed at or near the diseased site.

[0274] Preferably, radionuclide therapy uses or is based on various forms of radiation emitted by radionuclides. Such radiation includes, for example, the emission of photons, β - The radiation emitted by the radionuclide may be any one of alpha (α), beta (β), or gamma (γ) radiation caused by the emission of electrons, including (but not limited to) particles and Auger electrons, protons, neutrons, positrons, or α particles. Depending on the type of particle or radiation emitted by the radionuclide, radionuclide therapy may be distinguished, for example, as beta particle radionuclide therapy, α particle radionuclide therapy, or Auger electron radionuclide therapy. All these forms of radionuclide therapy are encompassed by the present invention, and all these forms of radionuclide therapy can be realized by the compounds of the present invention, preferably provided that the radionuclide bound to the compound of the present invention, more preferably bound as an effector, provides this type of radiation.

[0275] Radionuclide therapy preferably works by damaging cellular DNA. Damage is caused by direct or indirect ionization of the atoms that make up the DNA chain by beta particles, alpha particles, or Auger electrons. Indirect ionization occurs as a result of the ionization of water, which leads to the formation of free radicals, particularly hydroxyl radicals, which then damage DNA.

[0276] In the most common forms of radionuclide therapy, the majority of radiation effects are due to free radicals. Because cells have mechanisms for repairing DNA damage, breaking both strands of DNA has proven to be the most important technique for altering cellular properties. Because cancer cells are generally undifferentiated, stem cell-like cells, they replicate more and have a reduced ability to repair sublethal damage compared to most normal, differentiated cells. DNA damage is inherited through cell division, causing cancer cells to accumulate damage and die or replicate more slowly.

[0277] Oxygen is a potent radiosensitizer, enhancing the effects of a given dose of radiation by forming free radicals that damage DNA. Therefore, the use of hyperbaric oxygen tanks, blood substitutes that carry increased oxygen, hypoxic cell radiosensitizers such as misonidazole and metronidazole, and hypoxic cytotoxins such as tirapazamine may be applied.

[0278] The total radioactive dose can be fractionated, i.e., spread over time in one or more treatments, for several important reasons: Fractionation allows normal cells time to recover, while tumor cells generally repair less efficiently between treatments; Fractionation also allows tumor cells that were in a relatively radioresistant stage of the cell cycle during one treatment to progress to a sensitive stage of the cycle before the next fraction is administered.

[0279] It is generally known that the response of cancers to radiation therapy varies depending on the cancer. The response of cancers to radiation is expressed by their radiosensitivity. Cancer cells that are highly radiosensitive are rapidly killed by an appropriate dose of radiation. These include most leukemias, lymphomas, and germ cell tumors.

[0280] Radionuclide therapy itself is not painful. Many low-dose palliative treatments have minimal or no side effects. High-dose treatments may cause a variety of side effects during treatment (acute side effects), months or years after treatment (long-term side effects), or after further treatment (cumulative side effects). The nature, severity, and duration of side effects vary depending on the organ receiving radiation, the treatment itself (type of radionuclide, dose, fractionation, concurrent chemotherapy), and the patient.

[0281] To the extent that methods for treating the diseases of the present invention are known in the art, it is within the scope of the present invention that each and every one of the above strategies can be implemented, which constitute further embodiments of the present invention.

[0282] It is also within the scope of the present invention that the compounds of the present invention be used in methods for diagnosing the diseases disclosed herein, preferably comprising the step of administering to a subject in need thereof a diagnostically effective amount of a compound of the present invention.

[0283] According to the present invention, the imaging method is selected from the group consisting of scintigraphy, single photon emission computed tomography (SPECT) and positron emission tomography (PET).

[0284] Scintigraphy is a form of diagnostic test or method used in nuclear medicine, in which a radiopharmaceutical is internalized into cells, tissues, and / or organs, preferably in vivo, and radiation emitted from the internalized radiopharmaceutical is captured by an external detector (gamma camera) to form and display a two-dimensional image. In contrast, SPECT and PET form and display a three-dimensional image. For this reason, SPECT and PET are classified as separate techniques from scintigraphy, even though they also use a gamma camera to detect internal radiation. Scintigraphy differs from diagnostic x-rays, in which external radiation is passed through the body to form an image.

[0285] Single-photon emission computed tomography (SPECT) scans are a type of nuclear imaging technique that uses gamma rays. They are very similar to conventional nuclear medicine planar imaging, which uses a gamma camera. Before a SPECT scan, the patient is injected with a radiolabeled chemical that emits gamma rays that can be detected by the scanner. A computer collects information from the gamma camera and converts it into two-dimensional cross-sectional images. These cross-sectional images can be added together to form a three-dimensional image of the organ or tissue. SPECT detects gamma rays emitted singly or sequentially by the radionuclides provided by the radiolabeled chemical. To acquire a SPECT image, the gamma camera rotates around the patient. Typically, projection images are acquired every 3 to 6 degrees at predetermined points during the rotation. In most cases, a full 360-degree rotation is used to obtain an optimal reconstruction. The time required to acquire each projection image also varies, but 15 to 20 seconds is common. This results in a total scan time of 15 to 20 minutes. Multihead gamma cameras are faster. SPECT acquisition is very similar to planar gamma camera imaging, so the same radiopharmaceuticals can be used.

[0286] Positron emission tomography (PET) is a noninvasive diagnostic imaging technique for measuring biochemical, physiological, and pathophysiological processes within the human body. PET is unique because it can produce images of the body's basic biochemistry or function. Traditional diagnostic techniques, such as X-rays, CT scans, and MRIs, produce images of the body's anatomical structures or structures. The premise of these techniques is that they can visualize some changes in the structures or anatomy associated with disease. Disease also alters biochemical and physiological processes, sometimes occurring before visible anatomical changes. PET is an imaging technique that can visualize some of these early biochemical and physiological changes. PET scanners use radiation emitted by the patient to create images. Each patient is given a minute amount of a radioactive compound that either mimics a natural substance used in the body or specifically binds to a receptor or molecular structure. When the radioisotope undergoes positron-emitting decay (also known as positive beta decay), it emits a positron, the antiparticle counterpart of the electron. The positrons travel up to a few millimeters before encountering an electron and annihilating, producing a pair of annihilation (gamma) photons traveling in opposite directions. These are detected when they reach the scintillation material in the scanning device, generating a burst of light that is detected by a photomultiplier tube or silicon avalanche photodiode. The technique relies on the coincidence or coincidence detection of pairs of photons. Photons that do not arrive as a pair, i.e., within a few nanoseconds of each other, are ignored. All coincidence counts are forwarded to an image processing unit, which uses image reconstruction techniques to generate the final image data.

[0287] SPECT / CT and PET / CT are the combination of SPECT and PET with computed tomography (CT). The main advantage of combining these modalities is to improve the reliability and accuracy of the reader. With conventional PET and SPECT, the limited number of photons emitted from the abnormal region creates a very low level of background, which makes it difficult to identify the region anatomically. The addition of CT helps determine the location of the abnormal region from an anatomical perspective and classify its likelihood of representing disease.

[0288] To the extent that methods for diagnosing the diseases of the present invention are known in the art, it is within the scope of the present invention that each and every one of the above strategies can be implemented, constituting further embodiments of the present invention.

[0289] In an embodiment, and preferably as used herein, a bond is a bond between two atoms of two independent sites. A preferred bond is a chemical bond or multiple chemical bonds. More preferably, the chemical bond is a covalent bond or multiple chemical bonds. Most preferably, the bond is a covalent bond or a coordinate bond. As preferably used herein, a coordinate bond embodiment is a bond or group of bonds such as those realized when a metal is bound by a chelating agent. Different types of bonds occur depending on the type of atoms that are bound and their atomic environment. These types of bonds are defined by the type of atomic arrangement that occurs due to the bond.

[0290] For example, the bond between an amine-containing moiety and a carboxylic acid-containing moiety results in a bond termed an amide (also referred to as an amide bond, -CO-N-, -N-CO-). Those skilled in the art will recognize that this example and the examples of bond formation below are merely representative and in no way limit the scope of the present application. Those skilled in the art will recognize that the bond between an isothiocyanate-containing moiety and an amine-containing moiety results in a thiourea (also referred to as a thiourea bond, -N-CS-N-), and the bond between a C-atom-containing moiety and a thiol group (-C-SH) results in a thioether (also referred to as a thioether bond, -CSC-). A non-limiting list of bonds and their characteristic types of atomic configurations that are preferably used in connection with the chelators and linkers of the present invention is provided in Table 2.

[0291] [Table 1]

[0292] In some embodiments of the present invention, examples of reactive groups used to form a bond between a chelator and a linker, a direct bond between a chelator and a compound of the invention, a bond between a biodistribution modifier and a linker, or a bond between a biodistribution modifier and a compound of the invention are summarized in Table 3. However, one of skill in the art will understand that neither the bond that can be achieved in embodiments to form the conjugates of the present invention nor the reactive groups that form such bonds are limited to those in Table 3.

[0293] [Table 2]

[0294] Below are reactive groups and functional groups that are available or suitable for forming bonds between moieties or structures used in embodiments of the conjugates of the present invention.

[0295] Primary or secondary amino, carboxylic acid, activated carboxylic acid, chloro, bromo, iodo, sulfhydryl, hydroxyl, sulfonic acid, activated sulfonic acid, sulfonate ester, e.g., mesylate or tosylate, Michael acceptor, strained alkenes, e.g., trans cyclooctene, isocyanate, isothiocyanate, azide, alkyne, and tetrazine.

[0296] Preferably, as used herein, the term "activated carboxylic acid" refers to a carboxylic acid group having the general formula -CO-X, where X is a leaving group. For example, activated carboxylic acid groups may include, but are not limited to, acyl chlorides, symmetrical or asymmetrical anhydrides, and esters. In some embodiments, the activated carboxylic acid group is an ester having pentafluorophenol, nitrophenol, benzotriazole, azabenzotriazole, thiophenol, or N-hydroxysuccinimide (NHS) as the leaving group.

[0297] In an embodiment, and preferably as used herein, the term "via a bond" means that a bond or type of bond, preferably a bond between two moieties, is established. In a preferred embodiment, the bond or type of bond is as defined herein.

[0298] To the extent that this application refers to a range expressed by a lower integer and a higher integer, such as 1 to 4, such range represents the lower integer, the higher integer, and any integer between the lower and higher integers. To that extent, the range is actually a separate disclosure of said integers. Thus, in the example, the range 1 to 4 means 1, 2, 3, and 4.

[0299] In embodiments, and preferably as used herein, the term alkyl refers individually to a saturated, straight-chain or branched-chain hydrocarbon group, usually accompanied by a modifier specifying the number of carbon atoms it may contain. For example, the term (C1-C6) alkyl refers individually to any of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 1-ethylpropyl, 3-methylbutyl, 1,2-dimethylpropyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, n-hexyl, 1,1-dimethylbutyl, and any other isoform of an alkyl group containing 6 saturated carbon atoms.

[0300] In an embodiment, and preferably as used herein, (C1-C2) alkyl refers to each and individually either methyl or ethyl.

[0301] In an embodiment, and preferably as used herein, (C1-C3) alkyl refers to each and individually any of methyl, ethyl, n-propyl, and isopropyl.

[0302] In an embodiment, and preferably as used herein, (C2-C3) alkyl refers each and individually to any of ethyl, n-propyl, and isopropyl.

[0303] In an embodiment, and preferably as used herein, (C1-C4) alkyl refers each and individually to any of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.

[0304] In an embodiment, and preferably as used herein, (C2-C4) alkyl refers each and individually to any of ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.

[0305] In an embodiment, and preferably as used herein, (C1-C6) alkyl is each and individually methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methyl-butyl, 3-methyl-butyl, 3-pentyl, 3-methyl-but-2-yl, 2-methyl-but-2-yl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 2-methyl- pentyl, 3-methyl-pentyl, 4-methyl-pentyl, 3-hexyl, 2-ethyl-butyl, 2-methyl-pent-2-yl, 2,2-dimethyl-butyl, 3,3-dimethyl-butyl, 3-methyl-pent-2-yl, 4-methyl-pent-2-yl, 2,3-dimethyl-butyl, 3-methyl-pent-3-yl, 2-methyl-pent-3-yl, 2,3-dimethyl-but-2-yl and 3,3-dimethyl-but-2-yl.

[0306] In an embodiment, and preferably as used herein, "(C1-C8) alkyl" refers to a saturated or unsaturated, straight or branched chain hydrocarbon group having 1 to 8 carbon atoms. Representative (C1-C8) alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methyl-butyl, 3-methyl-butyl, 3-pentyl, 3-methyl-but-2-yl, 2-methyl-but-2-yl, 2,2-dimethylpropyl, n-hexyl, 2-hexyl, 2-methyl-pentyl, 3-methyl-pentyl, 4-methyl-pentyl, and the like. yl, 3-hexyl, 2-ethyl-butyl, 2-methyl-pent-2-yl, 2,2-dimethyl-butyl, 3,3-dimethyl-butyl, 3-methyl-pent-2-yl, 4-methyl-pent-2-yl, 2,3-dimethyl-butyl, 3-methyl-pent-3-yl, 2-methyl-pent-3-yl, 2,3-dimethyl-but-2-yl, 3,3-dimethyl-but-2-yl, n-heptyl, 2-heptyl, 2-methyl-hexyl, 3-methyl -hexyl, 4-methyl-hexyl, 5-methyl-hexyl, 3-heptyl, 2-ethyl-pentyl, 3-ethyl-pentyl, 4-heptyl, 2-methyl-hex-2-yl, 2,2-dimethyl-pentyl, 3,3-dimethyl-pentyl, 4,4-dimethyl-pentyl, 3-methyl-hex-2-yl, 4-methyl-hex-2-yl, 5-methyl-hex-2-yl, 2,3-dimethyl-pentyl, 2,4-dimethyl-pentyl, 3, 4-Dimethyl-pentyl, 3-methyl-hex-3-yl, 2-ethyl-2-methyl-butyl, 4-methyl-hex-3-yl, 5-methyl-hex-3-yl, 2-ethyl-3-methyl-butyl, 2,3-dimethyl-pent-2-yl, 2,4-dimethyl-pent-2-yl, 3,3-dimethyl-pent-2-yl, 4,4-dimethyl-pent-2-yl, 2,2,3-trimethyl-butyl, 2,3,3-trimethyl-butyl, 2,3,3-trimethyl-but-2-yl, n-octyl, 2-octyl, 2-methyl-heptyl, 3-methyl-heptyl, 4-methyl-heptyl, 5-methyl-heptyl, 6-methyl-heptyl, 3-octyl, 2-ethyl-hexyl, 3-ethyl-hexyl, 4-ethyl-hexyl, 4-octyl, 2-propyl-pentyl, 2-methyl-hept-2-yl, 2,2-dimethyl-hexyl, 3,3-dimethyl-hexyl, 4,4-dimethyl-hexyl, 5,5-dimethyl-hexyl, 3-methyl-hept-2-yl, 4-methyl-hept-2- yl, 5-methyl-hept-2-yl, 6-methyl-hept-2-yl, 2,3-dimethyl-hex-1-yl, 2,4-dimethyl-hex-1-yl, 2,5-dimethyl-hex-1-yl, 3,4-dimethyl-hex-1-yl, 3,5-dimethyl-hex-1-yl, 3-methyl-hept-3-yl, 2-ethyl-2-methyl-1-yl, 3-ethyl-3-methyl-1-yl, 4-methyl-hept-3-yl, 5-methyl-hept-3-yl, 6-methyl-hept-3-yl, 2-ethyl-3-methyl-pentyl, 2-ethyl-4- Methyl-pentyl, 3-ethyl-4-methyl-pentyl, 2,3-dimethyl-hex-2-yl, 2,4-dimethyl-hex-2-yl, 2,5-dimethyl-hex-2-yl, 3,3-dimethyl-hex-2-yl, 3,4-dimethyl-hex-2-yl, 3,5-dimethyl-hex-2-yl, 4,4-dimethyl-hex-2-yl, 4,5-dimethyl-hex-2-yl, 5,5-dimethyl-hex-2-yl, 2,2,3-trimethyl-pentyl, 2,2,4-trimethyl-pentyl, 2,3,3-trimethyl-pentyl, 2,3 , 4-trimethyl-pentyl, 2,4,4-trimethyl-pentyl, 3,3,4-trimethyl-pentyl, 3,4,4-trimethyl-pentyl, 2,3,3-trimethyl-pent-2-yl, 2,3,4-trimethyl-pent-2-yl, 2,4,4-trimethyl-pent-2-yl, 3,4,4-trimethyl-pent-2-yl, 2,2,3,3-tetramethyl-butyl, 3,4-dimethyl-hex-3-yl, 3,5-dimethyl-hex-3-yl, 4,4-dimethyl-hex-3-yl, 4,5-dimethyl-hex-3-yl, 5,Examples of alkyl groups include, but are not limited to, 5-dimethyl-hex-3-yl, 3-ethyl-3-methyl-pent-2-yl, 3-ethyl-4-methyl-pent-2-yl, 3-ethyl-hex-3-yl, 2,2-diethyl-butyl, 3-ethyl-3-methyl-pentyl, 4-ethyl-hex-3-yl, 5-methyl-hept-3-yl, 2-ethyl-3-methyl-pentyl, 4-methyl-hept-4-yl, 3-methyl-hept-4-yl, 2-methyl-hept-4-yl, 3-ethyl-hex-2-yl, 2-ethyl-2-methyl-pentyl, 2-isopropyl-pentyl, 2,2-dimethyl-hex-3-yl, 2,2,4-trimethyl-pent-3-yl, and 2-ethyl-3-methyl-pentyl. The (C1-C8) alkyl group may be unsubstituted or substituted with one or more groups. Such groups include, but are not limited to, (C1-C8) alkyl, -O-[(C1-C8) alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2, and -CN, where each R' is independently selected from -(C1-C8) alkyl and aryl.

[0307] In an embodiment, and preferably as used herein, a "nucleophile" refers to a chemical species that can donate an electron pair to form a chemical bond. In a more preferred embodiment, and preferably as used herein, a nucleophile comprises a heteroatom, wherein the heteroatom preferably comprises a nitrogen atom or a sulfur atom.

[0308] In an embodiment, and preferably as used herein, "bis-nucleophile" refers to a group comprising a first nucleophile and a second nucleophile, wherein each nucleophile of the bis-nucleophile comprises a heteroatom. The heteroatom of the first of the two nucleophiles is a nitrogen atom. The heteroatom of the second of the two nucleophiles is selected from the group comprising a nitrogen atom and a sulfur atom, and preferably, the heteroatom of the second of the two nucleophiles is a sulfur atom. In a more preferred embodiment, the "bis-nucleophile" is an aliphatic "bis-nucleophile." In an aliphatic "bis-nucleophile," the heteroatom of the nucleophile is covalently bonded to a terminal carbon atom of a (C1-C4) alkyl, preferably a (C1-C3) alkyl, more preferably a (C1-C2) alkyl, where each carbon atom is optionally substituted with one or more groups, preferably one group, where said groups are individually and independently selected from the group consisting of -CONH2, -CONHR, -COOH, and -CH2OH. Examples of bis-nucleophiles include, but are not limited to, 2-aminoethanethiol, 2-aminoethanol, ethylenediamine, 3-aminopropane-1-thiol, 3-amino-1-propanol, and 1,3-diaminopropane.

[0309] In an embodiment, and preferably as used herein, "aryl" or "aryl ring" refers to a carbocyclic aromatic group, wherein the carbocyclic aromatic group is selected from the group consisting of aromatic groups having a single ring and aromatic groups having two or more condensed rings, preferably two rings. Examples of carbocyclic aromatic groups having one benzene ring include, but are not limited to, phenyl, and examples of carbocyclic aromatic groups having two or more condensed benzene rings include, but are not limited to, naphthyl and anthracenyl. A carbocyclic aromatic group can be unsubstituted or substituted with one or more groups including, but not limited to, -(C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH, -CO-NHR', -CO-NR', -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH, -NHR', -NR'2, and -CN, where each R' is independently selected from -(C1-C8)alkyl and aryl. In a more preferred embodiment, the carbocyclic aromatic group includes two substituents of the one or more groups, wherein the first of the two groups is attached to a first ring atom of the carbocyclic aromatic group. The second of the two groups is attached to either a second ring atom of the carbocyclic aromatic group that is directly adjacent to the first ring atom or a second ring atom of the carbocyclic aromatic group, where the second ring atom is separated from the first ring atom by an additional ring atom.

[0310] In an embodiment, and preferably as used herein, " heteroaryl " or " heteroaryl ring " refers to a heteroaromatic group, wherein said heteroaromatic group is selected from the group consisting of the heteroaromatic group with a single ring and the heteroaromatic group with two or more condensed rings, preferably the heteroaromatic group with two rings.The examples of the heteroaromatic group with a single ring include but are not limited to furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, and the examples of the heteroaromatic group with two or more condensed rings include but are not limited to benzothiophenyl, benzofuranyl, indolyl, quinolinyl. Heteroaromatic groups can be unsubstituted or substituted with one or more groups including, but not limited to, -(C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH, -CO-NHR', -CO-NR', -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH, -NHR', -NR'2, and -CN, where each R' is independently selected from -(C1-C8)alkyl and aryl. In a more preferred embodiment, the heteroaromatic group includes two substituents of the one or more groups, wherein the first of the two groups is attached to a first ring atom of the heteroaromatic group. The second of the two groups is attached to either a second ring atom of the heteroaromatic group that is directly adjacent to the first ring atom or a second ring atom of the heteroaromatic group, where the second ring atom is separated from the first ring atom by an additional ring atom.

[0311] In an embodiment, and preferably as used herein, "aromatic residue" or / and "aromatic ring" refers to aryl as defined herein.

[0312] In an embodiment, and preferably as used herein, an "aromatic side chain" refers to a side chain that includes an "aromatic ring" as defined herein.

[0313] In an embodiment, and preferably as used herein, "bicyclic aromatic ring" refers to aryl as defined herein, wherein the aryl carbocyclic aromatic group is selected from the group of aromatic groups having two or more fused rings, preferably two rings.

[0314] In an embodiment, and preferably as used herein, a "bicyclic aromatic side chain" refers to a side chain that comprises a "bicyclic aromatic ring" as defined herein.

[0315] In an embodiment, and preferably as used herein, "(C9 to C 10 A "bicyclic aromatic ring" refers to a "bicyclic aromatic ring" containing 9 or 10 atoms forming the two rings of a bicyclic ring as defined herein.

[0316] In an embodiment, and preferably as used herein, "(C9 to C 10 ) bicyclic aromatic side chain" refers to a side chain having a "(C9-C 10 ) refers to a side chain containing a bicyclic aromatic ring.

[0317] In an embodiment, and preferably as used herein, "bicyclic non-aromatic residue" refers to a bicyclic heterocyclic group having two fused rings, wherein at least one atom is different from carbon, and preferably at least one atom is nitrogen, sulfur, or oxygen. Examples of bicyclic non-aromatic residues include, but are not limited to, octahydroquinoline and octahydroisoquinoline. The bicyclic non-aromatic residue may be unsubstituted or substituted with one or more groups including, but not limited to, -(C1-C8)alkyl, -O-[(C1-C8)alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2, and -CN, where each R' is independently selected from -(C1-C8)alkyl and aryl.

[0318] In an embodiment, and preferably as used herein, "(C9 to C 10 A "bicyclic non-aromatic residue" is defined herein and refers to a "bicyclic non-aromatic residue" that contains 9 or 10 atoms that form the two rings of the bicyclic ring.

[0319] In an embodiment, and preferably as used herein, a "heteroaromatic side chain" refers to a side chain that comprises a heteroaryl as defined herein.

[0320] In an embodiment, and preferably as used herein, "bicyclic heteroaromatic ring" refers to heteroaryl, as defined herein, wherein heteroaryl comprises two rings.

[0321] In an embodiment, and preferably as used herein, a "bicyclic heteroaromatic side chain" refers to a side chain that comprises a "bicyclic heteroaromatic ring" as defined herein.

[0322] In an embodiment, and preferably as used herein, "(C-C)heteroaryl" refers to heteroaryl as defined herein, wherein the heteroaryl heteroaromatic group is selected from the group consisting of heteroaromatic groups having a single ring.

[0323] In embodiments, and preferably as used herein, a "(C-C) heteroaromatic side chain" refers to a side chain that comprises a "(C-C) heteroaryl" as defined herein.

[0324] In an embodiment, and preferably as used herein, "(C9 to C 10 ") Bicyclic heteroaromatic ring" refers to heteroaryl as defined herein, wherein the heteroaromatic group of the heteroaryl is selected from the group of heteroaromatic groups having two rings, wherein the heteroaromatic group having two rings contains 9 to 10 ring atoms.

[0325] In an embodiment, and preferably as used herein, "(C9 to C 10 ) bicyclic heteroaromatic side chain" is defined herein as "(C9-C 10 ) refers to a side chain containing a bicyclic heteroaromatic ring.

[0326] In an embodiment, and preferably as used herein, an arylene has two covalent bonds and has the structure [ka] " refers to an aryl group, which can be in either the ortho, meta, or para configuration, as shown in Figure 1, where the phenyl group can be unsubstituted or substituted with four groups including (but not limited to) (C1-C8) alkyl, -O-[(C1-C8) alkyl], -aryl, -CO-R', -O-CO-R', -CO-OR', -CO-NH2, -CO-NHR', -CO-NR'2, -NH-CO-R', -SO2-R', -SO-R', -OH, -halogen, -N3, -NH2, -NHR', -NR'2, and -CN, where each R' is independently selected from -(C1-C8) alkyl and aryl.

[0327] In an embodiment, and preferably as used herein, the C-terminal group, C-term, is one amino acid residue or a dipeptide comprising two amino acid residues. When the C-terminus is a dipeptide, the first of the two amino acid residues is the N-terminal (assuming the two amino acid residues are covalently bonded to each other by a peptide bond), and the last of the two amino acid residues is the C-terminal residue. One of the two amino acids or the first amino acid is covalently bonded to the C-terminal amino acid residue of the compound of the present invention. In a more specific embodiment, and preferably as used herein, an optional linker is interposed between the C-terminal amino acid residue of the compound of the present invention and one of the amino acid residues or the first amino acid residue of the C-terminal dipeptide.

[0328] In embodiments, and preferably as used herein, any atom whose atomic mass number is not specified anywhere in the specification, including any structural formula or claim, can be either an unspecified isotopic composition, a natural mixture of isotopes, or an individual isotope. This applies in particular to carbon, oxygen, nitrogen, sulfur, phosphorus, halogen, and metal atoms, including, but not limited to, C, O, N, S, F, P, Cl, Br, At, Sc, Cr, Mn, Co, Fe, Cu, Ga, Sr, Zr, Y, Mo, Tc, Ru, Rh, Pd, Pt, Ag, In, Sb, Sn, Te, I, Pr, Pm, Dy, Sm, Gd, Tb, Ho, Dy, Er, Yb, Tm, Lu, Sn, Re, Rd, Os, Ir, Au, Pb, Bi, Po, Fr, Ra, Ac, Th, and Fm.

[0329] In an embodiment, and preferably as used herein, a chelating agent is a compound capable of forming a chelate, where the chelate is a compound, preferably a cyclic compound, in which a metal or a site having an electron gap or an unshared pair of electrons participates in the formation of a ring. More preferably, a chelating agent is a type of compound in which a single ligand occupies two or more coordination sites at a central atom.

[0330] In an embodiment, and preferably as used herein, a biodistribution modifier is a compound whose function can attenuate unintended or undesired biodistribution of a compound of the present invention by altering the physicochemical properties of the compound. Alternatively or additionally, the function of a biodistribution modifier can be to bind to components of serum, thereby altering serum half-life by extending serum half-life and / or modulating renal clearance.

[0331] In an embodiment, and preferably as used herein, "dicarboxylic acid residue" refers to a compound having two carboxylic acid groups, where the two carboxylic acid groups are attached to the terminal carbon atoms of a (C1-C6) alkyl. Examples of dicarboxylic acid residues include, but are not limited to, malonic acid, succinic acid, glutaric acid, and pimelic acid.

[0332] In an embodiment, and preferably as used herein, a "Z group" refers to (a) a chelator, optionally with a linker; (b) a biodistribution modifier, optionally with a linker; or (c) a combination of a chelator, optionally with a linker, and a biodistribution modifier, optionally with a linker, wherein the chelator and the biodistribution modifier are covalently linked together by an amino acid residue that either (i) directly bonds the chelator to the biodistribution modifier; (ii) bonds the chelator with a linker to the biodistribution modifier; (iii) bonds the chelator to the biodistribution modifier with a linker; or (iv) bonds the chelator with a linker to the biodistribution modifier with a linker. In a preferred embodiment, the amino acid residue connecting the chelator, optionally with a linker, and the biodistribution modifier, optionally with a linker, is also covalently attached to the Z group attachment point and the Z group attachment point, respectively, of the compound of the present invention, where the Z group attachment point and the Z group attachment point can be covalently attached to the chelator, optionally with a linker, and the biodistribution modifier, optionally with a linker. Each of the Z group attachment point and the Z group attachment point can be covalently attached to the compound of the present invention, where the Z group attachment point and the Z group attachment point can be covalently attached to the chelator, optionally with a linker, and the biodistribution modifier, optionally with a linker, can be covalently attached to the compound of the present invention, where the Z group attachment point and the Z group attachment point can be covalently attached to the compound of the present invention. Figure 6 shows various options for attaching the chelator, optionally with a linker, and the biodistribution modifier, optionally with a linker, to the Z group attachment point.

[0333] In accordance with the present invention, Z group attachment points are particularly the following: N-terminal modification group A, which may include both a first Z group and a second Z group; Xaa4, which includes one Z group; Xaa5, which includes one Z group; Xaa8, which includes one Z group; Yc, which includes one Z group; and C-terminal modification group C-term, which may include both a first Z group and a second Z group.

[0334] More preferred Z group attachment points are the N-terminal modification group A ...

Claims

1. Formula (Ia) 【Chemistry 492】 or a cyclic peptide represented by formula (Ib): 【Chemistry 493】 The cyclic peptide comprises: each optionally comprising an N-terminal modification group A attached to Xaa1; each optionally comprising a C-terminal group, C-term, attached to Xaa11; where: The peptide sequences are depicted from left to right, N- to C-terminally. Xaa1 is an α-amino acid residue containing a side chain, the side chain containing an acidic or polar group, or Xaa1 is a residue of an aliphatic carboxylic acid containing an acidic group or a polar group at the ω position, wherein the carbonyl group of Xaa1 is covalently bonded to the α-nitrogen atom of Xaa2; Xaa2 is an α-amino acid residue comprising a side chain that comprises a heteroaryl or aryl ring, preferably Xaa2 is an α-amino acid residue having a side chain that comprises a heteroaryl ring; wherein the carbonyl group of Xaa2 is covalently bonded to the α-nitrogen atom of Xaa3; Xaa3 is an α-amino acid residue comprising a side chain that comprises a heteroaryl or aryl ring, preferably Xaa3 is an α-amino acid residue comprising a side chain that comprises a heteroaryl ring; wherein the carbonyl group of Xaa3 is covalently bonded to the α-nitrogen atom of Xaa4; Xaa4 is an α-amino acid residue optionally containing a Z group or an N-alkylated α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa4 is covalently bonded to the α-nitrogen atom of Xaa5; Xaa5 is an α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa5 is covalently bonded to the α-nitrogen atom of Xaa6; Xaa6 is an α-amino acid residue comprising a side chain, the side chain comprising a branched aliphatic group; wherein the carbonyl group of Xaa6 is covalently bonded to the α-nitrogen atom of Xaa7; Xaa7 is an α-amino acid residue comprising a side chain, the side chain comprising a nucleophilic group, the nucleophilic group comprising a heteroatom, the heteroatom being selected from the group comprising a sulfur atom and a nitrogen atom; wherein the carbonyl group of Xaa7 is covalently bonded to the α-nitrogen atom of Xaa8; Xaa8 is an α-amino acid residue optionally containing a Z group; wherein the carbonyl group of Xaa8 is covalently bonded to the α-nitrogen atom of Xaa9; Xaa9 is an α-amino acid residue, wherein the carbonyl group of Xaa9 is covalently bonded to the α-nitrogen atom of Xaa10; Xaa10 is an α-amino acid residue comprising a side chain, the side chain comprising a branched aliphatic group or an unsubstituted aromatic ring; wherein the carbonyl group of Xaa10 is covalently bonded to the α-nitrogen atom of Xaa11 when Xaa11 is an α-amino acid residue comprising a side chain, the side chain comprising a nucleophilic group, the nucleophilic group comprising a heteroatom, the heteroatom being selected from the group comprising sulfur and nitrogen atoms, or when Xaa11 is a residue of an aliphatic bis-nucleophile, the first nucleophile of the bis-nucleophile being a nitrogen atom, and the second nucleophile of the bis-nucleophile being a heteroatom, the heteroatom being selected from the group comprising sulfur and nitrogen atoms for the first nucleophile; Xaa11 is an α-amino acid residue comprising a side chain, the side chain comprising a nucleophilic group, the nucleophilic group comprising a heteroatom, the heteroatom being selected from the group comprising a sulfur atom and a nitrogen atom; or Xaa11 is a residue of an aliphatic bis-nucleophile, wherein a first nucleophile of the bis-nucleophile is a nitrogen atom and a second nucleophile of the bis-nucleophile is a heteroatom selected from the group consisting of a sulfur atom and a nitrogen atom; Xaa7 and Xaa11 are indirectly linked or directly covalently linked to each other to form a macrocyclic ring; wherein Xaa7 and Xaa11 are indirectly bonded to form a cyclic peptide of formula (Ia), the heteroatom of Xaa7 and the heteroatom of Xaa11 are bonded via a ring interposed between the heteroatom of Xaa7 and the heteroatom of Xaa11 to form Yc, the ring being a heteroaryl ring, an aryl ring or a heterocycle optionally containing a Z group, and these heteroatoms are each individually selected from the group consisting of sulfur atoms and nitrogen atoms; is a sulfur atom, Xaa7 is covalently bonded to the ring by a thioether bond; when the heteroatom of Xaa7 is a nitrogen atom, Xaa7 is covalently bonded to the ring by an amine or amide bond; when the heteroatom of Xaa11 is a sulfur atom, Xaa11 is covalently bonded to the ring by a thioether bond; when the heteroatom of Xaa11 is a nitrogen atom, Xaa11 is covalently bonded to the ring by an amine or amide bond; or When Xaa7 and Xaa11 are directly covalently bonded to form a cyclic peptide represented by formula (Ib), the heteroatom of Xaa7 is a sulfur atom, and the heteroatom of Xaa11 is a sulfur atom, and they form a disulfide bond; and when N-terminal modifying group A is present, N-terminal modifying group A is a) a Z group (with a linker optionally interposed between the Z group and Xaa1); b) a blocking group AblN; c) an amino acid residue optionally comprising a Z group and an amino acid residue optionally comprising a blocking group AbIN; d) an N-terminal dipeptide group comprising a first amino acid residue and a second amino acid residue, wherein the first amino acid residue is the N-terminal amino acid residue and the second amino acid residue is the C-terminal amino acid residue, the first amino acid residue optionally comprises a blocking group AblN, the first amino acid residue and the second amino acid residue are covalently linked to each other, preferably by a peptide bond, the second amino acid residue is covalently linked to the Xaa1 residue or a linker is interposed between the second amino acid residue and the Xaa1 residue, and the Z group is optionally covalently linked to the first amino acid residue and / or the Z group is optionally covalently linked to the second amino acid residue. and selected from the group comprising: And, when a C-terminal group C-term is present, the C-terminal group C-term is a) an amino acid residue, wherein the amino acid residue is covalently linked to Xaa11 or a linker is interposed between the amino acid residue and Xaa11, a Z group is optionally covalently linked to the amino acid residue, and the amino acid residue comprises a blocking group AbIC; b) a C-terminal dipeptide group, the C-terminal dipeptide group comprising a first amino acid residue and a second amino acid residue, wherein the first amino acid residue is the N-terminal amino acid residue and the second amino acid residue is the C-terminal amino acid residue, the first amino acid residue and the second amino acid residue are preferably covalently linked to each other by a peptide bond, wherein the first amino acid residue is covalently linked to the Xaa1 residue or a linker is interposed between the first amino acid residue and the Xaa1 residue, and wherein a Z group is optionally covalently linked to the first amino acid residue and / or a Z group is optionally covalently linked to the second amino acid residue, the second amino acid residue comprising a blocking group AbIC; c) a Z group and d) Blocking Group AblC selected from the group comprising: compound.

2. Xaa1 is (a) an α-amino acid residue containing a side chain, the side chain containing an acidic or polar group; or (b) A residue of an aliphatic carboxylic acid containing an acidic group or a polar group at the ω position, preferably, Xaa1 is an amino acid residue represented by formula (IIa), (IIb) or (IIc), more preferably, Xaa1 is an amino acid residue represented by formula (IIa) 【Chemistry 494】 [In the formula, R 1a is -NH-, H, -NH((C 1 ~C 4 ) alkyl)-, OH and (C 1 ~C 4 ) alkyl; Here, R 1a -NH- and -NH((C 1 ~C 4 ) alkyl)-, the N-terminal modifying group A is selected from the group consisting of R 1a is covalently bonded to the nitrogen atom of R 1a is H, OH or (C 1 ~C 4 ) alkyl, when the N-terminal modifying group A is absent; R 1b is CO 2 H, SO 3 H, OPO 3 H 2 , C.O.N.H. 2 and OH, R 1c is R 1b CO 2 H, SO 3 H and CONH 2 H, OH and (C 1 ~C 2 ) alkyl, or R 1b OH and OPO 3 H 2 R is selected from the group consisting of 1c H and (C 1 ~C 2 ) alkyl; R 1d is H and (C 1 ~C 2 ) alkyl, preferably R 1c But (C 1 ~C 2 ) alkyl, R 1d But the same (C 1 ~C 2 ) alkyl, R 1e is H, OH and (C 1 ~C 2 ) alkyl; R 1f is H and (C 1 ~C 2 ) alkyl, preferably R 1e But (C 1 ~C 2 ) alkyl, R 1f But the same (C 1 ~C 2 ) alkyl] is an amino acid residue represented by the carbonyl group of Xaa1 is covalently bound to the α-nitrogen atom of Xaa2; Xaa2 is an α-amino acid residue having a side chain (a), the side chain comprising a heteroaryl or aryl ring, preferably Xaa2 is an amino acid residue of formula (IIIa) or (IIIb), more preferably formula (IIIa) 【Chemistry 495】 [In the formula, X 2a , NH, NCH 3 and S, preferably selected from the group consisting of NH and S; X 2b is N, CH, CF and C-CH 3 and preferably selected from the group consisting of N and CH; R 2a is H, halogen, methyl and OCH 3 and preferably R 2a is selected from the group consisting of H and F; R 2b is H, halogen, methyl and OCH 3 Preferably, the halogen is selected from the group consisting of Cl and Br, more preferably, R 2b is selected from the group consisting of H, Cl, and Br; R 2c is H, OH, halogen, methyl and OCH 3 Preferably, the halogen is selected from the group consisting of F, Cl and Br, more preferably, R 2c is selected from the group consisting of H, F, and OH; R 2d is H, halogen, methyl and OCH 3 wherein halogen is selected from the group consisting of F, Cl and Br, preferably R 2d is H, R 2e is selected from the group consisting of H, halogen and methyl, preferably halogen is Cl, more preferably R 2e is H, R 2f is H and OCH 3 and preferably R 2f is H, R 2g is H, OH, methyl and OCH 3 and preferably R 2g is H] or (b) Xaa2 is an α-amino acid residue comprising a side chain, said side chain comprising an aryl ring, preferably Xaa2 is an α-amino acid residue comprising a side chain of formula (IIIc), provided that Xaa3 is of formula (IVa) or (IVb), preferably Xaa3 is of formula (IVa). 【Chemistry 496】 [In the formula, R 2h is H, methyl, CF 3 , OH, OCH 3 , OCF 3 , C.O.N.H. 2 and halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R 2h is H, Cl or Br, R 2i is H, methyl, C(CH 3 ) 3 , C.F. 3 , OH, OCH 3 , OCH 2 CH 3 , OCF 3 , C.O.N.H. 2 , CO 2 H and halogen, preferably halogen is selected from the group consisting of Cl and Br, more preferably R 2i is selected from the group consisting of H, Cl, and Br; R 2k is H, methyl, CF 3 , OH, OCH 3 , OCF 3 , C.O.N.H. 2 and halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R 2k is selected from the group consisting of H, Cl, and Br; R 2m is H, methyl, CF 3 , OH, OCH 3 , OCF 3 , C.O.N.H. 2 and halogen, preferably the halogen is selected from the group consisting of Cl and Br, more preferably R 2m is selected from the group consisting of H, Cl and Br. is an amino acid residue represented by the carbonyl group of Xaa2 is covalently bound to the α-nitrogen atom of Xaa3; Xaa3 is (a) an α-amino acid residue containing a side chain, the side chain containing a heteroaryl ring or an aryl ring, preferably Xaa3 is an amino acid residue represented by formula (IVa) or (IVb), more preferably Xaa3 is an amino acid residue represented by formula (IVa) 【Chemistry 497】 [In the formula, X 3a , NH, NCH 3 and S, preferably selected from the group consisting of NH and S; X 3b is C—H, C—F, C—Cl, C—Br, C—CH 3 , C-OCH 3 and N, preferably X 3b is C—H or C—F, X 3c is selected from the group consisting of C and N, preferably X 3c is C, R 3b is H, halogen, methyl and OCH 3 Preferably, the halogen is selected from the group consisting of F and Cl, more preferably, R 3b is selected from the group consisting of H and F; R 3c is H, halogen, methyl and OCH 3 Preferably, the halogen is selected from the group consisting of Cl, Br and F, more preferably, R 3c is selected from the group consisting of Cl and Br; R 3d is H, halogen, methyl and OCH 3 Preferably, the halogen is F; R 3e is selected from the group consisting of H, halogen and methyl, preferably halogen is Cl; R 3f is H and OCH 3 selected from the group consisting of R 3g is H, F, OH, methyl and OCH 3 selected from the group consisting of or an amino acid residue represented by (b) Xaa3 is an α-amino acid residue containing a side chain, the side chain containing an aryl ring, provided that Xaa2 is an amino acid residue of formula (IIIa), and preferably Xaa3 is an α-amino acid residue containing an aryl ring, the side chain containing an aryl ring, provided that Xaa2 is an amino acid residue of formula (IIIa), 【Chemistry 498】 [In the formula, R 3h is halogen, OH, methyl, CF 3 , OCH 3 , OCF 3 and CONH 2 Preferably, the halogen is selected from the group consisting of Cl and Br; R 3i is halogen, OH, methyl, CF 3 , OCH 3 , OCF 3 and CONH 2 and preferably the halogen is selected from the group consisting of Cl and Br. is an amino acid residue represented by the carbonyl group of Xaa3 is covalently bound to the α-nitrogen atom of Xaa4; Xaa4 is (a) a cyclic non-aromatic α-amino acid residue, preferably Xaa4 is a residue of formula (Va): 【Chemistry 499】 [In the formula, R 4a is H, OH, methyl and CF 3 selected from the group consisting of R 4b is selected from the group consisting of H and methyl, preferably R 4a is methyl, R 4b is methyl, X 4 is CHR 4c , S, and O; R 4c is not present or NH 2 ,OH,H,NHR 4d , methyl and F, preferably R 4c But NH 2 or OH, where R 4d is selected from the group consisting of Ac and Z groups; m is 1 or 2, preferably m is 1. or (b) an N-alkylated amino acid residue, preferably Xaa4 is a group represented by formula (Vb): 【Chemical 500】 [In the formula, n is 0, 1, 2, 3, 4 or 5, preferably n is 0, 1 or 3; R 4e When n is 0, H, methyl, an aryl ring, COOH, CONH 2 and C(=O)R 4h or when n is 1, 2, 3, 4 or 5, R 4e is H, methyl, aryl ring, OH, NH 2 , COOH, CONH 2 and C(=O)R 4h selected from the group consisting of R 4f is H and (C 1 ~C 2 ) alkyl; R 4g is selected from the group consisting of H and methyl; R 4h is a Z group, preferably the Z group is a biodistribution modifier, more preferably the biodistribution modifier is AGLU. or an amino acid residue represented by (c) Xaa4 is a bicyclic non-aromatic amino acid residue, preferably Xaa4 is a group represented by formula (Vc): 【Chemistry 501】 wherein o is 1 or 2. is an amino acid residue represented by the carbonyl group of Xaa4 is covalently bound to the α-nitrogen atom of Xaa5; Xaa5 is (a) an α-amino acid residue optionally containing a Z group (the α-nitrogen atom of the α-amino acid is (C 1 ~C 4 ) optionally substituted by alkyl) or (b) a cyclic α-amino acid, wherein the carbonyl group of Xaa5 is covalently bonded to the α-nitrogen atom of Xaa6; Xaa6 is an α-amino acid residue comprising a side chain, the side chain comprising a branched chain aliphatic group, preferably Xaa6 is represented by formula (VIIa): 【Chemistry 502】 [In the formula, p is 1, 0 or 2, preferably p is 1; R 6a is (C 1 ~C 2 ) alkyl; R 6b is methyl, R 6c is H when p is 0, or is selected from the group consisting of H and methyl when p is 1 or 2. is an amino acid residue represented by the carbonyl group of Xaa6 is covalently bound to the α-nitrogen atom of Xaa7; Xaa7 is an α-amino acid residue comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, preferably Xaa7 is represented by formula (VIIIa) 【Chemistry 503】 [In the formula, X 7 contains a heteroatom and is selected from the group consisting of —S— and —NH—; q is 1 or 2, preferably q is 1. is an α-amino acid residue represented by the carbonyl group of Xaa7 is covalently bound to the α-nitrogen atom of Xaa8; Xaa8 is (a) an aliphatic cyclic α-amino acid residue, an aliphatic heterocyclic α-amino acid residue, or an aliphatic cyclic α-amino acid residue containing a cyclic aromatic ring, preferably an amino acid residue represented by formula (IXa) or (IXb), more preferably an amino acid residue represented by formula (IXa) 【Chemistry 504】 [In the formula, X 8 is NR 8a , O, NH and CH 2 wherein R 8a is a Z group or R 8a is acetyl, r is 2 or 1, preferably r is 2; s is 1 or 2, preferably s is 1; t is 1 or 2, and preferably, when s is 1, t is 1, and when s is 2, t is 2. or an amino acid residue represented by (b) Xaa8 is an α-amino acid residue or an α-alkyl-α-amino acid residue, wherein Xaa8 is preferably a group represented by formula (IXc): 【Chemistry 505】 [In the formula, R 8b is H, OH, NH 2 , N.H.R. 8e , (C 1 ~C 2 ) alkyl, COOH, CONH 2 , an aryl ring, and a heteroaryl ring, preferably the aryl ring is phenyl, the heteroaryl ring is 3-indolyl, and R 8e is a Z group, preferably the Z group is a chelator optionally including a linker; R 8b OH, NH 2 and N.H.R. 8e When selected from the group consisting of 8c is selected from the group consisting of H and methyl or R 8b is H, (C 1 ~C 2 ) alkyl, COOH, CONH 2 , an aryl ring, and a heteroaryl ring, R 8c is selected from the group consisting of H, methyl and OH; R 8d is H and (C 1 ~C 2 ) alkyl; u is 0, 1, 2, 3, 4 or 5, preferably u is 0, 1 or 3. is an amino acid residue represented by the carbonyl group of Xaa8 is covalently bound to the α-nitrogen atom of Xaa9; Xaa9 is an acyclic α-amino acid residue, the acyclic α-amino acid is in the L-configuration and the carbonyl group of Xaa9 is covalently bonded to the α-nitrogen atom of Xaa10; Xaa10 is an α-amino acid residue comprising a side chain, the side chain comprising a branched aliphatic group or an unsubstituted aromatic ring, preferably Xaa10 is represented by formula (XIa): 【Chemistry 506】 [In the formula, R 10a is (C 1 ~C 2 ) selected from the group consisting of alkyl and phenyl; R 10b is selected from the group consisting of methyl and H; R 10c is selected from the group consisting of H and methyl; w is 0 or 1. is an α-amino acid residue represented by when Xaa11 is an α-amino acid residue comprising a side chain, the side chain comprising a nucleophilic group, the nucleophilic group comprising a heteroatom, the heteroatom being selected from the group comprising S and N, or when Xaa11 is a residue of an aliphatic bis-nucleophile, the first nucleophile of the bis-nucleophile is a nitrogen atom, and the second nucleophile relative to the first nucleophile of the bis-nucleophile is a heteroatom, the heteroatom being selected from the group comprising S and N, then the carbonyl group of Xaa10 is covalently bonded to the α-nitrogen of Xaa11; Xaa11 is (a) an α-amino acid residue comprising a side chain, the side chain comprising a nucleophilic group, the nucleophilic group comprising a heteroatom, the heteroatom being selected from the group comprising a sulfur atom and a nitrogen atom; or (b) Xaa11 is a residue of an aliphatic bis-nucleophile, the first nucleophile of the bis-nucleophile being a nitrogen atom, and the second nucleophile of the bis-nucleophile being a heteroatom, the heteroatom being selected from the group comprising a sulfur atom and a nitrogen atom; Preferably, Xaa11 is a group represented by formula (XIIa) 【Chemistry 507】 [In the formula, X 11 contains a heteroatom and is selected from the group consisting of —S— and —NH—; R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, and R 11c is the C-term, x is 1 or 2. It is shown by where R in Xaa1 1a -NH- and -NH((C 1 ~C 4 ) alkyl)-, the N-terminal modifying group A is selected from the group consisting of R 1a and the N-terminal modifying group A is a) a Z group (optionally with a linker between the Z group and Xaa1); or b) a blocking group AblN (wherein the blocking group AblN is acetyl, formula (AblN-Ia) 【Chemistry 508】 [In the formula, R Abl1 is selected from the group consisting of H, OH and halogen, the halogen is preferably selected from the group consisting of F and Cl, preferably R Abl1 is OH] and Nph2p, preferably AblN is of formula (AblN-Ia) or is acetyl, more preferably AblN is acetyl), or c) an amino acid residue according to claim 1, wherein the amino acid is an α-amino acid, the amino acid residue optionally comprises a Z group covalently attached to a side chain of the amino acid residue, optionally comprises a Z group covalently attached to the α-amino group of the amino acid residue, or the amino acid residue optionally comprises a blocking group AbIN covalently attached to the α-amino group of the amino acid residue, preferably wherein the blocking group AbIN is acetyl and the carbonyl group of the amino acid residue is R of residue Xaa1 1a covalently bonded to a nitrogen atom in d) An N-terminal dipeptide group according to claim 1, wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally comprise a Z group, an optional blocking group AbIN is covalently attached to the α-amino group of the first amino acid residue, a linker is optionally interposed between the second amino acid residue and the Xaa1 residue, and in the absence of an intervening linker, the carbonyl group of the first amino acid residue is covalently attached to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is 1a or, if an intervening linker is present, the carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is covalently bonded to a nitrogen atom of the linker, and the carbonyl group of the linker is 1a (covalently bonded to the nitrogen atom in and wherein Xaa11 is of formula (XIIa) [In the formula, R 11b But C(=O)R 11c and R 11c is the C-terminal group C-term], when the C-term is an amino acid residue represented by a) an amino acid residue according to claim 1, which is an α-amino acid optionally containing a Z group and optionally containing an intervening linker between the residue Xaa11 and said amino acid residue, wherein if there is no intervening linker, the carbonyl group R of residue Xaa11 11b is covalently attached to the α-nitrogen of this amino acid residue or when an intervening linker is present, R 11b is covalently bonded to the nitrogen atom of the linker, the carbonyl group of the linker is covalently bonded to the α-nitrogen of the amino acid residue, and a blocking group AbIC is covalently bonded to the carbonyl group of the amino acid residue, and the blocking group AbIC is 2 and OH, and the blocking group AblC is preferably selected from the group consisting of NH 2 is) or b) a C-terminal dipeptide group (wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally contain a Z group, and a linker is optionally interposed between the residue Xaa11 and the first amino acid residue, and if no intervening linker is present, the carbonyl group R of residue Xaa11 11b is covalently linked to the α-nitrogen of the first amino acid residue, and the carbonyl group of the first amino acid residue is covalently linked to the α-nitrogen of the second amino acid residue, or if an intervening linker is present, the carbonyl group R of residue Xaa11 11b is covalently bonded to a nitrogen atom of the linker, a carbonyl group of the linker is covalently bonded to the α-nitrogen of a first amino acid residue, a carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of a second amino acid residue, a blocking group AbIC is covalently bonded to the carbonyl group of the second amino acid residue, and the blocking group AbIC is NH 2 and OH, and the blocking group AblC is preferably selected from the group consisting of NH 2 ) and c) Z group 2. The compound of claim 1 selected from the group comprising:

3. (a) Xaa7 is a group represented by formula (VIIIa) 【Chemistry 509】 [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a group represented by formula (XIIIa) 【Chemistry 510】 [In the formula, R Ya is -CH 2 - and R Yb is -CH 2 - and Y 1 is selected from the group consisting of N and CH; Y 2 is selected from the group consisting of CH and N. The structure is represented by Xaa11 is a group represented by formula (XIIa) 【Chemistry 511】 [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, and R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ic) 【Chemistry 512】 The cyclic peptide comprises: More preferably, the compound has the formula (Ic) [In the formula, X 7 is -S-, and X 11 is -S- and Y 1 is N or CH, and Y 2 is CH, q is 1, and x is 1. The cyclic peptide comprises: Most preferably, the compound has the formula (Ic) [In the formula, X 7 is -S-, and X 11 is -S- and Y 1 is N and Y 2 is CH, q is 1, and x is 1. The cyclic peptide comprises: (b) Xaa7 is a group represented by formula (VIIIa) 【Chemistry 513】 [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a group represented by formula (XIIIh): 【Chemistry 514】 [In the formula, R Ya is -CH 2 - and R Yb is -CH 2 - and R Yc is -CH 2 -R Yd and R Yd is represented by formula (XIIIc), (XIIId) or (XIIIe) 【Chemistry 515】 [In the formula, R Ye and R Yf are each independently H and (C 1 ~C 4 ) alkyl; Each i is independently 1, 2, 3, 4, 5, or 6, preferably 1 or 2; j and k are each independently 1, 2, or 3; X is O or S, preferably X is S; wherein in formulas (XIIIc) and (XIIIe): One of the two nitrogen atoms is R Yc No-CH 2 - is covalently bonded to In formula (XIIId), -X- is R Yc No-CH 2 - is covalently bonded to while the remaining nitrogen atom optionally has a Z group covalently attached thereto, preferably the Z group comprising a chelator and optionally a linker. The structure is represented by the formula: The structure is represented by Xaa11 is a group represented by formula (XIIa) 【Chemistry 516】 [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ii) 【Chemistry 517】 The cyclic peptide comprises: More preferably, the compound has the formula (Ii) [In the formula, X 7 is -S-, and X 11 is -S-, R Yc is -CH 2 -R Yd and R Yd is represented by formula (XIIId) or (XIIIe) [In the formula, R Yf is H, i is 1, j is 1, k is 1, In the formula (XIIId), -X- is S and R Yc No-CH 2 -, and in formula (XIIIe), one of the two nitrogen atoms is R Yc No-CH 2 - is bonded to while the remaining nitrogen atom of either (XIIId) or (XIIIe) optionally has a Z group covalently attached thereto, preferably the Z group comprises a chelator and optionally a linker; q is 1, x is 1. The cyclic peptide comprises: Most preferably, the compound has the formula (Ii) [In the formula, R Yd is a structure represented by formula (XIIId), where -X- is S and R Yf is H and i is 1] The cyclic peptide comprises: (c) Xaa7 is a group represented by formula (VIIIa) 【Chemistry 518】 [In the formula, X 7 is —S— or —NH—, q is 1 or 2, preferably q is 1. is a residue represented by Yc is a group represented by formula (XIIIb) 【Chemistry 519】 [In the formula, R Ya is -CH 2 - and R Yb is -CH 2 - is The structure is represented by Xaa11 is a group represented by formula (XIIa) 【Chemistry 520】 [In the formula, X 11 is —S— or —NH—, R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Id) 【Chemistry 521】 The cyclic peptide comprises: More preferably, the compound has the formula (Id) [In the formula, X 7 is -S-, and X 11 is -S-, q is 1, and x is 1. The cyclic peptide comprises: (d) Xaa7 is a group represented by formula (VIIIb) 【Chemistry 522】 [wherein q is 1 or 2, preferably q is 1] is a residue represented by Yc is a group represented by formula (XIIIg): 【Chemistry 523】 [In the formula, R Yi is H and (C 1 ~C 6 ) alkyl] The structure is represented by Xaa11 is a group represented by formula (XIIb) 【Chemical 524】 [In the formula, R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, wherein R 11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ig) 【Chemistry 525】 The cyclic peptide comprises: More preferably, the compound comprises a cyclic peptide of formula (Ig) wherein q is 1 and x is 1 or 2; (e) Yc is a group represented by formula (XIIIf) 【Chemistry 526】 [In the formula, R Yg is —C(═O)—, R Yh is -CH 2 - is The structure is represented by Xaa7 is a group represented by formula (VIIIa) 【Chemical Formula 527】 [In the formula, X 7 is —S— or —NH—, and R Yh is covalently bonded to q is 1 or 2, preferably q is 1. is a residue represented by Xaa11 is a group represented by formula (XIIa) 【Chemistry 528】 [In the formula, X 11 is —NH—, and R Yg is covalently bonded to R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, and R 11c is the C-terminal group C-term, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (If) 【Chemical 529】 The cyclic peptide comprises: More preferably, the compound has the formula (If) 7 is -S-, q is 1, and x is 1; (f) Yc is a group represented by formula (XIIIf) 【Chemistry 530】 [In the formula, R Yg is —C(═O)—, R Yh is -CH 2 - is The structure is represented by Xaa7 is a group represented by formula (VIIIa) 【Chemistry 531】 [In the formula, X 7 is —NH—, and R Yg is covalently bonded to q is 1 or 2, preferably q is 1. is a residue represented by Xaa11 is a group represented by formula (XIIa) 【Chemistry 532】 [In the formula, X 11 is —S— or —NH—, and R Yh is covalently bonded to R 11b is C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, wherein R 11c is the C-terminus, x is 1 or 2, preferably x is 1. is a residue represented by Preferably, the compound has the formula (Ie) 【Chemistry 533】 The cyclic peptide comprises: More preferably, the compound has the formula (Ie) 11 is -S-, q is 1, and x is 1; or (g) The compound has the formula (Ib) [In the formula, Xaa7 is a group represented by formula (VIIIc) 【Chemical 534】 is a residue represented by Xaa11 is a group represented by formula (XIIc) 【Chemistry 535】 [In the formula, R 11b But C(=O)R 11c , C.O.N.H. 2 , CO 2 H, CH 2 is selected from the group consisting of OH and H, wherein R 11c is the C-terminal group C-term] is a residue represented by the formula: The cyclic peptide comprises: Preferably, the compound has the formula (Ih) 【Chemistry 536】 3. The compound of claim 1, comprising a cyclic peptide of the formula:

4. Xaa1 is an α-amino acid residue containing a side chain, which side chain contains an acidic or polar group in the side chain or a residue of an aliphatic carboxylic acid containing an additional acidic or polar group at the ω position of formula (IId) or (IIe), preferably Xaa1 is a group of formula (IId): 【Chemistry 537】 [In the formula, R 1a is -NH-, H or -N(CH 3 )- is selected from the group consisting of R 1b is CO 2 H, CONH 2 , OH, SO 3 H and OPO 3 H 2 selected from the group consisting of R 1a is -NH- or -N(CH 3 )-, provided that the N-terminal modifying group A is R 1a covalently bonded to the nitrogen atom of is an amino acid residue represented by Preferably, Xaa1 is an α-L-amino acid residue selected from the group consisting of Asp, Asn, Glu, Gln, Hse, Cya and Ser, or Xaa1 is a dicarboxylic acid residue selected from the group consisting of succinyl and glutaric acid, More preferably, Xaa1 is an α-L-amino acid residue selected from the group consisting of Asp, Asn, Glu and Gln; Most preferably, the compound according to any one of claims 1 to 3, wherein Xaa1 is an Asp residue.

5. Xaa2 is a group represented by formula (IIId) 【Chemistry 538】 [In the formula, X 2a is NH or S, preferably NH, R 2a is H or F, R 2b is selected from the group consisting of H, F and Cl; R 2c is selected from the group consisting of H, F, Cl, Br and OH. is an α-L-amino acid residue represented by Preferably, Xaa2 is an α-L-amino acid residue selected from the group consisting of Trp, Hyw, 5Fw, 6Clw, 7Fw, 5Clw, 5Brw and 6Fw; More preferably, Xaa2 is an α-L-amino acid residue selected from the group consisting of Trp, Hyw, 5Fw and 7Fw; Most preferably, the compound according to any one of claims 1 to 4, wherein Xaa2 is a Trp residue.

6. Xaa3 is a group represented by formula (IVe) or (IVf) 【Chemical 539】 [In the formula, R 3b is H or F, R 3c is selected from the group consisting of Cl, Br, H and F; X 3a is NH or S, X 3b is selected from the group consisting of CH, CF and N; X 3c is CH or N, preferably X 3c is CH] is an amino acid residue represented by Preferably, Xaa3 is an α-L-amino acid residue selected from the group consisting of 5Clw, 5Brw, Trp, 1Ni, Bta, 5Fw, 6Fw and 7Fw; More preferably, Xaa3 is an α-L-amino acid residue selected from the group consisting of 5Clw and 5Brw; Most preferably, the compound according to any one of claims 1 to 5, wherein Xaa3 is a 5Clw residue.

7. (a) Xaa4 is a group represented by formula (Va) 【Chemistry 540】 [In the formula, m is 1 or 2, preferably m is 1; R 4a is selected from the group consisting of H, OH, and methyl; R 4b is either H or methyl, and R 4a is methyl, preferably R 4b is methyl, X 4 is CHR 4c , C.H. 2 , S, and O; R 4c However, NHR 4d , N.H. 2 , H, OH, methyl, and F; R 4d is Ac or a Z group, preferably when the Z group is a chelating agent optionally comprising a linker, more preferably the chelating agent is DOTA, and when the Z group is a biodistribution modifier optionally comprising a linker, more preferably the biodistribution modifier is AGLU, and the optional linker is preferably glutaric acid. is an amino acid residue represented by Preferably, Xaa4 is an α-L-amino acid residue selected from the group consisting of Tap, Hyp, Pro, 4Ap, 4Ap(Ac), Tap(DOTA), Tap(AGLU-glutaric), 4Tfp and H3p; More preferably, Xaa4 is an α-L-amino acid residue selected from the group consisting of Tap, Hyp, Pro and 4Ap; Most preferably, Xaa4 is a Tap residue or (b) Xaa4 is a group represented by formula (Vf) 【Chemical 541】 [In the formula, n is 0, 1 or 3; R 4e is selected from the group consisting of H and phenyl when n=0, or R 4e But NH 2 or when n=1, R 4e But methyl, CO 2 H and C(=O)R 4h and R 4h is a Z group, preferably the Z group is a biodistribution modifier optionally comprising a linker, the biodistribution modifier is more preferably AGLU; R 4f is selected from the group consisting of H and methyl. is an N-alkylated amino acid residue represented by Preferably, Xaa4 is an N-alkylated amino acid residue selected from the group consisting of Nmg, Nlys, Nleu, Nphe, Nglu and Nglu (AGLU); or (c) The compound according to any one of claims 1 to 6, wherein Xaa4 is an Oic residue.

8. Xaa5 is an α-amino acid residue optionally containing a Z group, the α-nitrogen atom of which is optionally substituted with a methyl group; Preferably, Xaa5 is an α-L-amino acid residue selected from the group consisting of Glu, Gln, Asp, Asn, Ser, Hse, Trp, Lys, Arg, His, Hly and Har; More preferably, Xaa5 is an α-L-amino acid selected from the group consisting of Glu, Gln, Asp, Asn, Ser, and Hse; Most preferably, the compound according to any one of claims 1 to 7, wherein Xaa5 is a GIu residue.

9. Xaa6 is a group represented by formula (VIIa) 【Chemical Formula 542】 [In the formula, p is 1 or 0, preferably p is 1; R 6a is (C 1 ~C 2 ) alkyl, R 6b is methyl, R 6c is H when p is 0, and is H or methyl when p is 1. is an amino acid residue represented by Preferably, Xaa6 is an α-amino acid residue selected from the group consisting of leu, Leu, Npg, Val, Ile, and Hle; More preferably, Xaa6 is an α-amino acid residue selected from the group consisting of leu, Leu, Npg, Val, and He; Most preferably, the compound according to any one of claims 1 to 8, wherein Xaa6 is a leu residue.

10. (a) Xaa8 is a group represented by formula (IXa) 【Chemical 543】 [In the formula, r is 2 or 1, preferably r is 2; X 8 is NR 8a , O, NH and CH 2 wherein R 8a is a Z group or R 8a is acetyl, and wherein when the Z group is a chelating agent optionally comprising a linker, preferably the chelating agent is DOTA, or when the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric, or when the Z group is a combination of a chelating agent optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelating agent optionally comprising a linker and the biodistribution modifier optionally comprising a linker, preferably the chelating agent is DOTA, the biodistribution modifier is preferably AGLU, and the amino acid residue linking the chelating agent and the biodistribution modifier is preferably a glu residue. is an amino acid residue represented by Preferably, Xaa8 is Apc(R 8a ), an α-amino acid residue selected from the group consisting of Apc, Thp, Egz, and Eca; 8a is a Z group, and when the Z group is a chelating agent optionally comprising a linker, preferably the chelating agent is DOTA, or when the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid; or when the Z group is a combination of a chelating agent optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and an amino acid residue linking the chelating agent optionally comprising a linker and the biodistribution modifier optionally comprising a linker, preferably the chelating agent is DOTA, the biodistribution modifier is preferably AGLU, and the amino acid residue linking the chelating agent and the biodistribution modifier is preferably glu or R 8a is acetyl, More preferably, Xaa8 is Apc(R 8a ), Apc and Thp, and R 8a is the Z group, and when the Z group is a chelator optionally comprising a linker, preferably the chelator is DOTA or when the Z group is a biodistribution modifier optionally comprising a linker, preferably the biodistribution modifier is AGLU, and the linker is preferably glutaric acid or R 8a is acetyl, Most preferably, Xaa8 is Apc(R 8a ), where R 8a is a Z group, the Z group is a chelating agent optionally including a linker, and the chelating agent is a) Preferably DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Mac Ropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, Sarcophagin, FSC, NETA, NE3TA, H4 Octapa, pycup, HYNIC, NxS4-x (N4, N2S2, N3S), 99m selected from the group consisting of Tc(CO)3-chelators and analogs thereof; b) more preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof; (b) Xaa8 is an Aic residue; (c) Xaa8 is Lys, Lys(R 8e ), lys(R 8e ), Amk(R 8e ), Dab (R 8e ) and dab(R 8e and R is an α-amino acid residue selected from the group consisting of 8e is a Z group, preferably the Z group is a chelator optionally including a linker, or (d) The compound according to any one of claims 1 to 9, wherein Xaa8 is an α-amino acid residue selected from the group consisting of Aib, Deg, Ams, ala, Ala, Gln, Thr, Trp, Phe, and Glu.

11. Xaa9 is a group represented by the formula (Xa) 【Chemical Formula 544】 [In the formula, R 9a is (C 1 ~C 4 ) alkyl, COOH, CONH 2 , OH, NH 2 ,NHC(=NH)NH 2 aryl rings and heteroaryl rings, preferably the aryl rings are phenyl and the heteroaryl rings are 3-indolyl and cyclohexyl; R 9b is methyl or H, R 9c is H or methyl, v is 0, 1, or 2, and preferably v is 1. is an amino acid residue represented by Preferably, Xaa9 is an α-L-amino acid residue selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe, Ser, Cha, Npg, and Tle; More preferably, Xaa9 is an α-L-amino acid residue selected from the group consisting of Leu, Hle, Ile, Arg, Trp, Glu, Phe and Ser; Most preferably, the compound according to any one of claims 1 to 10, wherein Xaa9 is a Leu residue.

12. Xaa10 is a group represented by formula (XIa) 【Chemical 545】 [In the formula, R 10a is (C 1 ~C 2 ) selected from the group consisting of alkyl and phenyl, preferably R 10a However, (C 1 ~C 2 ) alkyl, more preferably (C 1 ~C 2 ) alkyl is ethyl; R 10b is selected from the group consisting of methyl and H, preferably R 10b is methyl, R 10c is selected from the group consisting of H and methyl, and when w is 1, R 10C is H, preferably R 10c is H, w is 0 or 1, preferably w is 0. is an amino acid residue represented by Preferably, Xaa10 is an α-L-amino acid residue selected from the group consisting of Ile, Leu, Tle, Val and Phe; More preferably, Xaa10 is an α-L-amino acid residue selected from the group consisting of Ile, Leu, and Tle; Most preferably, the compound according to any one of claims 1 to 11, wherein XaalO is an Ile residue.

13. The N-terminal modifying group A is a) a Z group (wherein a linker is optionally interposed between the Z group and Xaa1, and the Z group is a chelator optionally comprising a linker, or the Z group is a biodistribution modifier optionally comprising a linker, or the Z group is a chelator optionally comprising a linker, a biodistribution modifier optionally comprising a linker, and a combination of amino acid residues linking the chelator optionally comprising a linker and the biodistribution modifier optionally comprising a linker); b) a blocking group AblN (wherein the blocking group AblN is a group consisting of acetyl and a group of formula (AblN-Ia) 【Chemical 546】 [In the formula, R Abl1 is selected from the group consisting of H, OH and halogen, preferably halogen is selected from the group consisting of F and Cl, preferably R Abl1 is OH] and preferably, AblN is selected from the group consisting of Ac, 4OHPhp, 4FPhp, 4ClPhp and Php. c) an amino acid residue, which is an α-amino acid, which optionally comprises a Z group covalently attached to a side chain of the amino acid residue, optionally comprises a Z group covalently attached to the α-amino group of the amino acid residue, or which optionally comprises a blocking group AbIN covalently attached to the α-amino group of the amino acid residue, preferably wherein the blocking group AbIN is acetyl, which amino acid residue is preferably a Tyr residue with an optional Z group covalently attached to the α-amino group of the Tyr residue, which Z group is a chelator with an optional linker, which chelator is preferably DOTA and which linker is preferably Ttds; d) an N-terminal dipeptide group (wherein the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally comprise a Z group, a blocking group AblN optionally covalently attached to the α-amino group of the first amino acid residue, and a linker optionally intervening between the second amino acid residue and residue Xaa1, wherein, in the absence of an intervening linker, the carbonyl group of the first amino acid residue is covalently attached to the α-nitrogen of the second amino acid residue, and the carbonyl group of the second amino acid residue is linked to R 1a or the α-nitrogen atom of residue Xaa1, the carbonyl group of the first amino acid residue is covalently bound to the α-nitrogen of the second amino acid residue, the carbonyl group of the second amino acid residue is covalently bound to the nitrogen atom of the linker, and the carbonyl group of the linker is covalently bound to the nitrogen atom of R 1a or the α-nitrogen atom of residue Xaa1, wherein the first amino acid residue is a Met residue and the second amino acid residue is selected from the group consisting of Ala, Tyr and tyr. and selected from the group comprising: Preferably, the Z group is a biodistribution modifier optionally comprising a linker, where the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) more preferably AGLU or NTASEROL with glutaric acid as the linker; c) Most preferably, AGLU with glutaric acid as the linker; More preferably, the compound of any one of claims 1 to 12, wherein the Z group is a biodistribution modifier optionally comprising a linker, the biodistribution modifier is AGLU and the linker is glutaric acid.

14. The C-terminal group C-term is a) an amino acid residue, which is an α-amino acid optionally containing a Z group and optionally containing an intervening linker between the residue at Xaa11 and said amino acid residue, wherein if no intervening linker is present, the carbonyl group R of residue Xaa11 11b is covalently attached to the α-nitrogen of this amino acid residue or when an intervening linker is present, R 11b is covalently bonded to the nitrogen atom of a linker, and the carbonyl group of the linker is covalently bonded to the α-nitrogen of the amino acid residue, wherein a blocking group AbIC is covalently bonded to the carbonyl group of the amino acid residue, and wherein the blocking group AbIC is NH 2 and OH, and the blocking group AblC is preferably selected from the group consisting of NH 2 is) or b) a C-terminal dipeptide group (wherein the first amino acid residue is an α-amino acid residue and the second amino acid residue is an α-amino acid residue, the first amino acid residue, the second amino acid residue, or both the first and second amino acid residues optionally contain a Z group, and a linker optionally intervenes between the residue at Xaa11 and the first amino acid residue, and if no intervening linker is present, the carbonyl group R of Xaa11 11b is covalently linked to the α-nitrogen of the first amino acid residue, and the carbonyl group of the first amino acid residue is covalently linked to the α-nitrogen of the second amino acid residue, or when an intervening linker is present, the carbonyl group R of Xaa11 11b is covalently bonded to a nitrogen atom of the linker, a carbonyl group of the linker is covalently bonded to the α-nitrogen of a first amino acid residue, a carbonyl group of the first amino acid residue is covalently bonded to the α-nitrogen of a second amino acid residue, a blocking group AbIC is covalently bonded to the carbonyl group of the second amino acid residue, and the blocking group AbIC is NH 2 and OH, and the blocking group AblC is preferably selected from the group consisting of NH 2 is) or c) Z group The compound according to any one of claims 1 to 13, wherein

15. The C-terminus group C-term is an α-amino acid residue, and the α-amino acid is i) an α-amino acid comprising a side chain AaaA, which side chain comprises an amino group to which a Z group is covalently attached by an amide bond, the Z group being a chelator optionally comprising a linker, the chelator being a) preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A″-DTPA, DFO, macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA, sarcofadin, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4-x(N4, N2S2, N3S), 99mTc(CO)3-chelators and analogues thereof; b) More preferably, selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NODA-MPAA, NOPO, HBED, DTPA, CHX-A″-DTPA, CB-TE2A, Macropa, PCTA, N4 and analogs thereof; c) most preferably selected from the group consisting of DOTA, DOTAGA, DOTAM, NOTA, NODAGA, PSC, NOPO, Macropa, PCTA and analogs thereof) or ii) an α-amino acid comprising a side chain AaaB, which side chain comprises an amino group to which a Z group is covalently attached via an amide bond, the Z group being a biodistribution modifier optionally comprising a linker, wherein the Z group is a) preferably selected from the group consisting of AGLU with glutaric acid as a linker, NTASEROL, GLUSEROL with glutaric acid as a linker, AHOL with glutaric acid as a linker, APOL with glutaric acid as a linker, ABOL with glutaric acid as a linker, APrOL with glutaric acid as a linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG; b) more preferably MeO36PEG or NTASEROL) or iii) an α-amino acid comprising a side chain AaaC, which side chain comprises a COOH group to which a Z group is covalently attached via an amide bond, the Z group being a biodistribution modifier optionally comprising a linker, wherein the biodistribution modifier is a) preferably selected from the group consisting of AGLU, GLUSEROL, AHOL, APOL, ABOL and APrOL; b) More preferably, it is AGLU. is selected from wherein the blocking group AblC is NH 2 and The compound according to any one of claims 1 to 14, preferably the compound according to any one of claims 13 and 14, wherein an optional linker is interposed between Xaa11 and the α-amino acid residue, said linker being preferably APAc or Ttds.

16. 16. The compound of any one of claims 1 to 15, wherein the compound comprises one Z group, two Z groups, three Z groups, or four Z groups.

17. The compound comprises three Z groups, one of which is a chelator optionally comprising a linker, and the other two of which are biodistribution modifiers optionally comprising linkers, and the chelator optionally comprising a linker is preferably a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), 8a is covalently bonded to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; or d) is part of or forms N-terminal modification group A; wherein either of the two biodistribution modifiers, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), 8a is covalently bonded to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of c) covalently attached to an α-amino acid residue at the C-terminus; or d) is part of or forms N-terminal modification group A; Preferably, the chelating agent, optionally including a linker, is a) providing that the residue Xaa8 has a structure represented by formula (XIa), (IXd) or (IXe), 8a or is covalently attached to or part of b) providing that the residue Xaa8 has a structure represented by formula (XIc), 8e is covalently bonded to or part of wherein one of the two biodistribution modifiers, each optionally comprising a linker, is part of or forms the N-terminal modifying group A; 17. The compound of claim 16, wherein the other of the two biodistribution modifiers, each optionally comprising a linker, is covalently bound to an α-amino acid residue at the C-terminus.

18. Xaa1 is Asp, Asn, Glu, Gln, succinyl, glutaric acid or Cya; Xaa2 is Trp, Hyw, 5Fw, 6Clw or 7Fw; Xaa3 is 5Clw, 5Brw, 5Fw, Trp, 1Ni, Bta, 6Fw or Trp; Xaa4 is Tap, Hyp, 4Tfp, Pro, H3p, Eaz, Oxa, Dtc, Nmg, Nleu, Nlys, Nphe, or Nglu; Xaa5 is Glu, glu, Nme, Gln, Asp, Asn, or Hse; Xaa6 is leu, Leu, Npg, Val, or He; Xaa7 is Cys or Hcy; Xaa8 is Apc(DOTA), Thp, Apc, Aib, Deg, Ams, Amk(DOTA), Egz, Eca, or ala; Xaa9 is Leu, Hle, Ile, Phe, Glu, Arg, Ser, or Trp; Xaa10 is Ile, Leu, Val, or Tle; Xaa11 is Cys, Hcy, or AET, and Yc is 3MeBn or 3Lut, or Xaa1 is Asp, Glu or succinyl; Xaa2 is Trp or Hyw; Xaa3 is 5Clw or 5Brw; Xaa4 is Tap, Hyp or Pro; Xaa5 is Glu, Xaa6 is leu or Leu; Xaa7 is Cys; Xaa8 is Apc(DOTA) or Thp; Xaa9 is Leu; Xaa10 is He, Xaa11 is Cys, and Yc is 3Lut, or Xaa1 is Asp, Xaa2 is Trp, Xaa3 is 5Clw; Xaa4 is Tap or Hyp, Xaa5 is Glu, Xaa6 is leu, Xaa7 is Cys; Xaa8 is Apc(DOTA), Xaa9 is Leu; Xaa10 is He, Xaa11 is Cys, and Yc is 3Lut, Preferably, the compound comprises three Z groups, wherein the first of the three Z groups is a chelating agent; a chelator is covalently attached to Xaa8; Xaa8 is an Apc residue and the chelator is DOTA; wherein the second of the three Z groups is a biodistribution modifier, optionally including a linker; the biodistribution modifier and the linker form an N-terminal modifying group A; N-terminal modification group A is AGLU-glutaric acid; and wherein the third Z group of the three Z groups is a biodistribution modifier; a biodistribution modifier is covalently attached to an α-amino acid residue at the C-terminus; and The C-terminus is APAc-glu(AGLU)-NH 2 That is, The compound according to any one of claims 1 to 3.

19. The compound is The following formula 【Chemical 547】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-001), The following formula 【Chemical 548】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-002), The following formula 【Chemical Formula 549】 The compound represented by the formula: DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-003), The following formula 【Chemistry 550】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH 2 (GIP-004), The following formula 【Chemistry 551】 The compound represented by the formula: DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-005), The following formula ​ The compound represented by the formula: AGLU-glutaric-APAc-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-006), The following formula 【Chemical Formula 553】 The compound represented by the formula: AGLU-glutaric-APAc-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-007), The following formula 【Chemical 554】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-008), The following formula 【Chemical 555】 The compound represented by the formula: DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-009), The following formula 【Chemical Formula 556】 The compound represented by the formula: AGLU-glutaric-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutaric)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-010), The following formula 【Chemical 557】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-011), The following formula 【Chemical Formula 558】 The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-012), The following formula 【Chemical Formula 559】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-013), The following formula 【Chemistry 560】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-014), The following formula 【Chemistry 561】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-015), The following formula 【Chemical 562】 The compound represented by the formula: AGLU-glutar-Hse-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-016), The following formula 【Chemical Formula 563】 The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-017), The following formula 【Chemical 564】 The compound represented by the formula: DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-018), The following formula 【Chemistry 565】 The compound represented by the formula: DOTA-glu(AGLU)-PEG6-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-019), The following formula 【Chemical 566】 The compound represented by the formula: DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-020), The following formula 【Chemical 567】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH 2 (GIP-021), The following formula 【Chemical 568】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH 2 (GIP-022), The following formula 【Chemical 569】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-023), The following formula 【Chemistry 570】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-024), The following formula 【Chemistry 571】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-025), The following formula 【Chemical 572】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-026), The following formula 【Chemical 573】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-027), The following formula 【Chemical 574】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-028), The following formula 【Chemistry 575】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NOPO)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-029), The following formula 【Chemical Formula 576】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(N4Ac)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-030), The following formula 【Chemical 577】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA-Gly)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-031), The following formula 【Chemical 578】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH 2 (GIP-033), The following formula 【Chemical 579】 The compound represented by the formula: AGLU-glutar-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-034), The following formula 【Chemistry 580】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-Leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-035), The following formula 【Chemistry 581】 The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-036), The following formula 【Chemistry 582】 The compound represented by the formula: DOTA-PEG6-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-037), The following formula 【Chemistry 583】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH 2 (GIP-038), The following formula 【Chemical 584】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-lys(MeO36PEG)-NH 2 (GIP-039), The following formula 【Chemistry 585】 The compound represented by the formula: MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH 2 (GIP-040), The following formula 【Chemistry 586】 The compound represented by the formula: MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-041), The following formula 【Chemistry 587】 The compound represented by the formula: MeO36PEG-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-042), The following formula 【Chemistry 588】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-043), The following formula 【Chemistry 589】 The compound represented by the formula: DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-044), The following formula 【Chemistry 590】 The compound represented by the formula: DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-045), The following formula 【Chemistry 591】 The compound represented by the formula: AGLU-glutaric-APAc-Ser-Trp-5Clw-Tap(AGLU-glutaric)-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-046), The following formula 【Chemical Formula 592】 The compound represented by the formula: AGLU-glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-047), The following formula 【Chemistry 593】 The compound represented by the formula: AGLU-glutar-APAc-Ser-Trp-5Clw-Tap-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-048), The following formula 【Chemical 594】 The compound represented by the formula: AGLU-glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-049), The following formula 【Chemistry 595】 The compound represented by the formula: AGLU-glutar-APAc-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-050), The following formula 【Chemistry 596】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-051), The following formula 【Chemical 597】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH 2 (GIP-052), The following formula 【Chemistry 598】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-AET] (GIP-053), The following formula 【Chemistry 599】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH 2 (GIP-054), The following formula 【Chemical 600】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH 2 (GIP-055), The following formula 【Chemistry 601】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH 2 (GIP-056), The following formula 【Chemistry 602】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-059), The following formula 【Chemistry 603】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-060), The following formula 【Chemistry 604】 The compound represented by the formula: AGLU-glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-061), The following formula 【Chemistry 605】 The compound represented by the formula: LuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-062), The following formula 【Chemistry 606】 The compound represented by the formula: InDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-063), The following formula 【Chemistry 607】 The compound represented by the formula: EuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-064), The following formula 【Chemistry 608】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-065), The following formula 【Chemistry 609】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-066), The following formula 【Chemistry 610】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-067), The following formula 【611】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-068), The following formula 【Hua 612】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-069), The following formula 【Hua 613】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-070), The following formula 【Hua 614】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaNODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-071), The following formula 【Chemistry 615】 the compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-072), The following formula 【Hua 616】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-glutar)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-073), The following formula 【Hua 617】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-074), The following formula 【Hua 618】 The compound represented by the formula: Ac-Asp-Trp-Bta-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-075), The following formula 【Hua 619】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-076), The following formula 【Hua 620】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-077), The following formula 【Hua 621】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-078), The following formula 【Hua 622】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-079), The following formula 【Hua 623】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-080), The following formula 【Chemical Formula 624】 The compound represented by the formula: Ac-Asp-Trp-5Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-081), The following formula 【Hua 625】 The compound represented by the formula: Ac-Asp-Trp-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-082), The following formula 【Hua 626】 The compound represented by the formula: Ac-Asp-5Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-083), The following formula 【Hua 627】 The compound represented by the formula: Ac-Asp-6Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-084), The following formula 【Hua 628】 The compound represented by the formula: HO-succinyl-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-085), The following formula 【Chemical 629】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-AET] (GIP-086), The following formula 【Chemistry 630】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-087), The following formula 【Chemistry 631】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc-Leu-Ile-AET] (GIP-088), The following formula 【632】 The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-089), The following formula 【Hua 633】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-090), The following formula 【Chemical Formula 634】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3Lut)-Aib-Leu-Ile-AET] (GIP-091), The following formula 【Chemistry 635】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AET] (GIP-092), The following formula 【Hua 636】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-en] (GIP-093), The following formula 【Hua 637】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-094), The following formula 【Chemical Formula 638】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-095), The following formula 【Chemical 639】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-4Ap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-096), The following formula 【Hua 640】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(Ac)-Leu-Ile-AET] (GIP-097), The following formula 【Hua 641】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AETO] (GIP-098), The following formula 【Chemical 642】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Hle-Ile-AET] (GIP-099), The following formula 【Chemical Formula 643】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-100), The following formula 【Chemical Formula 644】 the compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-101), The following formula 【Chemical 645】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-H3p-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-102), The following formula 【Chemical 646】 the compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-103), The following formula 【Chemical Formula 647】 The compound represented by the formula: DOTA-Ttds-Asp-6Fw-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-104), The following formula 【Chemical Formula 648】 The compound represented by the formula: DOTA-Ttds-Asp-6Fw-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-105), The following formula 【Chemical Formula 649】 The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(2Lut)-Thp-Leu-Ile-AET] (GIP-106), The following formula 【Chemistry 650】 The compound represented by the formula: DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(3MeBn)-Thp-Leu-Ile-AET] (GIP-107), The following formula 【Chemistry 651】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-108), The following formula 【652】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-109), The following formula 【Chemistry 653】 the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-110), The following formula 【Chemical Formula 654】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-4Ap(Ac)-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-111), The following formula 【Chemistry 655】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-112), The following formula 【Hua 656】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Dap(2Lut)-Apc-Leu-Ile-AET] (GIP-113), The following formula 【Hua 657】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-114), The following formula 【658】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH 2 (GIP-115), The following formula 【Chemical Formula 659】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH 2 (GIP-116), The following formula 【Hua 660】 the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ape-DOTA (GIP-117), The following formula 【Chemical Formula 661】 the compound HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-PP-DOTA (GIP-118), The following formula 【Chemical 662】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-119), The following formula 【Chemical Formula 663】 The compound represented by the formula: MeO2kDaPEGAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH 2 (GIP-120), The following formula 【Chemical 664】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-121), The following formula 【Chemical Formula 665】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH 2 (GIP-122), The following formula 【Chemical Formula 666】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH 2 (GIP-123), The following formula 【Chemical 667】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-AET))-Thp-Leu-Ile-Cys]-NH 2 (GIP-124), The following formula 【Chemical Formula 668】 The compound represented by the formula: DOTA-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-125), The following formula 【Chemical Formula 669】 The compound represented by the formula: DOTA-Ttds-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-126), The following formula 【Chemistry 670】 The compound represented by the formula: Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-127), The following formula 【671】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-128), The following formula 【Chemical 672】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-129), The following formula 【Chemical Formula 673】 The compound represented by the formula: DOTA-Ttds-Nmd-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-130), The following formula 【Chemical 674】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-131), The following formula 【675】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Npg-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-132), The following formula 【Chemical Formula 676】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Npg-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-133), The following formula 【Chemical 677】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Cha-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-134), The following formula 【Chemical 678】 The compound represented by the formula: Php-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-135), The following formula 【Chemical Formula 679】 The compound 4FPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-136), The following formula 【Chemistry 680】 The compound represented by the formula: 4OHPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-137), The following formula 【681】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Val-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-138), The following formula 【682】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Deg-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-139), The following formula 【683】 The compound represented by the formula: Ac-Asp-Trp-6Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-140), The following formula 【Chemical Formula 684】 The compound represented by the formula: DOTA-Ttds-Asp-6Clw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-141), The following formula 【Chemistry 685】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO10kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-142), The following formula 【Hua 686】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO2kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH 2 (GIP-143), The following formula 【Hua 687】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH 2 (GIP-144), The following formula 【Hua 688】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-PP))-Thp-Leu-Ile-Cys]-NH 2 (GIP-145), The following formula 【689】 the compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-146), The following formula 【Chemistry 690】 the compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(ZnDOTA)-Leu-Ile-AET] (GIP-147), The following formula 【Chemical Formula 691】 the compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-148), The following formula 【Chemical Formula 692】 the compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-149), The following formula 【Chemical Formula 693】 a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-150), The following formula 【Chemical Formula 694】 a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-151), The following formula 【Chemical Formula 695】 a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-152), The following formula 【Chemical 696】 a compound represented by the formula: InDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-153), The following formula 【Chemical Formula 697】 a compound represented by the formula: InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-154), The following formula 【Chemical Formula 698】 a compound represented by the formula: InDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-155), The following formula 【Chemical Formula 699】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH 2 (GIP-156), The following formula 【Chemical 700】 The compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-157), The following formula 【Chemistry 701】 the compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-158), The following formula 【Chemistry 702】 the compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-159), The following formula 【Chemistry 703】 the compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-160), The following formula 【Chemistry 704】 the compound represented by the formula: LuDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-161), The following formula 【Chemistry 705】 the compound represented by the formula: LuDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-162), The following formula 【Chemistry 706】 the compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-163), The following formula 【Chemistry 707】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH 2 (GIP-164), The following formula 【Chemistry 708】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH 2 (GIP-165), The following formula 【Chemistry 709】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH 2 (GIP-166), The following formula 【Chemistry 710】 the compound represented by the formula: LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-167), The following formula 【Chemistry 711】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(InDOTA)-NH 2 (GIP-168), The following formula 【Chemical 712】 the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-169), The following formula 【Chemical 713】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(LuDOTA)-NH 2 (GIP-170), The following formula 【Chemical 714】 the compound represented by the formula: HO-succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-AET] (GIP-171), The following formula 【Chemistry 715】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH 2 (GIP-172), The following formula 【Chemical Formula 716】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH 2 (GIP-173), The following formula 【Hua717】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-174), The following formula 【Chemical 718】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Tap(AGLU-glutaric)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-175), The following formula 【Chemical 719】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nglu(AGLU)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-176), The following formula 【Hua720】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-177), The following formula 【Hua721】 The compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-178), The following formula 【Chemical 722】 the compound represented by the formula: Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-179), The following formula 【Chemical 723】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-180), The following formula 【Chemical 724】 the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-OH (GIP-181), The following formula 【Chemical 725】 the compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cysol]-OH (GIP-182), The following formula 【Chemical 726】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-183), The following formula 【Hua727】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nleu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-184), The following formula 【Chemical 728】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nphe-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-185), The following formula 【Chemical 729】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nlys-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-186), The following formula 【Chemistry 730】 The compound represented by the formula: Ac-Asp-Trp-5Clw-4Tfp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-187), The following formula 【Hua731】 The compound represented by the formula: Ac-Ser-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-188), The following formula 【Chemical 732】 The compound represented by the formula: Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-189), The following formula 【Chemical 733】 The compound represented by the formula: Ac-Asn-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-190), The following formula 【Chemical 734】 The compound represented by the formula: Ac-Glu-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-191), The following formula 【Chemical 735】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Asp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-192), The following formula 【Chemical Formula 736】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Gln-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-193), The following formula 【Hua737】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Hse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-194), The following formula 【Chemical 738】 The compound represented by the formula: Ac-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-195), The following formula 【Chemical 739】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Nglu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-196), The following formula 【Chemical 740】 The compound represented by the formula: Ac-Hse-Trp-5Brw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-197), The following formula 【Chemical 741】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-198), The following formula 【Chemical 742】 The compound represented by the formula: HO-succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH 2 (GIP-199), The following formula 【Chemical 743】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-200), The following formula 【Chemical 744】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Hcy]-NH 2 (GIP-201), The following formula 【Chemical 745】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Hcy]-NH 2 (GIP-202), The following formula 【Chemical 746】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Eca-Leu-Ile-Cys]-NH 2 (GIP-203), The following formula 【Hua747】 The compound represented by the formula: Ac-Gln-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-204), The following formula 【Chemical 748】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Asn-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-205), The following formula 【Chemical 749】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aic-Leu-Ile-Cys]-NH 2 (GIP-206), The following formula 【Chemistry 750】 The compound represented by the formula: Ac-Pse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-207), The following formula 【Chemistry 751】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Pse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-208), The following formula 【Chemical 752】 The compound represented by the formula: Ac-Asp-Mcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-209), The following formula 【Chemical 753】 The compound represented by the formula: Ac-Asp-Pcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-210), The following formula 【Chemical 754】 The compound represented by the formula: Ac-Asp-Eaa-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-211), The following formula 【Chemistry 755】 The compound represented by the formula: Ac-Asp-Egm-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-212), The following formula 【Chemical 756】 The compound represented by the formula: Ac-Asp-Trp-Eaa-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-213), The following formula 【Chemical 757】 The compound represented by the formula: HO-glutar-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-214), The following formula 【Chemical 758】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Dtc-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-215), The following formula 【Chemical 759】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Oxa-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-216), The following formula 【Hua760】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Nme-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-217), The following formula 【Chemical 761】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-Ile-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-218), The following formula 【Chemical 762】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-Val-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-219), The following formula 【Chemical 763】 The compound represented by the formula: Ac-Asp-Hyw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-220), The following formula 【Chemical 764】 The compound represented by the formula: Ac-Asp-7Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-221), The following formula 【Chemical 765】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Eaz-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-222), The following formula 【Chemical 766】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-glu-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-223), The following formula 【Chemical 767】 The compound represented by the formula: Ac-Asp-Phe-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-224), The following formula 【Chemical 768】 The compound represented by the formula: Ac-Asp-Egp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-226), The following formula 【Chemical 769】 The compound represented by the formula: Ac-Asp-Trp-7Fw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-227), The following formula 【Chemical 770】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Phe-Leu-Ile-Cys]-NH 2 (GIP-228), The following formula 【Chemical 771】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ile-Ile-Cys]-NH 2 (GIP-229), The following formula 【Chemical 772】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Arg-Ile-Cys]-NH 2 (GIP-230), The following formula 【Chemical 773】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Glu-Ile-Cys]-NH 2 (GIP-231), The following formula 【Chemical 774】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Phe-Ile-Cys]-NH 2 (GIP-232), The following formula 【Chemical 775】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Trp-Ile-Cys]-NH 2 (GIP-233), The following formula 【Chemical 776】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Trp-Leu-Ile-Cys]-NH 2 (GIP-234), The following formula 【Chemical 777】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Glu-Leu-Ile-Cys]-NH 2 (GIP-235), The following formula 【Chemical 778】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ser-Ile-Cys]-NH 2 (GIP-236), The following formula 【Chemical 779】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Leu-Cys]-NH 2 (GIP-237), The following formula 【Hua780】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Tle-Cys]-NH 2 (GIP-238), The following formula 【Chemical 781】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-239), The following formula 【Chemical 782】 The compound represented by the formula: Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-240), The following formula 【Chemical 783】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Gln-Leu-Ile-Cys]-NH 2 (GIP-241), The following formula 【Chemical 784】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thr-Leu-Ile-Cys]-NH 2 (GIP-242), The following formula 【Chemical 785】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Lys-Leu-Ile-Cys]-NH 2 (GIP-243), The following formula 【Chemical 786】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-244), The following formula 【Chemical 787】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-245), The following formula 【Hua788】 The compound represented by the formula: H-Met-tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-246), The following formula 【Chemical 789】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-247), The following formula 【Chemical 790】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH 2 (GIP-248), The following formula 【Chemical 791】 The compound represented by the formula: H-Met-Ala-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-249), The following formula 【Chemical 792】 the compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-AET] (GIP-250), The following formula 【Chemical 793】 the compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-251), The following formula 【Chemical 794】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Oic-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-252), The following formula 【Chemical 795】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pip-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-253), The following formula 【Chemical 796】 The compound represented by the formula: H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-254), The following formula 【Chemical 797】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH 2 (GIP-255), The following formula 【Chemical 798】 the compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-AET] (GIP-256), The following formula 【Chemical 799】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(2Lut)-Ala-Leu-Ile-Cys]-NH 2 (GIP-257), The following formula 【Hua800】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-258), The following formula 【Chemistry 801】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-259), The following formula 【Chemical 802】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Hle-Ile-Cys]-NH 2 (GIP-260), The following formula 【Chemistry 803】 The compound represented by the formula: HO-succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH 2 (GIP-261), The following formula 【Chemistry 804】 The compound represented by the formula: Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-262), The following formula 【Chemistry 805】 The compound represented by the formula: Ac-Asp-Egn-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-263), The following formula 【Chemistry 806】 The compound represented by the formula: Ac-Asp-Trp-Egp-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-265), The following formula 【Chemical 807】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH 2 (GIP-266), The following formula 【Chemical 808】 The compound represented by the formula: Ac-Asp-Trp-7Nw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-267), The following formula 【Chemistry 809】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-270), The following formula 【Chemical 810】 The compound represented by the formula: DOTA-Ttds-asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH 2 (GIP-271), The following formula 【Hua 811】 The compound represented by the formula: Ac-Asp-Bta-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-273), The following formula 【Hua 812】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Nme-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-274), The following formula 【Hua 813】 The compound represented by the formula: Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Tle-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-276), The following formula 【Hua 814】 The compound represented by the formula: Ac-Asp-5Clw-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-277), The following formula 【Chemistry 815】 The compound 4ClPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-279), The following formula 【Hua 816】 The compound represented by the formula: Nph2p-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-281), The following formula 【Hua 817】 The compound represented by the formula: Ac-Asp-Trp-6Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH 2 (GIP-282), The following formula 【Hua 818】 The compound represented by the formula: DOTA-Ttds-Asp-6Fw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-283), The following formula 【Hua 819】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-315), The following formula 【Hua 820】 The compound represented by the formula: HO-succinyl-Trp-Trp-Hyp-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-319), The following formula 【Hua 821】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBz)-Aib-Leu-Ile-AET] (GIP-358), The following formula 【Hua 822】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3CbBn)-Aib-Leu-Ile-en] (GIP-359), The following formula 【Hua 823】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Cys]-NH 2 (GIP-360), The following formula 【Hua 824】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Hcy]-NH 2 (GIP-361), The following formula 【Hua 825】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(mli)-Thp-Leu-Ile-Cys]-NH 2 (GIP-362), The following formula 【Hua 826】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy-Thp-Leu-Ile-Hcy]-NH 2 (GIP-363), The following formula 【Hua 827】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTAM)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-370), The following formula 【Hua 828】 The compound represented by the formula: AGLU-glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH 2 (GIP-371), The following formula 【Hua 829】 the compound represented by the formula: AGLU-Glutarate-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-372), The following formula 【Chemical 830】 The compound represented by the formula: NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-dap(NTASEROL)-NH 2 (GIP-373), The following formula 【Hua 831】 the compound NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-374), The following formula 【Hua 832】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Lys-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-375), The following formula 【Hua 833】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Arg-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-376), The following formula 【Chemical 834】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-His-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-377), The following formula 【Chemistry 835】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Hly-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-378), The following formula 【Hua 836】 The compound represented by the formula: Ac-Asp-5Clw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-379), The following formula 【Hua 837】 The compound represented by the formula: Ac-Asp-1Ni-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-380), The following formula 【Hua 838】 The compound represented by the formula: Ac-asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-381), The following formula 【Chemical 839】 The compound represented by the formula: Ac-Asp-5Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-382), The following formula 【Chemistry 840】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Cha-Ile-Cys]-NH 2 (GIP-383), The following formula 【Hua 841】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Ser-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-384), The following formula 【Chemical 842】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Val-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-385), The following formula 【Hua 843】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Ala-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-386), The following formula 【Chemical 844】 The compound represented by the formula: DOTA-Ttds-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-387), The following formula 【Chemistry 845】 The compound represented by the formula: DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH 2 (GIP-388), The following formula 【Hua 846】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-lys(DOTA)-NH 2 (GIP-389), The following formula 【Hua 847】 The compound represented by the formula: Ac-Asp-Ocf-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-390), The following formula 【Hua 848】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH 2 (GIP-391), The following formula 【Chemical 849】 The compound represented by the formula: Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH 2 (GIP-392), The following formula 【Chemical 850】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Phe-Cys]-NH 2 (GIP-393), The following formula 【Chemistry 851】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Tap(DOTA)-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH 2 (GIP-394), The following formula 【Hua 852】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Har-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-395), The following formula 【Hua 853】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Phe-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-396), The following formula 【Hua 854】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Trp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-397), The following formula 【Chemistry 855】 The compound represented by the formula: Ac-Asp-Trp-5Clw-Hyp-Pro-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH 2 (GIP-398), The following formula 【Hua 856】 The compound represented by the formula: Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH 2 (GIP-399) and The following formula 【Hua 857】 The compound represented by the formula: Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-Cys]-NH 2 (GIP-400) selected from the group consisting of Preferably, the compound is a) GIP-001 to GIP-031, GIP-033 to GIP056, GIP-059 to GIP-224, GIP-226 to GIP263, GIP-265 to GIP-267, GIP-270, GIP-271, GIP-273, GIP-27 4, selected from the group consisting of GIP-276, GIP-277, GIP-279, GIP-281, GIP-283, GIP-315, GIP-319, GIP-358, GIP-359, GIP-363 and GIP-370 to GIP-400; b) preferably selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-059 to GIP-224, GIP-226 to GIP-263, GIP-265 to GIP-267 and GIP-370 to GIP-386; c) more preferably selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-059 to GIP-071 and GIP-370 to GIP-374; d) A compound according to any one of claims 1 to 18, most preferably selected from the group consisting of GIP-001 to GIP-024 and GIP-370 to GIP-374.

20. Any S atom may be oxidized, and preferably any sulfur atom of the thioether group is -S-, -S(O)- or -S(O 2 20. The compound of any one of claims 1 to 19, wherein the compound is present as:

21. 21. The compound of any one of claims 1 to 20, wherein the compound comprises a radionuclide, the radionuclide being a radionuclide suitable for diagnostics.

22. The radioactive nuclide 43 Sc, 44 Sc, 51 Mn, 52 Mn, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 94m Tc, 99m Tc, 111 In, 152 Tb, 155 Tb, 177 Lu, 201 Tl, 203 Pb, 18 F. 76 Br, 77 Br, 123 I, 124 I and 125 I, preferably selected from the group comprising: 43 Sc, 44 Sc, 64 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 111 In, 152 Tb, 155 Tb and 203 Pb, more preferably selected from the group 64 Cu, 68 Ga, 111 In and 203 22. The compound of claim 21, selected from the group comprising Pb.

23. 21. The compound of any one of claims 1 to 20, wherein the compound comprises a radionuclide, the radionuclide being a therapeutically suitable radionuclide.

24. The radioactive nuclide 47 Sc, 67 Cu, 89 Sr, 90 Y. 111 In, 153 Sm, 149 Tb, 161 Tb, 177 Lu, 186 Re, 188 Re, 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I and 211 At, preferably selected from the group comprising: 47 Sc, 67 Cu, 90 Y. 177 Lu, 212 Pb, 213 Bi, 225 Ac and 227 Th, more preferably selected from the group including 90 Y. 177 Lu, 212 Pb, 225 Ac and 227 24. The compound of claim 23, wherein the compound is selected from the group comprising Th.

25. A compound according to any one of claims 1 to 24 for use in a method for diagnosing a disease.

26. A compound according to any one of claims 1 to 24 for use in a method for treating a disease.

27. 25. A compound according to any one of claims 1 to 24 for use in a method for identifying a subject, said subject likely to respond or not likely to respond to treatment of a disease, wherein the method for identifying the subject comprises carrying out a method for diagnosing the disease using a compound according to any one of claims 1 to 24.

28. 25. A compound according to any one of claims 1 to 24 for use in a method for selecting a subject from a group of subjects, said subject being likely to respond or not to respond to treatment of a disease, the method for selecting a subject from a group of subjects comprising carrying out a method for diagnosing the disease using a compound according to any one of claims 1 to 24.

29. 25. A compound according to any one of claims 1 to 24 for use in a method for stratifying a group of subjects into those likely to respond to treatment of a disease and those likely to not respond to treatment of a disease, wherein the method for stratifying a group of subjects comprises carrying out a method for diagnosing the disease using a compound according to any one of claims 1 to 24.

30. The compound for use according to any one of claims 25 to 29, wherein the disease is cancer.

31. 31. The compound for use according to claim 30, wherein the cancer expresses the gastric inhibitory peptide receptor (GIPR), preferably the cancer overexpresses GIPR.

32. 32. The compound for use according to any one of claims 30 and 31, wherein the cancer is a neuroendocrine cancer or a neuroendocrine neoplasm.

33. 33. The compound for use according to any one of claims 30 to 32, wherein the cancer is selected from the group consisting of medullary thyroid carcinoma, gastrointestinal neuroendocrine neoplasm, ileal neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm, non-functioning neuroendocrine neoplasm, insulinoma, gastrinoma, glucagonoma, VIP-producing tumor, somatostatinoma, ACTH-producing tumor, pulmonary neuroendocrine neoplasm, typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumor, Merkel cell carcinoma, adrenal pheochromocytoma, adrenal carcinoma, parathyroid carcinoma, paraganglioma, pituitary tumor, ovarian neuroendocrine tumor, and testicular neuroendocrine tumor.

34. The compound for use according to any one of claims 25 to 29, wherein the disease is a metabolic disease.

35. 35. The compound for use according to claim 34, wherein the diseased cells and / or tissue, preferably the diseased cells and / or tissue of a metabolic disease, express GIPR.

36. 36. The compound for use according to claim 35, wherein the diseased cells and / or diseased tissue overexpress GIPR.

37. 37. The compound for use according to claim 35 or 36, wherein the diseased cells are pancreatic cells.

38. 38. The compound for use according to any one of claims 34 to 37, wherein the metabolic disease is selected from the group consisting of type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose and impaired glucose tolerance.

39. A composition comprising a compound according to any one of claims 1 to 24 and a pharmaceutically acceptable excipient. composition.

40. 40. The composition of claim 39, wherein the composition is a pharmaceutical composition.

41. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24, one or more optional excipients, and optionally one or more devices. kit.

42. 42. The kit of claim 41, wherein the device is selected from the group comprising a labeling device, a purification device, a handling device, a radiation protection device, an analytical device or an administration device.

Citation Information

Patent Citations

  • Method for selecting a candidate drug compound

    WO2004077062A2

  • Cyclic analogs of GLP-1 and GLP-1 related peptides and uses thereof

    WO2013051938A2